BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF, Perugorria MJ, Fabris L, Boulter L, Macias RIR, Gaudio E, Alvaro D, Gradilone SA, Strazzabosco M, Marzioni M, Coulouarn C, Fouassier L, Raggi C, Invernizzi P, Mertens JC, Moncsek A, Rizvi S, Heimbach J, Koerkamp BG, Bruix J, Forner A, Bridgewater J, Valle JW, Gores GJ. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol 2020;17:557-88. [PMID: 32606456 DOI: 10.1038/s41575-020-0310-z] [Cited by in Crossref: 622] [Cited by in F6Publishing: 599] [Article Influence: 207.3] [Reference Citation Analysis]
Number Citing Articles
1 Jantawong C, Chamgramol Y, Intuyod K, Priprem A, Pairojkul C, Klungsaeng S, Dangtakot R, Pongking T, Sitthirach C, Pinlaor P, Waraasawapati S, Pinlaor S. Curcumin-loaded nanocomplexes alleviate the progression of fluke-related cholangiocarcinoma in hamsters. Cancer Nano 2023;14:5. [DOI: 10.1186/s12645-023-00155-0] [Reference Citation Analysis]
2 Fowler M, Ward JD, Hertel JD, Sasatomi E. Small duct type intrahepatic cholangiocarcinoma with extensive intraductal extension mimics an intraductal tubulopapillary neoplasm. Human Pathology Reports 2023;31:300687. [DOI: 10.1016/j.hpr.2022.300687] [Reference Citation Analysis]
3 Shiode Y, Kodama T, Shigeno S, Murai K, Tanaka S, Newberg JY, Kondo J, Kobayashi S, Yamada R, Hikita H, Sakamori R, Suemizu H, Tatsumi T, Eguchi H, Jenkins NA, Copeland NG, Takehara T. TNF receptor-related factor 3 inactivation promotes the development of intrahepatic cholangiocarcinoma through NF-κB-inducing kinase-mediated hepatocyte transdifferentiation. Hepatology 2023;77:395-410. [PMID: 34995376 DOI: 10.1002/hep.32317] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Deng M, Ran P, Chen L, Wang Y, Yu Z, Cai K, Feng J, Qin Z, Yin Y, Tan S, Liu Y, Xu C, Shi G, Ji Y, Zhao JY, Zhou J, Fan J, Hou Y, Ding C. Proteogenomic characterization of cholangiocarcinoma. Hepatology 2023;77:411-29. [PMID: 35716043 DOI: 10.1002/hep.32624] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Hathaway QA, Lakhani DA, Balar AB, Santiago SP, Krafft MR, Zitun M, Schmidt CR, Smith KT, Kim C. Distal cholangiocarcinoma: case report and brief review of the literature. Radiology Case Reports 2023;18:423-429. [DOI: 10.1016/j.radcr.2022.10.072] [Reference Citation Analysis]
6 Supimon K, Sangsuwannukul T, Sujjitjoon J, Chieochansin T, Junking M, Yenchitsomanus PT. Cytotoxic activity of anti-mucin 1 chimeric antigen receptor T cells expressing PD-1-CD28 switch receptor against cholangiocarcinoma cells. Cytotherapy 2023;25:148-61. [PMID: 36396553 DOI: 10.1016/j.jcyt.2022.10.006] [Reference Citation Analysis]
7 Bowlus CL, Arrivé L, Bergquist A, Deneau M, Forman L, Ilyas SI, Lunsford KE, Martinez M, Sapisochin G, Shroff R, Tabibian JH, Assis DN. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology 2023;77:659-702. [PMID: 36083140 DOI: 10.1002/hep.32771] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Feng X, Cai W, Zheng R, Tang L, Zhou J, Wang H, Liao J, Luo B, Cheng W, Wei A, Zhao W, Jing X, Liang P, Yu J, Huang Q. Diagnosis of hepatocellular carcinoma using deep network with multi-view enhanced patterns mined in contrast-enhanced ultrasound data. Engineering Applications of Artificial Intelligence 2023;118:105635. [DOI: 10.1016/j.engappai.2022.105635] [Reference Citation Analysis]
9 Zhang J, He Q, Jiang S, Li M, Xue H, Zhang D, Li S, Peng H, Liang J, Liu Z, Rao S, Wang J, Zhang R, Zhang L. [(18)F]FAPI PET/CT in the evaluation of focal liver lesions with [(18)F]FDG non-avidity. Eur J Nucl Med Mol Imaging 2023;50:937-50. [PMID: 36346437 DOI: 10.1007/s00259-022-06022-1] [Reference Citation Analysis]
10 Greten TF, Schwabe R, Bardeesy N, Ma L, Goyal L, Kelley RK, Wang XW. Immunology and immunotherapy of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol 2023. [PMID: 36697706 DOI: 10.1038/s41575-022-00741-4] [Reference Citation Analysis]
11 Munir MM, Woldesenbet S, Endo Y, Lima HA, Alaimo L, Moazzam Z, Shaikh C, Cloyd J, Ejaz A, Azap R, Azap L, Pawlik TM. Racial Segregation Among Patients with Cholangiocarcinoma-Impact on Diagnosis, Treatment, and Outcomes. Ann Surg Oncol 2023. [PMID: 36695990 DOI: 10.1245/s10434-023-13122-1] [Reference Citation Analysis]
12 Tang Z, Yang Y, Zhang Q, Liang T. Epigenetic dysregulation-mediated COL12A1 upregulation predicts worse outcome in intrahepatic cholangiocarcinoma patients. Clin Epigenetics 2023;15:13. [PMID: 36694230 DOI: 10.1186/s13148-022-01413-5] [Reference Citation Analysis]
13 Nakshabandi AA, Lee JH. Contemporary advances in the endoscopic management of cholangiocarcinoma: a review of accomplished milestones and prospective opportunities. Expert Rev Gastroenterol Hepatol 2023. [PMID: 36683580 DOI: 10.1080/17474124.2023.2170875] [Reference Citation Analysis]
14 Zhou S, Yang K, Chen S, Lian G, Huang Y, Yao H, Zhao Y, Huang K, Yin D, Lin H, Li Y. CCL3 secreted by hepatocytes promotes the metastasis of intrahepatic cholangiocarcinoma by VIRMA-mediated N6-methyladenosine (m(6)A) modification. J Transl Med 2023;21:43. [PMID: 36691046 DOI: 10.1186/s12967-023-03897-y] [Reference Citation Analysis]
15 Rhee H, Lim HJ, Han K, Yeom SK, Choi SH, Park JH, Cho ES, Park S, Lee MJ, Choi GH, Han DH, Lee SS, Park MS. A preoperative scoring system to predict lymph node metastasis in intrahepatic cholangiocarcinoma. Hepatol Int 2023. [PMID: 36689090 DOI: 10.1007/s12072-022-10477-7] [Reference Citation Analysis]
16 Mehmood A, Nawab S, Jin Y, Kaushik AC, Wei D. Mutational Impacts on the N and C Terminal Domains of the MUC5B Protein: A Transcriptomics and Structural Biology Study. ACS Omega 2023. [DOI: 10.1021/acsomega.2c04871] [Reference Citation Analysis]
17 Elvevi A, Laffusa A, Gallo C, Invernizzi P, Massironi S. Any Role for Microbiota in Cholangiocarcinoma? A Comprehensive Review. Cells 2023;12:370. [DOI: 10.3390/cells12030370] [Reference Citation Analysis]
18 Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, Abrams TA, Furuse J, Kelley RK, Cassier PA, Klümpen HJ, Chang HM, Chen LT, Tabernero J, Oh DY, Mahipal A, Moehler M, Mitchell EP, Komatsu Y, Masuda K, Ahn D, Epstein RS, Halim AB, Fu Y, Salimi T, Wacheck V, He Y, Liu M, Benhadji KA, Bridgewater JA; FOENIX-CCA2 Study Investigators. Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma. N Engl J Med 2023;388:228-39. [PMID: 36652354 DOI: 10.1056/NEJMoa2206834] [Reference Citation Analysis]
19 Miao GY, Qian XL, Zhang YF, Wu F, Huang P, Wang F, Zhou CW, Lu X, Yang C, Zeng MS. A nomogram based on radiomics to predict microvascular invasion and overall survival in intrahepatic cholangiocarcinoma.. [DOI: 10.21203/rs.3.rs-2482282/v1] [Reference Citation Analysis]
20 Sae-fung A, Mutirangura A, Jitkaew S. Identification and validation of a novel ferroptosis-related gene signature for prognosis and potential therapeutic target prediction in cholangiocarcinoma. Front Immunol 2023;13. [DOI: 10.3389/fimmu.2022.1051273] [Reference Citation Analysis]
21 Serra-Camprubí Q, Verdaguer H, Oliveros W, Lupión-Garcia N, Llop-Guevara A, Molina C, Vila-Casadesús M, Turpin A, Neuzillet C, Frigola J, Querol J, Yáñez-Bartolomé M, Castet F, Fabregat-Franco C, Escudero-Iriarte C, Escorihuela M, Arenas EJ, Bernadó-Morales C, Haro N, Giles FJ, Pozo ÓJ, Miquel JM, Nuciforo PG, Vivancos A, Melé M, Serra V, Arribas J, Tabernero J, Peiró S, Macarulla T, Tian TV. Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation. Clin Cancer Res 2023;29:432-45. [PMID: 36374558 DOI: 10.1158/1078-0432.CCR-22-2551] [Reference Citation Analysis]
22 Lee HS, Han DH, Cho K, Park SB, Kim C, Leem G, Jung DE, Kwon SS, Kim CH, Jo JH, Lee HW, Song SY, Park JY. Integrative analysis of multiple genomic data from intrahepatic cholangiocarcinoma organoids enables tumor subtyping. Nat Commun 2023;14:237. [PMID: 36646721 DOI: 10.1038/s41467-023-35896-4] [Reference Citation Analysis]
23 Luo S, Wu L, Li M, Wang J, Wang C, Yang J, Zhang L, Ge J, Sun C, Li E, Lei J, Zhou F, Liao W. Validation of the Prognostic Role for Surgical Treatment in Stage II Intrahepatic Cholangiocarcinoma: A SEER Population-Based Study. J Clin Med 2023;12. [PMID: 36675604 DOI: 10.3390/jcm12020675] [Reference Citation Analysis]
24 Nagao M, Fukuda A, Seno H. The role of Kras and canonical Wnt pathways for tumorigenesis of extrahepatic biliary system. Oncotarget 2023;14:54-56. [DOI: 10.18632/oncotarget.28349] [Reference Citation Analysis]
25 Sukphokkit S, Kiatwuthinon P, Kumkate S, Janvilisri T. Distinct cholangiocarcinoma cell migration in 2D monolayer and 3D spheroid culture based on galectin-3 expression and localization. Front Oncol 2023;12. [DOI: 10.3389/fonc.2022.999158] [Reference Citation Analysis]
26 Chen L, He Y, Han Z, Gong W, Tian X, Guo L, Guo H, Song T, Chen L. The impact of decreased expression of SVEP1 on abnormal neovascularization and poor prognosis in patients with intrahepatic cholangiocarcinoma. Front Genet 2022;13:1127753. [PMID: 36699464 DOI: 10.3389/fgene.2022.1127753] [Reference Citation Analysis]
27 Conticchio M, Maggialetti N, Rescigno M, Brunese MC, Vaschetti R, Inchingolo R, Calbi R, Ferraro V, Tedeschi M, Fantozzi MR, Avella P, Calabrese A, Memeo R, Scardapane A. Hepatocellular Carcinoma with Bile Duct Tumor Thrombus: A Case Report and Literature Review of 890 Patients Affected by Uncommon Primary Liver Tumor Presentation. J Clin Med 2023;12. [PMID: 36675352 DOI: 10.3390/jcm12020423] [Reference Citation Analysis]
28 Iezzi R, Gangi A, Posa A, Pua U, Liang P, Santos E, Kurup AN, Tanzilli A, Tenore L, De Leoni D, Filippiadis D, Giuliante F, Valentini V, Gasbarrini A, Goldberg SN, Meijerink M, Manfredi R, Kelekis A, Colosimo C, Madoff DC. Emerging Indications for Interventional Oncology: Expert Discussion on New Locoregional Treatments. Cancers (Basel) 2023;15. [PMID: 36612304 DOI: 10.3390/cancers15010308] [Reference Citation Analysis]
29 Sapuppo E, Brunetti O, Tessitore D, Brandi G, Di Giovanni N, Fadda G, Luchini C, Martini M, Quaresmini D, Russo A, Santarpia M, Scarpa A, Scartozzi M, Tuccari G, Franchina T, Silvestris N. Rare histotypes of epithelial biliary tract tumors: A literature review. Crit Rev Oncol Hematol 2023;181:103892. [PMID: 36481306 DOI: 10.1016/j.critrevonc.2022.103892] [Reference Citation Analysis]
30 Jeon Y, Kwon SM, Rhee H, Yoo JE, Chung T, Woo HG, Park YN. Molecular and radiopathologic spectrum between HCC and intrahepatic cholangiocarcinoma. Hepatology 2023;77:92-108. [PMID: 35124821 DOI: 10.1002/hep.32397] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
31 Chen Z, Li H, Li Z, Chen S, Huang X, Zheng Z, Qian X, Zhang L, Long G, Xie J, Wang Q, Pan W, Zhang D. SHH/GLI2-TGF-β1 feedback loop between cancer cells and tumor-associated macrophages maintains epithelial-mesenchymal transition and endoplasmic reticulum homeostasis in cholangiocarcinoma. Pharmacol Res 2023;187:106564. [PMID: 36423790 DOI: 10.1016/j.phrs.2022.106564] [Reference Citation Analysis]
32 Ma J, Li J, Jin C, Yang J, Zheng C, Chen K, Xie Y, Yang Y, Bo Z, Wang J, Su Q, Wang J, Chen G, Wang Y. Association of gut microbiome and primary liver cancer: A two-sample Mendelian randomization and case-control study. Liver Int 2023;43:221-33. [PMID: 36300678 DOI: 10.1111/liv.15466] [Reference Citation Analysis]
33 Na-Bangchang K, Plengsuriyakarn T, Karbwang J. The Role of Herbal Medicine in Cholangiocarcinoma Control: A Systematic Review. Planta Med 2023;89:3-18. [PMID: 35468650 DOI: 10.1055/a-1676-9678] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Zou G, Park JI. Wnt signaling in liver regeneration, disease, and cancer. Clin Mol Hepatol 2023;29:33-50. [PMID: 35785913 DOI: 10.3350/cmh.2022.0058] [Reference Citation Analysis]
35 Chueh CH, Tsai YW, Chen ZR, Shiu MN, Wen YW, Chiang NJ. Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy. Pharmacoeconomics 2022. [PMID: 36575331 DOI: 10.1007/s40273-022-01227-6] [Reference Citation Analysis]
36 Rattanasinchai C, Navasumrit P, Ruchirawat M. Elevated ITGA2 expression promotes collagen type I-induced clonogenic growth of intrahepatic cholangiocarcinoma. Sci Rep 2022;12:22429. [PMID: 36575207 DOI: 10.1038/s41598-022-26747-1] [Reference Citation Analysis]
37 Guedj N. Pathology of Cholangiocarcinomas. Curr Oncol 2022;30:370-80. [PMID: 36661679 DOI: 10.3390/curroncol30010030] [Reference Citation Analysis]
38 Zhang X, Tang H, Fan J, Wang R, Han Y, Su S, Gan Y, Peng F, Rao M, Zhang J, Li B, Yang X. Case report: A report of the complete pathological response of intrahepatic cholangiocarcinoma after conversion therapy. Front Immunol 2022;13:1051130. [PMID: 36618353 DOI: 10.3389/fimmu.2022.1051130] [Reference Citation Analysis]
39 Tabari A, Chan SM, Omar OMF, Iqbal SI, Gee MS, Daye D. Role of Machine Learning in Precision Oncology: Applications in Gastrointestinal Cancers. Cancers (Basel) 2022;15. [PMID: 36612061 DOI: 10.3390/cancers15010063] [Reference Citation Analysis]
40 Munir MM, Ruff SM, Endo Y, Lima HA, Alaimo L, Moazzam Z, Shaikh C, Pawlik TM. Does Adjuvant Therapy Benefit Low-Risk Resectable Cholangiocarcinoma? An Evaluation of the NCCN Guidelines. J Gastrointest Surg 2022. [PMID: 36538255 DOI: 10.1007/s11605-022-05558-9] [Reference Citation Analysis]
41 Kupietzky A, Ariche A. Surgical Aspects of Intrahepatic Cholangiocarcinoma. Cancers (Basel) 2022;14. [PMID: 36551749 DOI: 10.3390/cancers14246265] [Reference Citation Analysis]
42 Li T, Tian Y, Ren W, Chen P, Luo M, Sang H. Gab1 regulates invadopodia and autocrine VEGF through SHP2/ERK1/2 in hilar cholangiocarcinoma cells. Am J Transl Res 2022;14:8934-46. [PMID: 36628230] [Reference Citation Analysis]
43 Little A, Medford A, O'brien A, Childs J, Pan S, Machado J, Chakraborty S, Glaser S. Recent Advances in Intrahepatic Biliary Epithelial Heterogeneity. Semin Liver Dis 2022. [DOI: 10.1055/s-0042-1758833] [Reference Citation Analysis]
44 Giraldo NA, Drill E, Satravada BA, Dika IE, Brannon AR, Dermawan J, Mohanty A, Ozcan K, Chakravarty D, Benayed R, Vakiani E, Abou-Alfa GK, Kundra R, Schultz N, Li BT, Berger MF, Harding JJ, Ladanyi M, O'Reilly EM, Jarnagin W, Vanderbilt C, Basturk O, Arcila ME. Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention. Clin Cancer Res 2022;28:5359-67. [PMID: 36228155 DOI: 10.1158/1078-0432.CCR-22-1954] [Reference Citation Analysis]
45 Xu L, Xiao T, Xu L, Yao W. Identification of therapeutic targets and prognostic biomarkers in cholangiocarcinoma via WGCNA. Front Oncol 2022;12:977992. [PMID: 36591499 DOI: 10.3389/fonc.2022.977992] [Reference Citation Analysis]
46 Ahmed O, Yu Q, Patel M, Hwang G, Pillai A, Liao CY, Fung J, Baker T. Yttrium-90 Radioembolization and Concomitant Systemic Gemcitabine, Cisplatin, and Capecitabine as the First-Line Therapy for Locally Advanced Intrahepatic Cholangiocarcinoma. J Vasc Interv Radiol 2022:S1051-0443(22)01414-2. [PMID: 36521794 DOI: 10.1016/j.jvir.2022.12.017] [Reference Citation Analysis]
47 Intarawichian P, Sangpaibool S, Prajumwongs P, Sa-Ngiamwibool P, Sangkhamanon S, Kunprom W, Thanee M, Loilome W, Khuntikeo N, Titapun A, Jareanrat A, Thanasukarn V, Srisuk T, Luvira V, Eurboonyanun K, Promsorn J, Koonmee S, Wee A, Aphivatanasiri C. Prognostic significance of tumor-infiltrating lymphocytes in predicting outcome of distal cholangiocarcinoma in Thailand. Front Oncol 2022;12:1004220. [PMID: 36582790 DOI: 10.3389/fonc.2022.1004220] [Reference Citation Analysis]
48 Wang J, Wang W, Chen X, Ma D, Du G, Xia T, Jiang Z, Jin B. Laparoscopic versus open hepatectomy for intrahepatic cholangiocarcinoma in patients aged 60 and older: a retrospective cohort study. World J Surg Oncol 2022;20:396. [PMID: 36510298 DOI: 10.1186/s12957-022-02870-1] [Reference Citation Analysis]
49 Zhang FP, Zhu K, Zhu TF, Liu CQ, Zhang HH, Xu LB, Xiao G, Liu C. Intra-Tumoral Secondary Follicle-like Tertiary Lymphoid Structures Are Associated with a Superior Prognosis of Overall Survival of Perihilar Cholangiocarcinoma. Cancers (Basel) 2022;14. [PMID: 36551593 DOI: 10.3390/cancers14246107] [Reference Citation Analysis]
50 Cremen S, Kelly ME, Gallagher TK. The role of neo-adjuvant therapy in cholangiocarcinoma: A systematic review. Front Oncol 2022;12:975136. [PMID: 36568243 DOI: 10.3389/fonc.2022.975136] [Reference Citation Analysis]
51 Chmiel P, Gęca K, Rawicz-Pruszyński K, Polkowski WP, Skórzewska M. FGFR Inhibitors in Cholangiocarcinoma-A Novel Yet Primary Approach: Where Do We Stand Now and Where to Head Next in Targeting This Axis? Cells 2022;11. [PMID: 36497187 DOI: 10.3390/cells11233929] [Reference Citation Analysis]
52 de Braud F, Valle J, Lamarca A, Malka D, Hollebecque A. Targeting Fibroblast Growth Factor Receptor Alterations in Cholangiocarcinoma and Other Solid Tumours: A New Frontier in Personalised Medicine. EMJ Oncol 2022. [DOI: 10.33590/emjoncol/10184268] [Reference Citation Analysis]
53 Inoue H, Aimono E, Kasuga A, Tanaka H, Iwasaki A, Saya H, Arima Y. Pixel-Level Clustering of Hematoxylin-Eosin-Stained Sections of Mouse and Human Biliary Tract Cancer. Biomedicines 2022;10. [PMID: 36551889 DOI: 10.3390/biomedicines10123133] [Reference Citation Analysis]
54 Wang G, Heij LR, Liu D, Dahl E, Lang SA, Ulmer TF, Luedde T, Neumann UP, Bednarsch J. The Role of Single-Nucleotide Polymorphisms in Cholangiocarcinoma: A Systematic Review. Cancers (Basel) 2022;14. [PMID: 36497451 DOI: 10.3390/cancers14235969] [Reference Citation Analysis]
55 Wu WS, Chen RF, Cheng CC, Wei JL, Lin CF, You RI, Chen YC, Lee MC, Chen YC. Suppressing of Src-Hic-5-JNK-AKT Signaling Reduced GAPDH Expression for Preventing the Progression of HuCCT1 Cholangiocarcinoma. Pharmaceutics 2022;14. [PMID: 36559193 DOI: 10.3390/pharmaceutics14122698] [Reference Citation Analysis]
56 Colyn L, Alvarez-sola G, Latasa MU, Uriarte I, Herranz JM, Arechederra M, Vlachogiannis G, Rae C, Pineda-lucena A, Casadei-gardini A, Pedica F, Aldrighetti L, López-lópez A, López-gonzálvez A, Barbas C, Ciordia S, Van Liempd SM, Falcón-pérez JM, Urman J, Sangro B, Vicent S, Iraburu MJ, Prosper F, Nelson LJ, Banales JM, Martinez-chantar ML, Marin JJG, Braconi C, Trautwein C, Corrales FJ, Cubero FJ, Berasain C, Fernandez-barrena MG, Avila MA. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming. J Exp Clin Cancer Res 2022;41:183. [DOI: 10.1186/s13046-022-02386-2] [Reference Citation Analysis]
57 Vithayathil M, Khan SA. Current epidemiology of cholangiocarcinoma in Western countries. J Hepatol 2022;77:1690-8. [PMID: 35977611 DOI: 10.1016/j.jhep.2022.07.022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Calderaro J, Di Tommaso L, Maillé P, Beaufrère A, Nguyen CT, Heij L, Gnemmi V, Graham RP, Charlotte F, Chartier S, Wendum D, Vij M, Allende D, Diaz A, Fuster C, Rivière B, Herrero A, Augustin J, Evert K, Calvisi DF, Leow WQ, Leung HHW, Bednarsch J, Boleslawski E, Rela M, Chan AW, Forner A, Reig M, Pujals A, Favre L, Allaire M, Scatton O, Uguen A, Trépo E, Sanchez LO, Chatelain D, Remmelink M, Boulagnon-Rombi C, Bazille C, Sturm N, Menahem B, Frouin E, Tougeron D, Tournigand C, Kempf E, Kim H, Ningarhari M, Michalak-Provost S, Kather JN, Gouw ASH, Gopal P, Brustia R, Vibert E, Schulze K, Rüther DF, Weidemann SA, Rhaiem R, Nault JC, Laurent A, Amaddeo G, Regnault H, de Martin E, Sempoux C, Navale P, Shinde J, Bacchuwar K, Westerhoff M, Lo RC, Sebbagh M, Guettier C, Lequoy M, Komuta M, Ziol M, Paradis V, Shen J, Caruso S. Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma. J Hepatol 2022;77:1586-97. [PMID: 35987274 DOI: 10.1016/j.jhep.2022.07.019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Abdel-Rahman AA, Farag MAH, Naguib M, Abdelsameea E, Abdel-Bary HM. Study of the association between a MICA gene polymorphism and cholangiocarcinoma in Egyptian patients. Clin Exp Hepatol 2022;8:293-9. [PMID: 36683874 DOI: 10.5114/ceh.2022.122293] [Reference Citation Analysis]
60 Ruiz de Gauna M, Biancaniello F, González-Romero F, Rodrigues PM, Lapitz A, Gómez-Santos B, Olaizola P, Di Matteo S, Aurrekoetxea I, Labiano I, Nieva-Zuluaga A, Benito-Vicente A, Perugorria MJ, Apodaka-Biguri M, Paiva NA, Sáenz de Urturi D, Buqué X, Delgado I, Martín C, Azkargorta M, Elortza F, Calvisi DF, Andersen JB, Alvaro D, Cardinale V, Bujanda L, Banales JM, Aspichueta P. Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids. Hepatology 2022;76:1617-33. [PMID: 35030285 DOI: 10.1002/hep.32344] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
61 Zhou L, Deng X, Xiao X, Liao Y, Chen W, Dai Q. Kruppel-like factor 9 inhibits growth and metastasis of cholangiocarcinoma cells by targeted regulation of metallothionein 1 M transcription. Tissue and Cell 2022;79:101962. [DOI: 10.1016/j.tice.2022.101962] [Reference Citation Analysis]
62 Zhang J, Chen W, Ma W, Han C, Song K, Kwon H, Wu T. EZH2 Promotes Cholangiocarcinoma Development and Progression through Histone Methylation and microRNA-Mediated Down-Regulation of Tumor Suppressor Genes. Am J Pathol 2022;192:1712-24. [PMID: 36456043 DOI: 10.1016/j.ajpath.2022.08.008] [Reference Citation Analysis]
63 Paradis V. [Cholangiocarcinoma: Description and classification]. Ann Pathol 2022;42:6S3-4. [PMID: 36577540 DOI: 10.1016/S0242-6498(22)00214-0] [Reference Citation Analysis]
64 Björkström NK. Immunobiology of the biliary tract system. J Hepatol 2022;77:1657-69. [PMID: 36116989 DOI: 10.1016/j.jhep.2022.08.018] [Reference Citation Analysis]
65 Wang T, Xu C, Xu D, Yang X, Liu Y, Li X, Li Z, Dang N, Lv Y, Zhang Z, Li L, Ye K. Integrating cell interaction with transcription factors to obtain a robust gene panel for prognostic prediction and therapies in cholangiocarcinoma. Front Genet 2022;13. [DOI: 10.3389/fgene.2022.981145] [Reference Citation Analysis]
66 Prasopporn S, Suppramote O, Ponvilawan B, Jamyuang C, Chanthercrob J, Chaiboonchoe A, More-Krong P, Kongsri K, Suntiparpluacha M, Chanwat R, Korphaisarn K, Okada S, Sampattavanich S, Jirawatnotai S. Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma. Front Oncol 2022;12:1021632. [PMID: 36531039 DOI: 10.3389/fonc.2022.1021632] [Reference Citation Analysis]
67 Mancarella S, Gigante I, Serino G, Pizzuto E, Dituri F, Valentini MF, Wang J, Chen X, Armentano R, Calvisi DF, Giannelli G. Crenigacestat blocking notch pathway reduces liver fibrosis in the surrounding ecosystem of intrahepatic CCA viaTGF-β inhibition. J Exp Clin Cancer Res 2022;41:331. [PMID: 36443822 DOI: 10.1186/s13046-022-02536-6] [Reference Citation Analysis]
68 Rattanaburee T, Sermmai P, Tangthana-Umrung K, Thongpanchang T, Graidist P. Anticancer Activity of (±)-Kusunokinin Derivatives towards Cholangiocarcinoma Cells. Molecules 2022;27. [PMID: 36500383 DOI: 10.3390/molecules27238291] [Reference Citation Analysis]
69 Hare AE, Makary MS. Locoregional Approaches in Cholangiocarcinoma Treatment. Cancers (Basel) 2022;14. [PMID: 36497334 DOI: 10.3390/cancers14235853] [Reference Citation Analysis]
70 Zhao F, Yang D, He J, Ju X, Ding Y, Li X. Establishment and validation of a prognostic nomogram for extrahepatic cholangiocarcinoma. Front Oncol 2022;12:1007538. [PMID: 36505787 DOI: 10.3389/fonc.2022.1007538] [Reference Citation Analysis]
71 Leelawat S, Leelawat K, Yimsoo T, Wunnakup T, Monton C, Khamthong N, Madaka F, Maha A, Songsak T. Antitumor Effects of Delta (9)-Tetrahydrocannabinol and Cannabinol on Cholangiocarcinoma Cells and Xenograft Mouse Models. Evidence-Based Complementary and Alternative Medicine 2022;2022:1-14. [DOI: 10.1155/2022/6477132] [Reference Citation Analysis]
72 Lei S, Cao W, Zeng Z, Zhang Z, Jin B, Tian Q, Wu Y, Zhang T, Li D, Hu C, Lan J, Zhang J, Chen T. JUND/linc00976 promotes cholangiocarcinoma progression and metastasis, inhibits ferroptosis by regulating the miR-3202/GPX4 axis. Cell Death Dis 2022;13:967. [PMID: 36400758 DOI: 10.1038/s41419-022-05412-5] [Reference Citation Analysis]
73 van Tienderen GS, Willemse J, van Loo B, van Hengel EVA, de Jonge J, van der Laan LJW, Leijten J, Verstegen MMA. Scalable Production of Size-Controlled Cholangiocyte and Cholangiocarcinoma Organoids within Liver Extracellular Matrix-Containing Microcapsules. Cells 2022;11. [PMID: 36429084 DOI: 10.3390/cells11223657] [Reference Citation Analysis]
74 Hou J, Maithel SK, Weber SM, Poultsides G, Wolfgang CL, Fields RC, He J, Scoggins C, Idrees K, Shen P, Zhang X, Pawlik TM. Impact of adjuvant therapy on outcomes after curative‐intent resection for distal cholangiocarcinoma. Journal of Surgical Oncology 2022. [DOI: 10.1002/jso.27146] [Reference Citation Analysis]
75 Merters J, Lamarca A. Integrating cytotoxic, targeted and immune therapies for cholangiocarcinoma. J Hepatol 2022:S0168-8278(22)03296-2. [PMID: 36400328 DOI: 10.1016/j.jhep.2022.11.005] [Reference Citation Analysis]
76 Fründt T, von Felden J, Krause J, Heumann A, Li J, Riethdorf S, Pantel K, Huber S, Lohse AW, Wege H, Schulze K. Circulating tumor cells as a preoperative risk marker for occult metastases in patients with resectable cholangiocarcinoma. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.941660] [Reference Citation Analysis]
77 Tomita H, Hara A. Development of extrahepatic bile ducts and mechanisms of tumorigenesis: Lessons from mouse models. Pathology International 2022. [DOI: 10.1111/pin.13287] [Reference Citation Analysis]
78 Gringeri E, Biasiolo A, Di Giunta M, Mescoli C, Guzzardo V, Sartori A, Cirillo G, Nieddu E, D'Amico FE, Pontisso P, Cillo U. Bile detection of squamous cell carcinoma antigen (SCCA) in extrahepatic cholangiocarcinoma. Dig Liver Dis 2022:S1590-8658(22)00740-X. [PMID: 36369195 DOI: 10.1016/j.dld.2022.10.010] [Reference Citation Analysis]
79 Chen F, Li Y, Aye L, Wu Y, Dong L, Yang Z, Gao Q, Zhang S. FUT8 is regulated by miR‐122‐5p and promotes malignancies in intrahepatic cholangiocarcinoma via PI3K/AKT signaling. Cell Oncol 2022. [DOI: 10.1007/s13402-022-00736-y] [Reference Citation Analysis]
80 Sarantis P, Trifylli E, Koustas E, Papavassiliou KA, Karamouzis MV, Papavassiliou AG. Immune Microenvironment and Immunotherapeutic Management in Virus-Associated Digestive System Tumors. IJMS 2022;23:13612. [DOI: 10.3390/ijms232113612] [Reference Citation Analysis]
81 Cristóbal I, Lamarca A. Role of the PP2A Pathway in Cholangiocarcinoma: State of the Art and Future Perspectives. Cancers 2022;14:5422. [DOI: 10.3390/cancers14215422] [Reference Citation Analysis]
82 Nanashima A, Komi M, Imamura N, Hiyoshi M, Hamada T, Tsuchimochi Y, Ichiki N, Enzaki M, Azuma M. Novel Mathematical Diagnostic Analysis of Malignant Biliary Stenosis Using Magnetic Resonance Cholangiography in Patients Undergoing Pancreaticoduodenectomy. Cancer Diagn Progn 2022;2:668-80. [PMID: 36340462 DOI: 10.21873/cdp.10158] [Reference Citation Analysis]
83 Endo Y, Moazzam Z, Alaimo L, Lima HA, Munir MM, Shaikh CF, Guglielmi A, Aldrighetti L, Weiss M, Bauer TW, Alexandrescu S, Poultsides GA, Kitago M, Maithel SK, Marques HP, Martel G, Pulitano C, Shen F, Cauchy F, Koerkamp BG, Endo I, Pawlik TM. Predictive risk-score model to select patients with intrahepatic cholangiocarcinoma for adjuvant chemotherapy. HPB (Oxford) 2022:S1365-182X(22)01636-7. [PMID: 36396550 DOI: 10.1016/j.hpb.2022.10.011] [Reference Citation Analysis]
84 Kawano T, Inokuchi J, Eto M, Murata M, Kang J. Protein Kinase C (PKC) Isozymes as Diagnostic and Prognostic Biomarkers and Therapeutic Targets for Cancer. Cancers 2022;14:5425. [DOI: 10.3390/cancers14215425] [Reference Citation Analysis]
85 Chung A, Nasralla D, Quaglia A. Understanding the Immunoenvironment of Primary Liver Cancer: A Histopathology Perspective. J Hepatocell Carcinoma 2022;9:1149-69. [PMID: 36349146 DOI: 10.2147/JHC.S382310] [Reference Citation Analysis]
86 Montori M, Scorzoni C, Argenziano ME, Balducci D, De Blasio F, Martini F, Buono T, Benedetti A, Marzioni M, Maroni L. Cancer-Associated Fibroblasts in Cholangiocarcinoma: Current Knowledge and Possible Implications for Therapy. JCM 2022;11:6498. [DOI: 10.3390/jcm11216498] [Reference Citation Analysis]
87 Safdar NZ, Hakeem AR, Faulkes R, James F, Mason L, Masson S, Powell J, Rowe I, Shetty S, Jones R, Spiers HVM, Halliday N, Baker J, Thorburn D, Prasad R, Parker R. Outcomes After Liver Transplantation With Incidental Cholangiocarcinoma. Transpl Int 2022;35:10802. [PMID: 36406780 DOI: 10.3389/ti.2022.10802] [Reference Citation Analysis]
88 Sa-Ngiamwibool P, Aphivatanasiri C, Sangkhamanon S, Intarawichian P, Kunprom W, Thanee M, Prajumwongs P, Loilome W, Khuntikeo N, Titapun A, Jareanrat A, Thanasukarn V, Srisuk T, Luvira V, Eurboonyanun K, Promsorn J, Wee A, Koonmee S. Modification of the AJCC/UICC 8th edition staging system for intrahepatic cholangiocarcinoma: proposal for an alternative staging system from cholangiocarcinoma-prevalent Northeast Thailand. HPB (Oxford) 2022;24:1944-56. [PMID: 35810105 DOI: 10.1016/j.hpb.2022.06.004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
89 Alvisi G, Termanini A, Soldani C, Portale F, Carriero R, Pilipow K, Costa G, Polidoro M, Franceschini B, Malenica I, Puccio S, Lise V, Galletti G, Zanon V, Colombo FS, De Simone G, Tufano M, Aghemo A, Di Tommaso L, Peano C, Cibella J, Iannacone M, Roychoudhuri R, Manzo T, Donadon M, Torzilli G, Kunderfranco P, Di Mitri D, Lugli E, Lleo A. Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target. J Hepatol 2022;77:1359-72. [PMID: 35738508 DOI: 10.1016/j.jhep.2022.05.043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
90 Mas L, Perrier A, Coulet F, Bachet J. Cholangiocarcinomes avancés et gènes de fusion. Bulletin du Cancer 2022;109:11S28-11S34. [DOI: 10.1016/s0007-4551(22)00466-0] [Reference Citation Analysis]
91 Schlick K, Neumayer B, Neureiter D. What is the management of resected cholangiocarcinoma in terms of intra- and postoperative status of tumor margins and lymph nodes? A current view. Expert Rev Gastroenterol Hepatol 2022;16:1019-22. [PMID: 36472068 DOI: 10.1080/17474124.2022.2155633] [Reference Citation Analysis]
92 Wu L, Yang J, Ke RS, Liu Y, Guo P, Feng L, Li Z. Impact of lncRNA SOX9-AS1 overexpression on the prognosis and progression of intrahepatic cholangiocarcinoma. Clin Res Hepatol Gastroenterol 2022;46:101999. [PMID: 35870795 DOI: 10.1016/j.clinre.2022.101999] [Reference Citation Analysis]
93 Liao W, Feng Q, Liu H, Du J, Chen X, Zeng Y. Circular RNAs in cholangiocarcinoma. Cancer Letters 2022. [DOI: 10.1016/j.canlet.2022.215980] [Reference Citation Analysis]
94 Vogel A, Bridgewater J, Edeline J, Kelley R, Klümpen H, Malka D, Primrose J, Rimassa L, Stenzinger A, Valle J, Ducreux M. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology 2022. [DOI: 10.1016/j.annonc.2022.10.506] [Reference Citation Analysis]
95 Wang T, Xu C, Zhang Z, Wu H, Li X, Zhang Y, Deng N, Dang N, Tang G, Yang X, Shi B, Li Z, Li L, Ye K. Cellular heterogeneity and transcriptomic profiles during intrahepatic cholangiocarcinoma initiation and progression. Hepatology 2022;76:1302-17. [PMID: 35340039 DOI: 10.1002/hep.32483] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
96 Andersen JB. Stromal yin-yang of myofibroblasts and endothelial cells in the progression of intrahepatic cholangiocarcinoma. Hepatology 2022;76:1233-6. [PMID: 35506195 DOI: 10.1002/hep.32558] [Reference Citation Analysis]
97 Xu H, Xu G, Xu Q, Xu C, Zhou X, Bai Y, Yin L, Ding Y, Wang W. MLN2238 exerts its anti-tumor effects via regulating ROS/JNK/mitochondrial signaling pathways in intrahepatic cholangiocarcinoma. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.1040847] [Reference Citation Analysis]
98 Li Y, Li K, Liu Z, Tang Y, Hu X, Li X, Shi A, Zhao L, Shu L, Lian S, Yan Z, Huang S, Sheng G, Song Y, Liu Y, Huan F, Zhang M, Zhang Z. Research progress of bile biomarkers and their immunoregulatory role in biliary tract cancers. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1049812] [Reference Citation Analysis]
99 Wang J, Zhu W, Tu J, Zheng Y. Identification and Validation of Novel Biomarkers and Potential Targeted Drugs in Cholangiocarcinoma: Bioinformatics, Virtual Screening, and Biological Evaluation. J Microbiol Biotechnol 2022;32:1262-74. [PMID: 36224755 DOI: 10.4014/jmb.2207.07037] [Reference Citation Analysis]
100 Wang C, Ciren P, Danzeng A, Li Y, Zeng C, Zhang Z, Huang Z, Chen Y, Zhang W, Zhang B, Zhang B, Chen X. Anatomical Resection Improved the Outcome of Intrahepatic Cholangiocarcinoma: A Propensity Score Matching Analysis of a Retrospective Cohort. Journal of Oncology 2022;2022:1-16. [DOI: 10.1155/2022/4446243] [Reference Citation Analysis]
101 Phansila N, Pansila P, Wongkongdech A, Turnbull N, Azam M, Wongkongdech R. Survival rate of patients with combined hepatocellular cholangiocarcinoma receiving medical cannabis treatment: A retrospective, cohort comparative study. F1000Res 2022;11:1212. [DOI: 10.12688/f1000research.123250.1] [Reference Citation Analysis]
102 Pan Y, Wu C, Huang W, Chen M, Lan K, Yeh C. Chimeric immune checkpoint protein vaccines inhibit the tumorigenesis and growth of rat cholangiocarcinoma. Front Immunol 2022;13:982196. [DOI: 10.3389/fimmu.2022.982196] [Reference Citation Analysis]
103 Tella SH, Mahipal A. An evaluation of ivosidenib for the treatment of IDH1-mutant cholangiocarcinoma. Expert Opin Pharmacother 2022;:1-7. [PMID: 36257911 DOI: 10.1080/14656566.2022.2138331] [Reference Citation Analysis]
104 Ge T, Gu X, Jia R, Ge S, Chai P, Zhuang A, Fan X. Crosstalk between metabolic reprogramming and epigenetics in cancer: updates on mechanisms and therapeutic opportunities. Cancer Commun (Lond) 2022. [PMID: 36266736 DOI: 10.1002/cac2.12374] [Reference Citation Analysis]
105 Gadaleta-Caldarola G, Rizzo A, Dadduzio V, Lombardi L, Gadaleta-Caldarola A, Infusino S, Cusmai A, Citrigno C, Palmiotti G. Pemigatinib in Intrahepatic Cholangiocarcinoma: A Work in Progress. Curr Oncol 2022;29:7925-31. [PMID: 36290903 DOI: 10.3390/curroncol29100626] [Reference Citation Analysis]
106 Ding X, Zakharia K, Moser CD, Campbell NA, Hu C, Razumilava N, Chaiteerakij R, Shaleh HM, Greipp PT, Graham RP, Zou X, Chandan VS, Roberts LR. Establishment and Characterization of a New Human Intrahepatic Cholangiocarcinoma Cell Line LIV27. Cancers 2022;14:5080. [DOI: 10.3390/cancers14205080] [Reference Citation Analysis]
107 Yoshida M, Yukawa H, Hayashi K, Naitoh I, Miyabe K, Hori Y, Natsume M, Jinno N, Kato A, Kachi K, Asano G, Sahashi H, Toyohara T, Kuno K, Kito Y, Kondo H, Hirano A, Okumura F, Anbe K, Baba Y, Kataoka H, Tanaka Y. Clinical impact of bile-derived exosomal microRNAs as novel diagnostic and prognostic biomarkers for biliary tract cancers. Cancer Sci 2023;114:295-305. [PMID: 36168845 DOI: 10.1111/cas.15597] [Reference Citation Analysis]
108 Chung YS, Jeon Y, Yoo JE, Chung T, Ryu HJ, Kim H, Rhee H, Park YN. Albumin, filamin-A and cytokeratin 19 help distinguish intrahepatic cholangiocarcinoma from extrahepatic adenocarcinoma. Hepatol Int 2022. [PMID: 36253584 DOI: 10.1007/s12072-022-10428-2] [Reference Citation Analysis]
109 Ma K, Wang Y, Zhang Y, Sun H, Zhang X, Sun C, Zhang B, Zhang Y, Cheng H, Liu A, Wang M, Han B. Clinical Practice of Targeted Capture Sequencing to Identify Actionable Alterations in Cholangiocarcinoma. Cancers (Basel) 2022;14:5062. [PMID: 36291846 DOI: 10.3390/cancers14205062] [Reference Citation Analysis]
110 Wang J, Ge F, Yuan T, Qian M, Yan F, Yang B, He Q, Zhu H. The molecular mechanisms and targeting strategies of transcription factors in cholangiocarcinoma. Expert Opin Ther Targets 2022. [PMID: 36243001 DOI: 10.1080/14728222.2022.2137020] [Reference Citation Analysis]
111 Saoudi González N, Castet F, Élez E, Macarulla T, Tabernero J. Current and emerging anti-angiogenic therapies in gastrointestinal and hepatobiliary cancers. Front Oncol 2022;12:1021772. [DOI: 10.3389/fonc.2022.1021772] [Reference Citation Analysis]
112 Prasopdee S, Yingchutrakul Y, Krobthong S, Pholhelm M, Wongtrakoongate P, Butthongkomvong K, Kulsantiwong J, Phanaksri T, Kunjantarachot A, Sathavornmanee T, Tesana S, Thitapakorn V. Differential plasma proteomes of the patients with Opisthorchiasis viverrini and cholangiocarcinoma identify a polymeric immunoglobulin receptor as a potential biomarker. Heliyon 2022;8:e10965. [PMID: 36247154 DOI: 10.1016/j.heliyon.2022.e10965] [Reference Citation Analysis]
113 Zhao J, Guo Y, Ding W, Han G, Jiang C, Yang C, Hu Y, Zhang L, Wu C, Ni M, Kong X, Huang T, Zhang C, Xia Y. Immune checkpoint inhibitors plus capecitabine and oxaliplatin in unresectable or advanced biliary tract cancer patients: A retrospective study. Front Oncol 2022;12:965711. [DOI: 10.3389/fonc.2022.965711] [Reference Citation Analysis]
114 Schmelzle M, Benzing C, Fischer L, Herden U, Sterneck M, Settmacher U, Bauschke A, Neumann U, Pelzer U, Müller T, Strassburg C, Lang H, Becker T, Königsrainer A, Nadalin S, Quante M, Paul A, Friess H, Klempnauer J, Richter N, Vondran F, Pascher A, Rösch T, Schöning W, Krenzien F, Öllinger R, Seehofer D, Neuhaus P, Pratschke J. Feasibility and Efficacy of Adjuvant Chemotherapy With Gemcitabine After Liver Transplantation for Perihilar Cholangiocarcinoma - A Multi-Center, Randomized, Controlled Trial (pro-duct001). Front Oncol 2022;12:910871. [DOI: 10.3389/fonc.2022.910871] [Reference Citation Analysis]
115 Qin LX. Immunotherapy for hepatobiliary malignancies: Progress and prospective. Hepatobiliary Pancreat Dis Int 2022;21:409-12. [PMID: 36117110 DOI: 10.1016/j.hbpd.2022.09.002] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
116 Yuan ZG, Zeng TM, Tao CJ. Current and emerging immunotherapeutic approaches for biliary tract cancers. Hepatobiliary Pancreat Dis Int 2022;21:440-9. [PMID: 36115807 DOI: 10.1016/j.hbpd.2022.08.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
117 Duwe L, Munoz-garrido P, Lewinska M, Lafuente-barquero J, Satriano L, Høgdall D, Taranta A, Nielsen BS, Ghazal A, Matter MS, Banales JM, Aldana BI, Gao Y, Marquardt JU, Roberts LR, Oliveira RC, Koshiol J, O'rourke CJ, Andersen JB. MicroRNA-27a-3p targets FoxO signalling to induce tumour-like phenotypes in bile duct cells. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.10.012] [Reference Citation Analysis]
118 Høgdall D, O'Rourke CJ, Larsen FO, Zarforoushan S, Christensen TD, Ghazal A, Boisen MK, Muñoz-Garrido P, Johansen JS, Andersen JB. Whole blood microRNAs capture systemic reprogramming and have diagnostic potential in patients with biliary tract cancer. J Hepatol 2022;77:1047-58. [PMID: 35750139 DOI: 10.1016/j.jhep.2022.05.036] [Reference Citation Analysis]
119 Tanaka M, Kunita A, Yamagishi M, Katoh H, Ishikawa S, Yamamoto H, Abe J, Arita J, Hasegawa K, Shibata T, Ushiku T. KRAS mutation in intrahepatic cholangiocarcinoma: Linkage with metastasis-free survival and reduced E-cadherin expression. Liver Int 2022;42:2329-40. [PMID: 35833881 DOI: 10.1111/liv.15366] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
120 Gilbert TM, Hackett J, Holt L, Bird N, Quinn M, Gordon-weeks A, Diaz-nieto R, Fenwick SW, Malik HZ, Jones RP. Long-term morbidity after surgery for perihilar cholangiocarcinoma: A cohort study. Surgical Oncology 2022. [DOI: 10.1016/j.suronc.2022.101875] [Reference Citation Analysis]
121 Lu Y, Li X, Zhao K, Shi Y, Deng Z, Yao W, Wang J. Proteomic and Phosphoproteomic Profiling Reveals the Oncogenic Role of Protein Kinase D Family Kinases in Cholangiocarcinoma. Cells 2022;11:3088. [PMID: 36231050 DOI: 10.3390/cells11193088] [Reference Citation Analysis]
122 Naqvi AAT, Rizvi SAM, Hassan MI. Pan-cancer analysis of Chromobox (CBX) genes for prognostic significance and cancer classification. Biochim Biophys Acta Mol Basis Dis 2022;:166561. [PMID: 36183965 DOI: 10.1016/j.bbadis.2022.166561] [Reference Citation Analysis]
123 Gao X, Zhang W, Jia Y, Xu H, Zhu Y, Pei X. Identification of a prognosis-related ceRNA network in cholangiocarcinoma and potentially therapeutic molecules using a bioinformatic approach and molecular docking. Sci Rep 2022;12:16247. [PMID: 36171401 DOI: 10.1038/s41598-022-20362-w] [Reference Citation Analysis]
124 Huang P, Huang X, Zhou Y, Yang G, Sun Q, Shi G, Chen Y, Lai Q. The Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Based on FOLFIRI for Advanced Intrahepatic Cholangiocarcinoma as Second-Line and Successive Treatment: A Real-World Study. Canadian Journal of Gastroenterology and Hepatology 2022;2022:1-7. [DOI: 10.1155/2022/9680933] [Reference Citation Analysis]
125 Yao X, Chen B, Wang M, Zhang S, He B, Shi Z, Deng T, Bao W, Wang Y, Chen G, Bo Z. Exploration and validation of a novel ferroptosis-related gene signature predicting the prognosis of intrahepatic cholangiocarcinoma. Acta Biochim Biophys Sin (Shanghai) 2022;54:1376-85. [PMID: 36111744 DOI: 10.3724/abbs.2022125] [Reference Citation Analysis]
126 Conboy CB, Yonkus JA, Buckarma EH, Mun DG, Werneburg NW, Watkins RD, Alva-Ruiz R, Tomlinson JL, Guo Y, Wang J, O'Brien D, McCabe CE, Jessen E, Graham RP, Buijsman RC, Vu D, de Man J, Ilyas SI, Truty MJ, Borad M, Pandey A, Gores GJ, Smoot RL. LCK inhibition downregulates YAP activity and is therapeutic in patient-derived models of cholangiocarcinoma. J Hepatol 2022:S0168-8278(22)03121-X. [PMID: 36162702 DOI: 10.1016/j.jhep.2022.09.014] [Reference Citation Analysis]
127 Borad MJ, Bai LY, Richards D, Mody K, Hubbard J, Rha SY, Soong J, McCormick D, Tse E, O'Brien D, Bayat A, Ahn D, Davis SL, Park JO, Oh DY. Silmitasertib plus gemcitabine and cisplatin first-line therapy in locally advanced/metastatic cholangiocarcinoma: A Phase 1b/2 study. Hepatology 2022. [PMID: 36152015 DOI: 10.1002/hep.32804] [Reference Citation Analysis]
128 Elshami M, Hue JJ, Ahmed FA, Kakish H, Hoehn RS, Rothermel LD, Hardacre JM, Ammori JB, Winter JM, Ocuin LM. Defining Facility Volume Threshold for Optimization of Short- and Long-Term Outcomes in Patients Undergoing Resection of Perihilar Cholangiocarcinoma. J Gastrointest Surg 2022. [PMID: 36138311 DOI: 10.1007/s11605-022-05465-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
129 Chaiyadet S, Tangkawattana S, Smout MJ, Ittiprasert W, Mann VH, Deenonpoe R, Arunsan P, Loukas A, Brindley PJ, Laha T. Knockout of liver fluke granulin, Ov-grn-1, impedes malignant transformation during chronic infection with Opisthorchis viverrini. PLoS Pathog 2022;18:e1010839. [PMID: 36137145 DOI: 10.1371/journal.ppat.1010839] [Reference Citation Analysis]
130 Wu X, Qin F, Zhang Q, Qiao J, Qi Y, Liu B. Immunotherapy improved cancer related pain management in patients with advanced Hepato-Pancreatic Biliary Cancers: A propensity score-matched (PSM) analysis. Front Oncol 2022;12:914591. [DOI: 10.3389/fonc.2022.914591] [Reference Citation Analysis]
131 Harding JJ, Khalil DN, Fabris L, Abou-Alfa GK. Rational development of combination therapies for biliary tract cancers. J Hepatol 2022:S0168-8278(22)03078-1. [PMID: 36150578 DOI: 10.1016/j.jhep.2022.09.004] [Reference Citation Analysis]
132 Shi GM, Huang XY, Wen TF, Song TQ, Kuang M, Mou HB, Bao LQ, Zhao HT, Zhao H, Feng XL, Zhang BX, Peng T, Zhang YB, Li XC, Yu HS, Cao Y, Liu LX, Zhang T, Wang WL, Ran JH, Liu YB, Gong W, Chen MX, Cao L, Luo Y, Wang Y, Zhou H, Yang GH, Fan J, Zhou J. Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II study. Cancer Med 2022. [PMID: 36127767 DOI: 10.1002/cam4.5273] [Reference Citation Analysis]
133 Gorji L, Beal EW. Surgical Treatment of Distal Cholangiocarcinoma. Current Oncology 2022;29:6674-6687. [DOI: 10.3390/curroncol29090524] [Reference Citation Analysis]
134 Brandi G, Rizzo A. IDH Inhibitors and Immunotherapy for Biliary Tract Cancer: A Marriage of Convenience? Int J Mol Sci 2022;23:10869. [PMID: 36142781 DOI: 10.3390/ijms231810869] [Reference Citation Analysis]
135 Kinzler MN, Schulze F, Bankov K, Gretser S, Becker N, Leichner R, Stehle A, Abedin N, Trojan J, Zeuzem S, Schnitzbauer AA, Wild PJ, Walter D. Impact of small duct- and large duct type on survival in patients with intrahepatic cholangiocarcinoma: Results from a German tertiary center. Pathol Res Pract 2022;238:154126. [PMID: 36137398 DOI: 10.1016/j.prp.2022.154126] [Reference Citation Analysis]
136 Jin H, Liu W, Xu W, Zhou L, Luo H, Xu C, Chen X, Chen W, Fiscon G. Identification of Prognostic Factors in Cholangiocarcinoma Based on Integrated ceRNA Network Analysis. Computational and Mathematical Methods in Medicine 2022;2022:1-15. [DOI: 10.1155/2022/7102736] [Reference Citation Analysis]
137 Brown ZJ, Patwardhan S, Bean J, Pawlik TM. Molecular diagnostics and biomarkers in cholangiocarcinoma. Surg Oncol 2022;44:101851. [PMID: 36126350 DOI: 10.1016/j.suronc.2022.101851] [Reference Citation Analysis]
138 Duwe L, Fouassier L, Lafuente-Barquero J, Andersen JB. Unraveling the actin cytoskeleton in the malignant transformation of cholangiocyte biology. Transl Oncol 2022;26:101531. [PMID: 36113344 DOI: 10.1016/j.tranon.2022.101531] [Reference Citation Analysis]
139 Lairmore TC, Abdulsattar J, Benedetti A, Shi R, Huang S, Khalil MI, Witt SN. Loss of Tumor Suppressor Menin Expression in High Grade Cholangiocarcinomas.. [DOI: 10.21203/rs.3.rs-2042863/v1] [Reference Citation Analysis]
140 Suo H, Hochnadel I, Petriv N, Franke R, Schmidt J, Limanska N, Tugai A, Jedicke N, Broenstrup M, Manns MP, Yevsa T. Elucidating the mechanism behind and investigating the efficacy of Traditional Chinese Medicine and Traditional Tibetan Medicine in combination with standard therapeutics in hepatocellular carcinoma and cholangiocarcinoma in vitro. Front Pharmacol 2022;13:906468. [DOI: 10.3389/fphar.2022.906468] [Reference Citation Analysis]
141 Songjang W, Nensat C, Nernpermpisooth N, Seenak P, Pankhong P, Jumroon N, Kumphune S, Jiraviriyakul A. Tumor-Promoting Activity and Proteomic Profiling of Cisplatin/Oxaliplatin-Derived DAMPs in Cholangiocarcinoma Cells. Int J Mol Sci 2022;23:10540. [PMID: 36142453 DOI: 10.3390/ijms231810540] [Reference Citation Analysis]
142 Islam MA, Barshetty MM, Srinivasan S, Dudekula DB, Rallabandi VPS, Mohammed S, Natarajan S, Park J. Identification of Novel Ribonucleotide Reductase Inhibitors for Therapeutic Application in Bile Tract Cancer: An Advanced Pharmacoinformatics Study. Biomolecules 2022;12:1279. [PMID: 36139117 DOI: 10.3390/biom12091279] [Reference Citation Analysis]
143 Zeng T, Pan Y, Yuan Z, Chen D, Song Y, Gao Y. Immune-related RNA signature predicts outcome of PD-1 inhibitor-combined GEMCIS therapy in advanced intrahepatic cholangiocarcinoma. Front Immunol 2022;13:943066. [DOI: 10.3389/fimmu.2022.943066] [Reference Citation Analysis]
144 Dong R, Zhang B, Zhang X. Liver organoids: an in vitro 3D model for liver cancer study. Cell Biosci 2022;12:152. [DOI: 10.1186/s13578-022-00890-8] [Reference Citation Analysis]
145 Xu L, Yan M, Long J, liu M, Yang H, Li W. Identification of macrophage correlated biomarkers to predict the prognosis in patients with intrahepatic cholangiocarcinoma. Front Oncol 2022;12:967982. [DOI: 10.3389/fonc.2022.967982] [Reference Citation Analysis]
146 Berchuck JE, Facchinetti F, DiToro DF, Baiev I, Majeed U, Reyes S, Chen C, Zhang K, Sharman R, Junior PLSU, Maurer J, Shroff RT, Pritchard CC, Wu MJ, Catenacci DVT, Javle M, Friboulet L, Hollebecque A, Bardeesy N, Zhu AX, Lennerz JK, Tan B, Borad M, Parikh AR, Kiedrowski LA, Kelley RK, Mody K, Juric D, Goyal L. The Clinical Landscape of Cell-Free DNA Alterations in 1,671 Patients with Advanced Biliary Tract Cancer. Ann Oncol 2022:S0923-7534(22)04141-2. [PMID: 36089135 DOI: 10.1016/j.annonc.2022.09.150] [Reference Citation Analysis]
147 Charbel A, Tavernar L, Albrecht T, Brinkmann F, Verheij J, Roos E, Vogel MN, Köhler B, Springfeld C, Brobeil A, Schirmacher P, Singer S, Mehrabi A, Roessler S, Goeppert B. Spatiotemporal analysis of tumour-infiltrating immune cells in biliary carcinogenesis. Br J Cancer 2022. [PMID: 36068277 DOI: 10.1038/s41416-022-01933-0] [Reference Citation Analysis]
148 Guo Y, Li Q, Ren W, Wu H, Wang C, Li X, Xue B, Qiu Y, Zhang J, Chen J, Fang L. Quantitative Proteomics Reveals Down-Regulated Glycolysis/Gluconeogenesis in the Large-Duct Type Intrahepatic Cholangiocarcinoma. J Proteome Res 2022. [PMID: 36066509 DOI: 10.1021/acs.jproteome.2c00472] [Reference Citation Analysis]
149 Hewitt DB, Aziz H, Brown ZJ, Pawlik TM. Role of genetic testing in hepatic, pancreatic, and biliary cancers. Surg Oncol 2022;44:101844. [PMID: 36116416 DOI: 10.1016/j.suronc.2022.101844] [Reference Citation Analysis]
150 Marcus R, Christopher W, Keller J, Nassoiy S, Chang SC, Goldfarb M, Wolf R, Jutric Z. Systemic Therapy Is Associated with Improved Oncologic Outcomes in Resectable Stage II/III Intrahepatic Cholangiocarcinoma: An Examination of the National Cancer Database over the Past Decade. Cancers (Basel) 2022;14:4320. [PMID: 36077855 DOI: 10.3390/cancers14174320] [Reference Citation Analysis]
151 Cleary JM, Rouaisnel B, Daina A, Raghavan S, Roller LA, Huffman BM, Singh H, Wen PY, Bardeesy N, Zoete V, Wolpin BM, Losman JA. Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma. NPJ Precis Oncol 2022;6:61. [PMID: 36056177 DOI: 10.1038/s41698-022-00304-5] [Reference Citation Analysis]
152 Nagalo BM, Zhou Y, Loeuillard EJ, Dumbauld C, Barro O, Elliott NM, Baker AT, Arora M, Bogenberger JM, Meurice N, Petit J, Uson PLS Jr, Aslam F, Raupach E, Gabere M, Basnakian A, Simoes CC, Cannon MJ, Post SR, Buetow K, Chamcheu JC, Barrett MT, Duda DG, Jacobs B, Vile R, Barry MA, Roberts LR, Ilyas S, Borad MJ. Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers. Hepatology 2022. [PMID: 36052732 DOI: 10.1002/hep.32769] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
153 Liu J, Tao H, Yuan T, Li J, Li J, Liang H, Huang Z, Zhang E. Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy. Front Immunol 2022;13:992611. [DOI: 10.3389/fimmu.2022.992611] [Reference Citation Analysis]
154 Irwin D. Update on Cholangiocarcinoma. Digestive Disease Interventions 2022;06:209-218. [DOI: 10.1055/s-0042-1751238] [Reference Citation Analysis]
155 Lavacchi D, Caliman E, Rossi G, Buttitta E, Botteri C, Fancelli S, Pellegrini E, Roviello G, Pillozzi S, Antonuzzo L. Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions. Pharmacology & Therapeutics 2022;237:108170. [DOI: 10.1016/j.pharmthera.2022.108170] [Reference Citation Analysis]
156 Liu Z, Yi J, Yang J, Zhang X, Wang L, Liu S. Diagnostic and prognostic nomograms for newly diagnosed intrahepatic cholangiocarcinoma with brain metastasis: A population-based analysis. Exp Biol Med (Maywood) 2022;247:1657-69. [PMID: 35946168 DOI: 10.1177/15353702221113828] [Reference Citation Analysis]
157 Raggi C, Taddei ML, Rae C, Braconi C, Marra F. Metabolic reprogramming in cholangiocarcinoma. J Hepatol 2022;77:849-64. [PMID: 35594992 DOI: 10.1016/j.jhep.2022.04.038] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
158 Caligiuri A, Gitto S, Lori G, Marra F, Parola M, Cannito S, Gentilini A. Oncostatin M: From Intracellular Signaling to Therapeutic Targets in Liver Cancer. Cancers 2022;14:4211. [DOI: 10.3390/cancers14174211] [Reference Citation Analysis]
159 Guo B, Friedland SC, Alexander W, Myers JA, Wang W, O'Dell MR, Getman M, Whitney-Miller CL, Agostini-Vulaj D, Huber AR, Mello SS, Vertino PM, Land HK, Steiner LA, Hezel AF. Arid1a mutation suppresses TGF-β signaling and induces cholangiocarcinoma. Cell Rep 2022;40:111253. [PMID: 36044839 DOI: 10.1016/j.celrep.2022.111253] [Reference Citation Analysis]
160 He Q, Yin Y, Pan X, Wu Y, Li X. Albendazole-induced autophagy blockade contributes to elevated apoptosis in cholangiocarcinoma cells through AMPK/mTOR activation. Toxicol Appl Pharmacol 2022;:116214. [PMID: 36055539 DOI: 10.1016/j.taap.2022.116214] [Reference Citation Analysis]
161 Leem G, Jang S, Cho J, Jo JH, Lee HS, Chung MJ, Park JY, Bang S, Yoo D, Cheon H, Kim J, Lim K, Jung I, Im J, Chung Y, Park SW. Safety and Efficacy of Allogeneic Natural Killer Cells in Combination with Pembrolizumab in Patients with Chemotherapy-Refractory Biliary Tract Cancer: A Multicenter Open-Label Phase 1/2a Trial. Cancers 2022;14:4229. [DOI: 10.3390/cancers14174229] [Reference Citation Analysis]
162 Chen L, Fan Z, Sun X, Qiu W, Mu W, Chai K, Cao Y, Wang G, Lv G. Examination on the risk factors of cholangiocarcinoma: A Mendelian randomization study. Front Pharmacol 2022;13:900424. [DOI: 10.3389/fphar.2022.900424] [Reference Citation Analysis]
163 Kittirat Y, Suksawat M, Thongchot S, Padthaisong S, Phetcharaburanin J, Wangwiwatsin A, Klanrit P, Sangkhamanon S, Titapun A, Loilome W, Saya H, Namwat N. Interleukin-6-derived cancer-associated fibroblasts activate STAT3 pathway contributing to gemcitabine resistance in cholangiocarcinoma. Front Pharmacol 2022;13:897368. [DOI: 10.3389/fphar.2022.897368] [Reference Citation Analysis]
164 Chen X, Rao W, Shi Y, Liu J. Minimally Invasive Injectable Thermochemical Ablation Therapy of Malignant Tumor via Alkali Metal Fluid. Biomedical Materials & Devices 2022. [DOI: 10.1007/s44174-022-00016-1] [Reference Citation Analysis]
165 Roderburg C, Essing T, Kehmann L, Krieg S, Labuhn S, Kandler J, Luedde T, Loosen SH. Current Trends in Inpatient Care and In-Hospital Mortality of Cholangiocarcinoma in Germany: A Systematic Analysis between 2010 and 2019. Cancers (Basel) 2022;14:4038. [PMID: 36011031 DOI: 10.3390/cancers14164038] [Reference Citation Analysis]
166 Prinz C, Frese R, Grams M, Fehring L. Emerging Role of microRNA Dysregulation in Diagnosis and Prognosis of Extrahepatic Cholangiocarcinoma. Genes (Basel) 2022;13:1479. [PMID: 36011390 DOI: 10.3390/genes13081479] [Reference Citation Analysis]
167 Shi X, Li Z, Yao R, Cheng Q, Li W, Wu R, Xie Z, Zhu Y, Qiu X, Yang S, Zhou T, Hu J, Zhang Y, Wu T, Zhao Y, Zhang Y, Wu J, Wang H, Jiang X, Chen L. Single-cell atlas of diverse immune populations in the advanced biliary tract cancer microenvironment. NPJ Precis Oncol 2022;6:58. [PMID: 35982235 DOI: 10.1038/s41698-022-00300-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
168 Peng H, Zhu E, Zhang Y. Advances of cancer-associated fibroblasts in liver cancer. Biomark Res 2022;10:59. [PMID: 35971182 DOI: 10.1186/s40364-022-00406-z] [Reference Citation Analysis]
169 Borakati A, Froghi F, Bhogal RH, Mavroeidis VK. Stereotactic radiotherapy for intrahepatic cholangiocarcinoma. World J Gastrointest Oncol 2022; 14(8): 1478-1489 [DOI: 10.4251/wjgo.v14.i8.1478] [Reference Citation Analysis]
170 Carloni R, Rizzo A, Ricci AD, Federico AD, De Luca R, Guven DC, Yalcin S, Brandi G. Targeting tumor microenvironment for cholangiocarcinoma: Opportunities for precision medicine. Transl Oncol 2022;25:101514. [PMID: 35977458 DOI: 10.1016/j.tranon.2022.101514] [Reference Citation Analysis]
171 Bao F, Liu J, Chen H, Miao L, Xu Z, Zhang G. Diagnosis Biomarkers of Cholangiocarcinoma in Human Bile: An Evidence-Based Study. Cancers (Basel) 2022;14:3921. [PMID: 36010914 DOI: 10.3390/cancers14163921] [Reference Citation Analysis]
172 Sun H, Qi X. The role of insulin and incretin-based drugs in biliary tract cancer: epidemiological and experimental evidence. Discov Onc 2022;13. [DOI: 10.1007/s12672-022-00536-8] [Reference Citation Analysis]
173 Liu Z, Hu C, Zheng L, Liu J, Li K, Li X, Wang Y, Mu W, Chen T, Shi A, Qiu B, Zhang X, Zhang Z, Xu Y. BMI1 promotes cholangiocarcinoma progression and correlates with antitumor immunity in an exosome-dependent manner. Cell Mol Life Sci 2022;79:469. [PMID: 35932322 DOI: 10.1007/s00018-022-04500-1] [Reference Citation Analysis]
174 Zulfiqar M, Chatterjee D, Yoneda N, Hoegger MJ, Ronot M, Hecht EM, Bastati N, Ba-Ssalamah A, Bashir MR, Fowler K. Imaging Features of Premalignant Biliary Lesions and Predisposing Conditions with Pathologic Correlation. Radiographics 2022;:210194. [PMID: 35930475 DOI: 10.1148/rg.210194] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
175 Volpacchio MM. Invited Commentary: Early Detection of Biliary Malignancies: Are We There Yet? Radiographics 2022;:220003. [PMID: 35930476 DOI: 10.1148/rg.220003] [Reference Citation Analysis]
176 Madoff DC, Abi-Jaoudeh N, Braxton D, Goyal L, Jain D, Odisio BC, Salem R, Schattner M, Sheth R, Li D. An Expert, Multidisciplinary Perspective on Best Practices in Biomarker Testing in Intrahepatic Cholangiocarcinoma. Oncologist 2022:oyac139. [PMID: 35925597 DOI: 10.1093/oncolo/oyac139] [Reference Citation Analysis]
177 Xie P, Guo L, Zhang B, Xu Y, Song Q, Shi H, Ye Q, Li H, Xiao Y. Case report: immunotherapy successfully treated brain metastasis in intrahepatic cholangiocarcinoma and literature review. Front Oncol 2022;12:911202. [DOI: 10.3389/fonc.2022.911202] [Reference Citation Analysis]
178 Nadalin S, Peters M, Königsrainer A. Operative Therapiestrategien bei primären Lebertumoren, hepatozellulären und Cholangio- inkl. Gallenblasenkarzinomen. Allgemein- und Viszeralchirurgie up2date 2022;16:313-331. [DOI: 10.1055/a-1739-8909] [Reference Citation Analysis]
179 Param NJ, Bramel ER, Sia D. The Molecular Pathogenesis and Targeted Therapies for Cholangiocarcinoma. Surgical Pathology Clinics 2022. [DOI: 10.1016/j.path.2022.05.006] [Reference Citation Analysis]
180 Luvira V, Tipwaratorn T, Losuwarat K, Pruekprasert P, Theeragul S, Pugkhem A. Combined Intraoperative Biliary Stent with Choledochoduodenostomy: a Simplified Technique for Intraoperatively Found Advanced Perihilar Bile Duct Tumor Involving Both Hepatic Ducts. Indian J Surg 2022;84:546-50. [DOI: 10.1007/s12262-022-03489-y] [Reference Citation Analysis]
181 Macias RIR, Cardinale V, Kendall TJ, Avila MA, Guido M, Coulouarn C, Braconi C, Frampton AE, Bridgewater J, Overi D, Pereira SP, Rengo M, Kather JN, Lamarca A, Pedica F, Forner A, Valle JW, Gaudio E, Alvaro D, Banales JM, Carpino G. Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions. Gut 2022;71:1669-83. [PMID: 35580963 DOI: 10.1136/gutjnl-2022-327099] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
182 Lertpanprom M, Silsirivanit A, Tippayawat P, Proungvitaya T, Roytrakul S, Proungvitaya S. High expression of protein tyrosine phosphatase receptor S (PTPRS) is an independent prognostic marker for cholangiocarcinoma. Front Public Health 2022;10:835914. [DOI: 10.3389/fpubh.2022.835914] [Reference Citation Analysis]
183 Zhang Y, Xu H, Cui G, Liang B, Chen X, Ko S, Affo S, Song X, Liao Y, Feng J, Wang P, Wang H, Xu M, Wang J, Pes GM, Ribback S, Zeng Y, Singhi A, Schwabe RF, Monga SP, Evert M, Tang L, Calvisi DF, Chen X. β-Catenin Sustains and Is Required for YES-associated Protein Oncogenic Activity in Cholangiocarcinoma. Gastroenterology 2022;163:481-94. [PMID: 35489428 DOI: 10.1053/j.gastro.2022.04.028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
184 Kodali S, Saharia A, Ghobrial RM. Liver transplantation and intrahepatic cholangiocarcinoma: time to go forward again? Curr Opin Organ Transplant 2022;27:320-8. [PMID: 36354258 DOI: 10.1097/MOT.0000000000000983] [Reference Citation Analysis]
185 Lee HS. Neoadjuvant and Adjuvant Chemotherapy for Cholangiocarcinoma. Korean J Pancreas Biliary Tract 2022;27:111-115. [DOI: 10.15279/kpba.2022.27.3.111] [Reference Citation Analysis]
186 Rizzo A, Carloni R, Ricci AD, Di Federico A, Guven DC, Yalcin S, Brandi G. Molecular Profile and Prognostic Value of BAP1 Mutations in Intrahepatic Cholangiocarcinoma: A Genomic Database Analysis. JPM 2022;12:1247. [DOI: 10.3390/jpm12081247] [Reference Citation Analysis]
187 Haag F, Manikkam A, Kraft D, Bär C, Wilke V, Nowak AJ, Bertrand J, Omari J, Pech M, Gylstorff S, Relja B. Selective Internal Radiotherapy Changes the Immune Profiles of Extracellular Vesicles and Their Immune Origin in Patients with Inoperable Cholangiocarcinoma. Cells 2022;11. [PMID: 35954154 DOI: 10.3390/cells11152309] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
188 Zhou T, Mahn R, Möhring C, Sadeghlar F, Meyer C, Toma M, Kreppel B, Essler M, Glowka T, Matthaei H, Kalff JC, Strassburg CP, Gonzalez-carmona MA. Case Report: Sustained complete remission on combination therapy with olaparib and pembrolizumab in BRCA2-mutated and PD-L1-positive metastatic cholangiocarcinoma after platinum derivate. Front Oncol 2022;12:933943. [DOI: 10.3389/fonc.2022.933943] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
189 Liu D, Heij LR, Czigany Z, Dahl E, Dulk MD, Lang SA, Ulmer TF, Neumann UP, Bednarsch J. The prognostic value of neutrophil-to-lymphocyte ratio in cholangiocarcinoma: a systematic review and meta-analysis. Sci Rep 2022;12:12691. [PMID: 35879385 DOI: 10.1038/s41598-022-16727-w] [Reference Citation Analysis]
190 Chiawpanit C, Panwong S, Sawasdee N, Yenchitsomanus P, Panya A. Genistein Sensitizes Human Cholangiocarcinoma Cell Lines to Be Susceptible to Natural Killer Cells. Biology 2022;11:1098. [DOI: 10.3390/biology11081098] [Reference Citation Analysis]
191 Chen R, Zhang Y, Lin K, Huang D, You M, Lai Y, Wang J, Hu Y, Li N. Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers. Front Pharmacol 2022;13:871262. [DOI: 10.3389/fphar.2022.871262] [Reference Citation Analysis]
192 Balasubramanian B, Venkatraman S, Myint KZ, Krobthong S, Wongtrakoongate P, Sripa J, Rattanasinganchan P, Metheenukul P, Tohtong R. In Silico Target Identification of Galangin, as an Herbal Flavonoid against Cholangiocarcinoma. Molecules 2022;27:4664. [DOI: 10.3390/molecules27144664] [Reference Citation Analysis]
193 Rizzo A, Carloni R, Frega G, Palloni A, Di Federico A, Ricci AD, De Luca R, Tavolari S, Brandi G. Intensive Follow-Up Program and Oncological Outcomes of Biliary Tract Cancer Patients after Curative-Intent Surgery: A Twenty-Year Experience in a Single Tertiary Medical Center. Current Oncology 2022;29:5084-5090. [DOI: 10.3390/curroncol29070402] [Reference Citation Analysis]
194 Da Fonseca LG, Hashizume PH, de Oliveira IS, Izquierdo-sanchez L, Saud LRDC, Xerfan MP, Alves VAF, de Mello ES, Herman P, Banales JM, Oliveira CP, Carrilho FJ. Association between Metabolic Disorders and Cholangiocarcinoma: Impact of a Postulated Risk Factor with Rising Incidence. Cancers 2022;14:3483. [DOI: 10.3390/cancers14143483] [Reference Citation Analysis]
195 Qin H, Yuan B, Huang W, Wang Y. Utilizing Gut Microbiota to Improve Hepatobiliary Tumor Treatments: Recent Advances. Front Oncol 2022;12:924696. [DOI: 10.3389/fonc.2022.924696] [Reference Citation Analysis]
196 Ayala-sierra EF, Muñoz-maya O, Guerrero-pérez F, Cardona-jaramillo M. Colangitis biliar primaria: caracterización de una cohorte retrospectiva. Hepatología 2022. [DOI: 10.52784/27112330.159] [Reference Citation Analysis]
197 Scott AJ, Sharman R, Shroff RT. Precision Medicine in Biliary Tract Cancer. J Clin Oncol 2022;:JCO2102576. [PMID: 35839428 DOI: 10.1200/JCO.21.02576] [Reference Citation Analysis]
198 Fernández-Palanca P, Payo-Serafín T, Fondevila F, Méndez-Blanco C, San-Miguel B, Romero MR, Tuñón MJ, Marin JJG, González-Gallego J, Mauriz JL. Neuropilin-1 as a Potential Biomarker of Prognosis and Invasive-Related Parameters in Liver and Colorectal Cancer: A Systematic Review and Meta-Analysis of Human Studies. Cancers (Basel) 2022;14:3455. [PMID: 35884516 DOI: 10.3390/cancers14143455] [Reference Citation Analysis]
199 Keilson JM, Lindsey S, Bachini M, Medin CR, Berk A, Cornew S, Maithel SK. Patient reported outcomes: Financial toxicity is a barrier to clinical trials and personalized therapy in cholangiocarcinoma. J Surg Oncol 2022. [PMID: 35839090 DOI: 10.1002/jso.27012] [Reference Citation Analysis]
200 Park M. Review of Mass-Forming Intrahepatic Cholangiocarcinoma. Korean J Abdom Radiol 2022;6:1-11. [DOI: 10.52668/kjar.2022.00150] [Reference Citation Analysis]
201 Song Y, Zhang Y, Zhen Z, Huang Z. Effects of portal vein resection and hepatic artery resection on long-term survival in Klatskin tumor: a meta-analysis. World J Surg Oncol 2022;20:230. [PMID: 35821140 DOI: 10.1186/s12957-022-02692-1] [Reference Citation Analysis]
202 Song Y, Cai M, Li Y, Liu S. The focus clinical research in intrahepatic cholangiocarcinoma. Eur J Med Res 2022;27:116. [PMID: 35820926 DOI: 10.1186/s40001-022-00741-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
203 Yang X, Sun Y, Li D, Xu G, Huang X. Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization Combining Immune Checkpoint Inhibitors in Unresectable Intrahepatic Cholangiocarcinoma: A Propensity Score Matching Analysis. Front Immunol 2022;13:940009. [DOI: 10.3389/fimmu.2022.940009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
204 Liu X, Jiang Y, Sun X, Zhao J, Zhang L, Jing X. Prognostic Significance of the Systemic Immune-Inflammation Index in Patients With Cholangiocarcinoma: A Meta-Analysis. Front Oncol 2022;12:938549. [DOI: 10.3389/fonc.2022.938549] [Reference Citation Analysis]
205 Elvevi A, Laffusa A, Scaravaglio M, Rossi RE, Longarini R, Stagno AM, Cristoferi L, Ciaccio A, Cortinovis DL, Invernizzi P, Massironi S. Clinical treatment of cholangiocarcinoma: an updated comprehensive review. Ann Hepatol 2022;27:100737. [PMID: 35809836 DOI: 10.1016/j.aohep.2022.100737] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
206 Zhang X, He Y, Ren P, Chen L, Han Z, Qi L, Chen L, Luo Y, Zhang N, Lu W, Guo H. Low expression and Hypermethylation of ATP2B1 in Intrahepatic Cholangiocarcinoma Correlated With Cold Tumor Microenvironment. Front Oncol 2022;12:927298. [DOI: 10.3389/fonc.2022.927298] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
207 Jantalika T, Manochantr S, Kheolamai P, Tantikanlayaporn D, Saijuntha W, Pinlaor S, Chairoungdua A, Paraoan L, Tantrawatpan C. Human chorion-derived mesenchymal stem cells suppress JAK2/STAT3 signaling and induce apoptosis of cholangiocarcinoma cell lines. Sci Rep 2022;12:11341. [PMID: 35790790 DOI: 10.1038/s41598-022-15298-0] [Reference Citation Analysis]
208 Lüdde T, Boulter L. Joining the dots - NEDDylation in cancer cells regulates the tumour environment in cholangiocarcinoma. J Hepatol 2022;77:12-4. [PMID: 35490843 DOI: 10.1016/j.jhep.2022.04.018] [Reference Citation Analysis]
209 Olaizola P, Lee-Law PY, Fernandez-Barrena MG, Alvarez L, Cadamuro M, Azkargorta M, O'Rourke CJ, Caballero-Camino FJ, Olaizola I, Macias RIR, Marin JJG, Serrano-Maciá M, Martinez-Chantar ML, Avila MA, Aspichueta P, Calvisi DF, Evert M, Fabris L, Castro RE, Elortza F, Andersen JB, Bujanda L, Rodrigues PM, Perugorria MJ, Banales JM. Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models. J Hepatol 2022;77:177-90. [PMID: 35217064 DOI: 10.1016/j.jhep.2022.02.007] [Reference Citation Analysis]
210 Katabathina VS, Khanna L, Surabhi VR, Minervini M, Shanbhogue K, Dasyam AK, Prasad SR. Morphomolecular Classification Update on Hepatocellular Adenoma, Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma. Radiographics 2022;:210106. [PMID: 35776676 DOI: 10.1148/rg.210206] [Reference Citation Analysis]
211 Guo H, Qian Y, Yu Y, Bi Y, Jiao J, Jiang H, Yu C, Wu H, Shi Y, Kong X. An Immunity-Related Gene Model Predicts Prognosis in Cholangiocarcinoma. Front Oncol 2022;12:791867. [DOI: 10.3389/fonc.2022.791867] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
212 Ruffolo LI, Jackson KM, Kuhlers PC, Dale BS, Figueroa Guilliani NM, Ullman NA, Burchard PR, Qin SS, Juviler PG, Keilson JM, Morrison AB, Georger M, Jewell R, Calvi LM, Nywening TM, O'Dell MR, Hezel AF, De Las Casas L, Lesinski GB, Yeh JJ, Hernandez-Alejandro R, Belt BA, Linehan DC. GM-CSF drives myelopoiesis, recruitment and polarisation of tumour-associated macrophages in cholangiocarcinoma and systemic blockade facilitates antitumour immunity. Gut 2022;71:1386-98. [PMID: 34413131 DOI: 10.1136/gutjnl-2021-324109] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
213 Lavie D, Ben-Shmuel A, Erez N, Scherz-Shouval R. Cancer-associated fibroblasts in the single-cell era. Nat Cancer 2022;3:793-807. [PMID: 35883004 DOI: 10.1038/s43018-022-00411-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
214 Yoon SB, Moon SH, Ko SW, Lim H, Kang HS, Kim JH. Brush Cytology, Forceps Biopsy, or Endoscopic Ultrasound-Guided Sampling for Diagnosis of Bile Duct Cancer: A Meta-Analysis. Dig Dis Sci 2022;67:3284-97. [PMID: 34263382 DOI: 10.1007/s10620-021-07138-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
215 Hamura R, Haruki K, Shirai Y, Tanji Y, Taniai T, Okui N, Furukawa K, Shiozaki H, Onda S, Ikegami T. Preoperative cachexia index can predict the prognosis of extrahepatic bile tract cancer after resection. Surgical Oncology 2022. [DOI: 10.1016/j.suronc.2022.101825] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
216 Morita S, Duda DG. Refining genetic and molecular classifications to facilitate breakthrough treatments in intrahepatic cholangiocarcinoma: are we there yet? Gut 2022:gutjnl-2022-327782. [PMID: 35772925 DOI: 10.1136/gutjnl-2022-327782] [Reference Citation Analysis]
217 Cadamuro M, Romanzi A, Guido M, Sarcognato S, Cillo U, Gringeri E, Zanus G, Strazzabosco M, Simioni P, Villa E, Fabris L. Translational Value of Tumor-Associated Lymphangiogenesis in Cholangiocarcinoma. JPM 2022;12:1086. [DOI: 10.3390/jpm12071086] [Reference Citation Analysis]
218 Brandi G, Straif K, Mandrioli D, Curti S, Mattioli S, Tavolari S. Exposure to Asbestos and Increased Intrahepatic Cholangiocarcinoma Risk: Growing Evidences of a Putative Causal Link. Ann Glob Health 2022;88:41. [PMID: 35755315 DOI: 10.5334/aogh.3660] [Reference Citation Analysis]
219 Gerber TS, Müller L, Bartsch F, Gröger L, Schindeldecker M, Ridder DA, Goeppert B, Möhler M, Dueber C, Lang H, Roth W, Kloeckner R, Straub BK. Integrative Analysis of Intrahepatic Cholangiocarcinoma Subtypes for Improved Patient Stratification: Clinical, Pathological, and Radiological Considerations. Cancers 2022;14:3156. [DOI: 10.3390/cancers14133156] [Reference Citation Analysis]
220 Lieshout R, Faria AVS, Peppelenbosch MP, van der Laan LJW, Verstegen MMA, Fuhler GM. Kinome profiling of cholangiocarcinoma organoids reveals potential druggable targets that hold promise for treatment stratification. Mol Med 2022;28:74. [PMID: 35764936 DOI: 10.1186/s10020-022-00498-1] [Reference Citation Analysis]
221 Midorikawa Y. Treatment of biliary tract carcinoma over the last 30 years. Biosci Trends 2022. [PMID: 35732436 DOI: 10.5582/bst.2022.01267] [Reference Citation Analysis]
222 Koustas E, Trifylli EM, Sarantis P, Papadopoulos N, Karapedi E, Aloizos G, Damaskos C, Garmpis N, Garmpi A, Papavassiliou KA, Karamouzis MV, Papavassiliou AG. Immunotherapy as a Therapeutic Strategy for Gastrointestinal Cancer-Current Treatment Options and Future Perspectives. Int J Mol Sci 2022;23:6664. [PMID: 35743107 DOI: 10.3390/ijms23126664] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
223 Liu Y, Yeh MM. Bile duct dysplasia and associated invasive carcinoma: clinicopathological features, diagnosis, and practical challenges. Hum Pathol 2022:S0046-8177(22)00157-5. [PMID: 35714833 DOI: 10.1016/j.humpath.2022.06.012] [Reference Citation Analysis]
224 Suppramote O, Prasopporn S, Aroonpruksakul S, Ponvilawan B, Makjaroen J, Suntiparpluacha M, Korphaisarn K, Charngkaew K, Chanwat R, Pisitkun T, Okada S, Sampattavanich S, Jirawatnotai S. The Acquired Vulnerability Caused by CDK4/6 Inhibition Promotes Drug Synergism Between Oxaliplatin and Palbociclib in Cholangiocarcinoma. Front Oncol 2022;12:877194. [PMID: 35664774 DOI: 10.3389/fonc.2022.877194] [Reference Citation Analysis]
225 Kunprom W, Aphivatanasiri C, Sa-Ngiamwibool P, Sangkhamanon S, Intarawichian P, Bamrungkit W, Thanee M, Prajumwongs P, Loilome W, Khuntikeo N, Titapun A, Jareanrat A, Thanasukarn V, Srisuk T, Luvira V, Eurboonyanun K, Promsorn J, Koonmee S. Prognostic Significance of Growth Pattern in Predicting Outcome of Opisthorchis viverrini-Associated Distal Cholangiocarcinoma in Thailand. Front Public Health 2022;10:816028. [PMID: 35651852 DOI: 10.3389/fpubh.2022.816028] [Reference Citation Analysis]
226 Zhang X, Huang WJ, Zhang ML, Wang W, Niu Y, Wang RT, Liu ZY. Utility of mean platelet volume in differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma. BMC Gastroenterol 2022;22:288. [PMID: 35668355 DOI: 10.1186/s12876-022-02348-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
227 Cigliano A, Zhang S, Ribback S, Steinmann S, Sini M, Ament CE, Utpatel K, Song X, Wang J, Pilo MG, Berger F, Wang H, Tao J, Li X, Pes GM, Mancarella S, Giannelli G, Dombrowski F, Evert M, Calvisi DF, Chen X, Evert K. The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease. J Exp Clin Cancer Res 2022;41:192. [PMID: 35655220 DOI: 10.1186/s13046-022-02394-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
228 Cheng C, Chen C, Wu C. Precision Medicine in Cholangiocarcinoma: Past, Present, and Future. Life 2022;12:829. [DOI: 10.3390/life12060829] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
229 Arechederra M, Rullán M, Amat I, Oyon D, Zabalza L, Elizalde M, Latasa MU, Mercado MR, Ruiz-Clavijo D, Saldaña C, Fernández-Urién I, Carrascosa J, Jusué V, Guerrero-Setas D, Zazpe C, González-Borja I, Sangro B, Herranz JM, Purroy A, Gil I, Nelson LJ, Vila JJ, Krawczyk M, Zieniewicz K, Patkowski W, Milkiewicz P, Cubero FJ, Alkorta-Aranburu G, G Fernandez-Barrena M, Urman JM, Berasain C, Avila MA. Next-generation sequencing of bile cell-free DNA for the early detection of patients with malignant biliary strictures. Gut 2022;71:1141-51. [PMID: 34285068 DOI: 10.1136/gutjnl-2021-325178] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 14.0] [Reference Citation Analysis]
230 Pham L, Kyritsi K, Zhou T, Ceci L, Baiocchi L, Kennedy L, Chakraborty S, Glaser S, Francis H, Alpini G, Sato K. The Functional Roles of Immune Cells in Primary Liver Cancer. Am J Pathol 2022;192:826-36. [PMID: 35337836 DOI: 10.1016/j.ajpath.2022.02.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
231 Cao J, Hu J, Shen J, Zhang B, Topatana W, Li S, Chen T, Jeungpanich S, Tian Y, Lu Z, Peng S, Cai X, Chen M. Identification of publication characteristics and research trends in the management of gallbladder cancer. iLIVER 2022;1:127-138. [DOI: 10.1016/j.iliver.2022.06.004] [Reference Citation Analysis]
232 Zhuravleva E, O'Rourke CJ, Andersen JB. Mutational signatures and processes in hepatobiliary cancers. Nat Rev Gastroenterol Hepatol 2022;19:367-82. [PMID: 35273358 DOI: 10.1038/s41575-022-00587-w] [Reference Citation Analysis]
233 Liddell SS, Chakrabarti S, Wintheiser GA, Zemla TJ, Shi Q, Tella SH, Jin Z, Wookey VB, Hassan H, Tran NH, Borad MJ, Mahipal A. Tumor Mutational Burden Is a Potential Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Advanced Biliary Tract Cancer. JCO Precis Oncol 2022;6:e2200003. [PMID: 35772047 DOI: 10.1200/PO.22.00003] [Reference Citation Analysis]
234 Sorin S, Kubota S, Hamidi S, Yokomizo‐nakano T, Vaeteewoottacharn K, Wongkham S, Waraasawapati S, Pairojkul C, Bai J, Morii M, Sheng G, Sawanyawisuth K, Sashida G. HMGN3 represses transcription of epithelial regulators to promote migration of cholangiocarcinoma in a SNAI2‐dependent manner. The FASEB Journal 2022;36. [DOI: 10.1096/fj.202200386r] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
235 Ma M, Zeng G, Li J, Liang J, Huang L, Chen J, Lai J. Expressional and prognostic value of HPCAL1 in cholangiocarcinoma via integrated bioinformatics analyses and experiments. Cancer Med 2023;12:824-36. [PMID: 35645147 DOI: 10.1002/cam4.4897] [Reference Citation Analysis]
236 Lachiondo-ortega S, Delgado TC, Baños-jaime B, Velázquez-cruz A, Díaz-moreno I, Martínez-chantar ML. Hu Antigen R (HuR) Protein Structure, Function and Regulation in Hepatobiliary Tumors. Cancers 2022;14:2666. [DOI: 10.3390/cancers14112666] [Reference Citation Analysis]
237 Cho SM, Esmail A, Raza A, Dacha S, Abdelrahim M. Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma. Cancers (Basel) 2022;14:2641. [PMID: 35681621 DOI: 10.3390/cancers14112641] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
238 Konishi D, Umeda Y, Yoshida K, Shigeyasu K, Yano S, Toji T, Takeda S, Yoshida R, Yasui K, Fuji T, Matsumoto K, Kishimoto H, Michiue H, Teraishi F, Kato H, Tazawa H, Yanai H, Yagi T, Goel A, Fujiwara T. Regulatory T cells induce a suppressive immune milieu and promote lymph node metastasis in intrahepatic cholangiocarcinoma. Br J Cancer 2022. [PMID: 35597869 DOI: 10.1038/s41416-022-01838-y] [Reference Citation Analysis]
239 Lu C, Miao J, Li M, Zheng Q, Xu F, Pan Y, Wang Y, Yang Z, Xia X, Zhu H, Chen J, Bao S. Characterization of the Estrogen Response Helps to Predict Prognosis and Identify Potential Therapeutic Targets in Cholangiocarcinoma. Front Oncol 2022;12:870840. [DOI: 10.3389/fonc.2022.870840] [Reference Citation Analysis]
240 Deenonpoe R, Sa-Ngiamwibool P, Watcharadetwittaya S, Thanee M, Intuyod K, Kongpan T, Padthaisong S, Nutalai R, Chamgramol Y, Pairojkul C. Fluorescence in situ hybridization detection of chromosome 7 and/or 17 polysomy as a prognostic marker for cholangiocarcinoma. Sci Rep 2022;12:8441. [PMID: 35589822 DOI: 10.1038/s41598-022-11945-8] [Reference Citation Analysis]
241 Martin-Serrano MA, Kepecs B, Torres-Martin M, Bramel ER, Haber PK, Merritt E, Rialdi A, Param NJ, Maeda M, Lindblad KE, Carter JK, Barcena-Varela M, Mazzaferro V, Schwartz M, Affo S, Schwabe RF, Villanueva A, Guccione E, Friedman SL, Lujambio A, Tocheva A, Llovet JM, Thung SN, Tsankov AM, Sia D. Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications. Gut 2022:gutjnl-2021-326514. [PMID: 35584893 DOI: 10.1136/gutjnl-2021-326514] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
242 Machida K, Tahara SM. Immunotherapy and Microbiota for Targeting of Liver Tumor-Initiating Stem-like Cells. Cancers (Basel) 2022;14:2381. [PMID: 35625986 DOI: 10.3390/cancers14102381] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
243 Supradit K, Boonsri B, Duangdara J, Thitiphatphuvanon T, Suriyonplengsaeng C, Kangsamaksin T, Janvilisri T, Tohtong R, Yacqub-Usman K, Grabowska AM, Bates DO, Wongprasert K. Inhibition of serine/arginine-rich protein kinase-1 (SRPK1) prevents cholangiocarcinoma cells induced angiogenesis. Toxicol In Vitro 2022;:105385. [PMID: 35568131 DOI: 10.1016/j.tiv.2022.105385] [Reference Citation Analysis]
244 Zhou T, Zhang Y, Chen Y, Shan J, Wang J, Wang Y, Chang J, Jiang W, Chen R, Wang Z, Shi X, Yu Y, Li C, Li X. ROBO1 p.E280* Loses the Inhibitory Effects on the Proliferation and Angiogenesis of Wild-Type ROBO1 in Cholangiocarcinoma by Interrupting SLIT2 Signal. Front Oncol 2022;12:879963. [DOI: 10.3389/fonc.2022.879963] [Reference Citation Analysis]
245 Caputo V, De Falco V, Ventriglia A, Famiglietti V, Martinelli E, Morgillo F, Martini G, Corte CMD, Ciardiello D, Poliero L, De Vita F, Orditura M, Fasano M, Franco R, Caraglia M, Avitabile A, Scalamogna R, Marchi B, Ciardiello F, Troiani T, Napolitano S. Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience. Ther Adv Med Oncol 2022;14:175883592210968. [DOI: 10.1177/17588359221096878] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
246 Depciuch J, Parlinska-Wojtan M, Rahmi Serin K, Bulut H, Ulukaya E, Tarhan N, Guleken Z. Differential of cholangiocarcinoma disease using Raman spectroscopy combined with multivariate analysis. Spectrochim Acta A Mol Biomol Spectrosc 2022;272:121006. [PMID: 35151168 DOI: 10.1016/j.saa.2022.121006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
247 Roos FJM, van Tienderen GS, Wu H, Bordeu I, Vinke D, Albarinos LM, Monfils K, Niesten S, Smits R, Willemse J, Rosmark O, Westergren-Thorsson G, Kunz DJ, de Wit M, French PJ, Vallier L, IJzermans JNM, Bartfai R, Marks H, Simons BD, van Royen ME, Verstegen MMA, van der Laan LJW. Human branching cholangiocyte organoids recapitulate functional bile duct formation. Cell Stem Cell 2022;29:776-794.e13. [PMID: 35523140 DOI: 10.1016/j.stem.2022.04.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
248 Jiang Q, Huang J, Zhang B, Li X, Chen X, Cui B, Li S, Guo G. Efficacy and Safety of Anti-PD1/PDL1 in Advanced Biliary Tract Cancer: A Systematic Review and Meta-Analysis. Front Immunol 2022;13:801909. [PMID: 35309350 DOI: 10.3389/fimmu.2022.801909] [Reference Citation Analysis]
249 Rogalska-Taranta M, Andersen JB. Involvement of Epigenomic Factors in Bile Duct Cancer. Semin Liver Dis 2022;42:202-11. [PMID: 35738258 DOI: 10.1055/s-0042-1748188] [Reference Citation Analysis]
250 Izquierdo-Sanchez L, Lamarca A, La Casta A, Buettner S, Utpatel K, Klümpen HJ, Adeva J, Vogel A, Lleo A, Fabris L, Ponz-Sarvise M, Brustia R, Cardinale V, Braconi C, Vidili G, Jamieson NB, Macias RI, Jonas JP, Marzioni M, Hołówko W, Folseraas T, Kupčinskas J, Sparchez Z, Krawczyk M, Krupa Ł, Scripcariu V, Grazi GL, Landa-Magdalena A, Ijzermans JN, Evert K, Erdmann JI, López-López F, Saborowski A, Scheiter A, Santos-Laso A, Carpino G, Andersen JB, Marin JJ, Alvaro D, Bujanda L, Forner A, Valle JW, Koerkamp BG, Banales JM. Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. J Hepatol 2022;76:1109-21. [PMID: 35167909 DOI: 10.1016/j.jhep.2021.12.010] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 19.0] [Reference Citation Analysis]
251 Zimmer CL, Filipovic I, Cornillet M, O'Rourke CJ, Berglin L, Jansson H, Sun D, Strauss O, Hertwig L, Johansson H, von Seth E, Sparrelid E, Dias J, Glaumann H, Melum E, Ellis EC, Sandberg JK, Andersen JB, Bergquist A, Björkström NK. Mucosal-associated invariant T-cell tumor infiltration predicts long-term survival in cholangiocarcinoma. Hepatology 2022;75:1154-68. [PMID: 34719787 DOI: 10.1002/hep.32222] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
252 Faria LL, Darce GF, Bordini AL, Herman P, Jeismann VB, de Oliveira IS, Ortega CD, Rocha MS. Liver Surgery: Important Considerations for Pre- and Postoperative Imaging. Radiographics 2022;42:722-40. [PMID: 35363553 DOI: 10.1148/rg.210124] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
253 Casolino R, Braconi C, Prete M, González Romero F, Castro R, Banales J, Cardinale V, Morement H, Milne J, Krawczyk M, Krupa L, Anwar M, Poles E, Merz V, Perra T, Porcu A, Megdanova V, Popova Y, Meneses-medina M, Reyes Mondragón A, Burguete-torres A, Brandão Rego I, Magalhães J, Liz Pimenta J, Silva J, João Sousa M, Custódio S, Costa T, Cojocaru F, Drug V, Hassan S, Ain Azam N, Kupcinskas J, Kreivenaite E, Morkunas E, Nikolaieva O, Calvisi D, Evert M, Terhuja N, Das A, Hoang K, Nguyen H, Evseev V, Khuntikeo N, Abdihamid O, Mariamidze E, Tsiklauri K, Koyyala V, Medisetty P, Digumarti L, Digumarti R, Konkalla V, Mitra S, Sud R, Parikh P, Gupta S, Sen S, Chanda S, das D, Domadia K, Goyal P, Goyal S, Dhamne N, Acharya P, Jain P, Sharma M, War G, Singh S, Dodagoudar C, Patnaik R, Mashahary S, Paul R, Kannan T, Goel V, Patnaik N, Jajodia A, Pasricha S, Gupta M, Agarwal C, Mondal D, Bp A, Joga S, Mullapally S, Choudhary P, Saini R, Selvaraju T, Pahwa S, Durga G, Maheshwari U, Dhaka S, Lindsay S, Omar A, La Casta Muñoa A. Bridging the equity gap in patient education: the biliary tract cancer BABEL project. The Lancet Oncology 2022;23:568-70. [DOI: 10.1016/s1470-2045(22)00143-7] [Reference Citation Analysis]
254 Wu MJ, Shi L, Merritt J, Zhu AX, Bardeesy N. Biology of IDH mutant cholangiocarcinoma. Hepatology 2022;75:1322-37. [PMID: 35226770 DOI: 10.1002/hep.32424] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
255 Losurdo G, Gravina AG, Maroni L, Gabrieletto EM, Ianiro G, Ferrarese A; Young Investigator group of SIGE, the Italian Society of Gastroenterology. Future challenges in gastroenterology and hepatology, between innovations and unmet needs: A SIGE Young Editorial Board's perspective. Dig Liver Dis 2022;54:583-97. [PMID: 34509394 DOI: 10.1016/j.dld.2021.08.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
256 Trifylli E, Koustas E, Papadopoulos N, Sarantis P, Aloizos G, Damaskos C, Garmpis N, Garmpi A, Karamouzis MV. An Insight into the Novel Immunotherapy and Targeted Therapeutic Strategies for Hepatocellular Carcinoma and Cholangiocarcinoma. Life 2022;12:665. [DOI: 10.3390/life12050665] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
257 Hewitt DB, Brown ZJ, Pawlik TM. Current Perspectives on the Surgical Management of Perihilar Cholangiocarcinoma. Cancers (Basel) 2022;14:2208. [PMID: 35565335 DOI: 10.3390/cancers14092208] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
258 Li H, Liu R, Li J, Li J, Wu H, Wang G, Li Z, Li D. Prognostic significance of gamma-glutamyl transpeptidase to albumin ratio in patients with intrahepatic cholangiocarcinoma after hepatectomy. J Cell Mol Med 2022. [PMID: 35481993 DOI: 10.1111/jcmm.17321] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
259 Tan X, Bednarsch J, Rosin M, Appinger S, Liu D, Wiltberger G, Garcia Vallejo J, Lang SA, Czigany Z, Boroojerdi S, Gaisa NT, Boor P, Bülow RD, De Vos-Geelen J, Valkenburg-van Iersel L, Clahsen-van Groningen MC, de Jong EJM, Groot Koerkamp B, Doukas M, Rocha FG, Luedde T, Klinge U, Sivakumar S, Neumann UP, Heij LR. PD-1+ T-Cells Correlate with Nerve Fiber Density as a Prognostic Biomarker in Patients with Resected Perihilar Cholangiocarcinoma. Cancers (Basel) 2022;14:2190. [PMID: 35565318 DOI: 10.3390/cancers14092190] [Reference Citation Analysis]
260 Wu Y, Hayat K, Hu Y, Yang J. Long Non-Coding RNAs as Molecular Biomarkers in Cholangiocarcinoma. Front Cell Dev Biol 2022;10:890605. [DOI: 10.3389/fcell.2022.890605] [Reference Citation Analysis]
261 Carotenuto M, Sacco A, Forgione L, Normanno N. Genomic alterations in cholangiocarcinoma: clinical significance and relevance to therapy. Exploration of Targeted Anti-tumor Therapy. [DOI: 10.37349/etat.2022.00079] [Reference Citation Analysis]
262 Miyabe K, Chandrasekhara V, Wongjarupong N, Chen J, Yang L, Johnson S, Chia N, Walther-antonio M, Yao JZ, Harrington SC, Nordyke CK, Eaton JE, Gossard AA, Oli S, Ali HA, Lavu S, Giama NH, Hassan FA, Ali HM, Enders FT, Ilyas SH, Gores GJ, Topazian MD, Kashyap PC, Roberts LR. Potential Role of Inflammation-Promoting Biliary Microbiome in Primary Sclerosing Cholangitis and Cholangiocarcinoma. Cancers 2022;14:2120. [DOI: 10.3390/cancers14092120] [Reference Citation Analysis]
263 Quan B, Li M, Lu S, Li J, Liu W, Zhang F, Chen R, Ren Z, Yin X. Predicting Disease-Specific Survival for Patients With Primary Cholangiocarcinoma Undergoing Curative Resection by Using a Decision Tree Model. Front Oncol 2022;12:824541. [DOI: 10.3389/fonc.2022.824541] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
264 Parsons M, Lloyd S, Johnson S, Scaife C, Soares H, Kim R, Kim R, Garrido-Laguna I, Tao R. The Implications of Treatment Delays in Adjuvant Therapy for Resected Cholangiocarcinoma Patients. J Gastrointest Cancer 2022. [PMID: 35445343 DOI: 10.1007/s12029-022-00820-4] [Reference Citation Analysis]
265 Moon H, Park H, Chae MJ, Choi HJ, Kim DY, Ro SW. Activated TAZ induces liver cancer in collaboration with EGFR/HER2 signaling pathways. BMC Cancer 2022;22:423. [PMID: 35439973 DOI: 10.1186/s12885-022-09516-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
266 Hamura R, Haruki K, Taniai T, Yanagaki M, Shirai Y, Furukawa K, Usuba T, Fujioka S, Okamoto T, Nakabayashi Y, Uwagawa T, Ikegami T. The impact of S-1 for the patient with lymph nodal metastasis biliary tract cancer as adjuvant chemotherapy: a multicenter database analysis. Int J Clin Oncol. [DOI: 10.1007/s10147-022-02165-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
267 Lee Y, Oh SY, Kim KM, Go S, Kim JH, Huh SJ, Kang JH, Ji JH. Modified FOLFIRINOX as a Second-Line Treatment for Patients with Gemcitabine-Failed Advanced Biliary Tract Cancer: A Prospective Multicenter Phase II Study. Cancers 2022;14:1950. [DOI: 10.3390/cancers14081950] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
268 Wathikthinnakon M, Luangwattananun P, Sawasdee N, Chiawpanit C, Lee VS, Nimmanpipug P, Tragoolpua Y, Rotarayanont S, Sangsuwannukul T, Phanthaphol N, Wutti-In Y, Somboonpatarakun C, Chieochansin T, Junking M, Sujjitjoon J, Yenchitsomanus PT, Panya A. Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells. Sci Rep 2022;12:6154. [PMID: 35418130 DOI: 10.1038/s41598-022-09964-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
269 De B, Tran Cao HS, Vauthey JN, Manzar GS, Corrigan KL, Raghav KPS, Lee SS, Tzeng CD, Minsky BD, Smith GL, Holliday EB, Taniguchi CM, Koong AC, Das P, Javle M, Ludmir EB, Koay EJ. Ablative liver radiotherapy for unresected intrahepatic cholangiocarcinoma: Patterns of care and survival in the United States. Cancer 2022. [PMID: 35417569 DOI: 10.1002/cncr.34223] [Reference Citation Analysis]
270 Aung TM, Ciin MN, Silsirivanit A, Jusakul A, Lert-Itthiporn W, Proungvitaya T, Roytrakul S, Proungvitaya S. Serum Angiopoietin-Like Protein 4: A Potential Prognostic Biomarker for Prediction of Vascular Invasion and Lymph Node Metastasis in Cholangiocarcinoma Patients. Front Public Health 2022;10:836985. [PMID: 35392474 DOI: 10.3389/fpubh.2022.836985] [Reference Citation Analysis]
271 Lee DH, Kim B, Lee JM, Lee ES, Choi MH, Kim H. Multidetector CT of Extrahepatic Bile Duct Cancer: Diagnostic Performance of Tumor Resectability and Interreader Agreement. Radiology 2022;:212132. [PMID: 35412364 DOI: 10.1148/radiol.212132] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
272 Park H, Park H, Baek J, Moon H, Ro SW. Target Therapy for Hepatocellular Carcinoma: Beyond Receptor Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors. Biology 2022;11:585. [DOI: 10.3390/biology11040585] [Reference Citation Analysis]
273 Liu C, Li Y, Zhang L, Zhang P, Yu N, Liu X, Lu H, Du H, Hou S, Kang Z. MiRNA-196-5p Promotes Proliferation and Migration in Cholangiocarcinoma via HAND1/Wnt/β-Catenin Signaling Pathway. Journal of Oncology 2022;2022:1-10. [DOI: 10.1155/2022/4599676] [Reference Citation Analysis]
274 Wang J, Qiu Y, Yang Y, Shen S, Zhi M, Zhang B, Wang W. Impact of cirrhosis on long-term survival outcomes of patients with intrahepatic cholangiocarcinoma. Cancer Med 2022. [PMID: 35415945 DOI: 10.1002/cam4.4740] [Reference Citation Analysis]
275 Khankhel ZS, Goring S, Bobiak S, Lamy FX, Nayak D, Garside J, Reese ES, Schoenherr N. Second-line treatments in advanced biliary tract cancer: systematic literature review of efficacy, effectiveness and safety. Future Oncol 2022. [PMID: 35387496 DOI: 10.2217/fon-2021-1302] [Reference Citation Analysis]
276 Kinzler MN, Klasen C, Schulze F, Herrmann E, Schnitzbauer AA, Trojan J, Zeuzem S, Wild PJ, Walter D. Impact of Liver Fibrosis on Survival of Patients with Intrahepatic Cholangiocarcinoma Receiving Gemcitabine-Based Chemotherapy. J Clin Med 2022;11:2057. [PMID: 35407665 DOI: 10.3390/jcm11072057] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
277 Jegatheeswaran S, Stathakis P, Spiers HVM, Mohammed F, Petras P, Satyadas T, Parker MJ, Lamarca A, Jamdar S, Sheen AJ, Siriwardena AK. Work-Up and Outcome of Hepatic Resection for Peri-Hilar Cholangiocarcinoma (PH-CCA) without Staging Laparoscopy. Cancers (Basel) 2022;14:1841. [PMID: 35406612 DOI: 10.3390/cancers14071841] [Reference Citation Analysis]
278 Vaghiri S, Alaghmand Nejad S, Kasprowski L, Prassas D, Safi SA, Schimmöller L, Krieg A, Rehders A, Lehwald-Tywuschik N, Knoefel WT. A single center comparative retrospective study of in situ split plus portal vein ligation versus conventional two-stage hepatectomy for cholangiocellular carcinoma. Acta Chir Belg 2022;:1-12. [PMID: 35317718 DOI: 10.1080/00015458.2022.2056680] [Reference Citation Analysis]
279 Han SY, Kim DU, Nam HS, Kang DH, Jang SI, Lee DK, Shin DW, Cho KB, Yang MJ, Hwang JC, Kim JH, So H, Bang SJ, Sung MJ, Kwon C, Lee DW, Cho C, Cho JH. Comparison of the Malignant Predictors in Intrahepatic and Extrahepatic Intraductal Papillary Neoplasm of the Bile Duct. JCM 2022;11:1985. [DOI: 10.3390/jcm11071985] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
280 Kodama T, Takehara T. Reply. Hepatology 2022;75:1058. [PMID: 34927750 DOI: 10.1002/hep.32292] [Reference Citation Analysis]
281 Vogel A, Saborowski A. Aktuelle Systemtherapie für fortgeschrittene biliäre Tumoren. Onkologe 2022;28:287-298. [DOI: 10.1007/s00761-022-01115-w] [Reference Citation Analysis]
282 Rizzo A, Cusmai A, Ricci AD, Brandi G, Palmiotti G. Combination systemic therapies with immune checkpoint inhibitors in biliary tract cancer: effective but not enough? Expert Rev Gastroenterol Hepatol 2022;16:307-10. [PMID: 35302426 DOI: 10.1080/17474124.2022.2055548] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
283 Xu L, Yang W, Che J, Li D, Wang H, Li Y, Zhou W. Suppression of histone deacetylase 1 by JSL-1 attenuates the progression and metastasis of cholangiocarcinoma via the TPX2/Snail axis. Cell Death Dis 2022;13:324. [DOI: 10.1038/s41419-022-04571-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
284 Parama D, Girisa S, Khatoon E, Kumar A, Alqahtani MS, Abbas M, Sethi G, Kunnumakkara AB. An Overview of the Pharmacological Activities of Scopoletin against Different Chronic Diseases. Pharmacological Research 2022. [DOI: 10.1016/j.phrs.2022.106202] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
285 Chung T, Park YN. Up-to-Date Pathologic Classification and Molecular Characteristics of Intrahepatic Cholangiocarcinoma. Front Med 2022;9:857140. [DOI: 10.3389/fmed.2022.857140] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
286 Lee J, Lee J, Sim W, Kim JH. Soluble TGFBI aggravates the malignancy of cholangiocarcinoma through activation of the ITGB1 dependent PPARγ signalling pathway. Cell Oncol (Dordr) 2022. [PMID: 35357655 DOI: 10.1007/s13402-022-00668-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
287 Gray S, Lamarca A, Edeline J, Klümpen H, Hubner RA, Mcnamara MG, Valle JW. Targeted Therapies for Perihilar Cholangiocarcinoma. Cancers 2022;14:1789. [DOI: 10.3390/cancers14071789] [Reference Citation Analysis]
288 Nguyen TK, Nguyen HH, Luong TH, Le VK, Dang KK, Le VD. Right hepatic trisectionectomy combined total caudate lobectomy with non-touch technique for advanced hilar cholangiocarcinoma: A surgical case report (with video). Int J Surg Case Rep 2022;94:106987. [PMID: 35405510 DOI: 10.1016/j.ijscr.2022.106987] [Reference Citation Analysis]
289 Troncone E, Gadaleta F, Paoluzi OA, Gesuale CM, Formica V, Morelli C, Roselli M, Savino L, Palmieri G, Monteleone G, Del Vecchio Blanco G. Endoscopic Ultrasound Plus Endoscopic Retrograde Cholangiopancreatography Based Tissue Sampling for Diagnosis of Proximal and Distal Biliary Stenosis Due to Cholangiocarcinoma: Results from a Retrospective Single-Center Study. Cancers (Basel) 2022;14:1730. [PMID: 35406502 DOI: 10.3390/cancers14071730] [Reference Citation Analysis]
290 Kang S, El-Rayes BF, Akce M. Evolving Role of Immunotherapy in Advanced Biliary Tract Cancers. Cancers (Basel) 2022;14:1748. [PMID: 35406520 DOI: 10.3390/cancers14071748] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
291 Fiz F, Jayakody Arachchige VS, Gionso M, Pecorella I, Selvam A, Wheeler DR, Sollini M, Viganò L. Radiomics of Biliary Tumors: A Systematic Review of Current Evidence. Diagnostics (Basel) 2022;12:826. [PMID: 35453878 DOI: 10.3390/diagnostics12040826] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
292 Song G, Shi Y, Meng L, Ma J, Huang S, Zhang J, Wu Y, Li J, Lin Y, Yang S, Rao D, Cheng Y, Lin J, Ji S, Liu Y, Jiang S, Wang X, Zhang S, Ke A, Wang X, Cao Y, Ji Y, Zhou J, Fan J, Zhang X, Xi R, Gao Q. Single-cell transcriptomic analysis suggests two molecularly subtypes of intrahepatic cholangiocarcinoma. Nat Commun 2022;13:1642. [PMID: 35347134 DOI: 10.1038/s41467-022-29164-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
293 Bai Y, Chen J, Hu W, Wang L, Wu Y, Yu S. Silibinin Therapy Improves Cholangiocarcinoma Outcomes by Regulating ERK/Mitochondrial Pathway. Front Pharmacol 2022;13:847905. [DOI: 10.3389/fphar.2022.847905] [Reference Citation Analysis]
294 Bridgewater J, Fletcher P, Palmer DH, Malik HZ, Prasad R, Mirza D, Anthony A, Corrie P, Falk S, Finch-jones M, Wasan H, Ross P, Wall L, Wadsley J, Evans TR, Stocken D, Stubbs C, Praseedom R, Ma YT, Davidson B, Neoptolemos J, Iveson T, Cunningham D, Garden OJ, Valle JW, Primrose J; on behalf of the BILCAP study group. Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study. JCO. [DOI: 10.1200/jco.21.02568] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
295 Sangsuwannukul T, Supimon K, Chieochansin T, Choomee K, Sujjitjoon J, Junking M, Yenchitsomanus P. Antitumor activity of T cells secreting αCD133-αCD3 bispecific T-cell engager against cholangiocarcinoma. PLoS ONE 2022;17:e0265773. [DOI: 10.1371/journal.pone.0265773] [Reference Citation Analysis]
296 Gao Z, Chen J, Li X, Shi Y, Tang Z, Liu W, Zhang X, Huang A, Luo X, Gao Q, Shi G, Ke A, Zhou J, Fan J, Fu X, Ding Z. KRAS acting through ERK signaling stabilizes PD-L1 via inhibiting autophagy pathway in intrahepatic cholangiocarcinoma. Cancer Cell Int 2022;22. [DOI: 10.1186/s12935-022-02550-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
297 Rizzo A, Brandi G. FGFR Inhibitors in Cholangiocarcinoma: A Real-World Experience at a Tertiary Center. JCO Precis Oncol 2022;6:e2100511. [PMID: 35294226 DOI: 10.1200/PO.21.00511] [Reference Citation Analysis]
298 Holster JJ, El Hassnaoui M, Franssen S, IJzermans JNM, de Jonge J, Mostert B, Polak WG, de Wilde RF, Homs MYV, Groot Koerkamp B. Hepatic Arterial Infusion Pump Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis. Ann Surg Oncol 2022. [PMID: 35294656 DOI: 10.1245/s10434-022-11439-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
299 Khosla D, Zaheer S, Gupta R, Madan R, Goyal S, Kumar N, Kapoor R. Role of intraluminal brachytherapy in palliation of biliary obstruction in cholangiocarcinoma: A brief review. World J Gastrointest Endosc 2022; 14(3): 106-112 [DOI: 10.4253/wjge.v14.i3.106] [Reference Citation Analysis]
300 Zhang G, Liu X, Jian A, Zheng K, Wang H, Hao J, Zhi S, Zhang X. CHST4 might promote the malignancy of cholangiocarcinoma. PLoS ONE 2022;17:e0265069. [DOI: 10.1371/journal.pone.0265069] [Reference Citation Analysis]
301 Deng M, Li S, Wang Q, Zhao R, Zou J, Lin W, Mei J, Wei W, Guo R. Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapy. Ann Med 2022;54:803-11. [PMID: 35272564 DOI: 10.1080/07853890.2022.2048416] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
302 Ceci L, Zhou T, Lenci I, Meadows V, Kennedy L, Li P, Ekser B, Milana M, Zhang W, Wu C, Sato K, Chakraborty S, Glaser SS, Francis H, Alpini G, Baiocchi L. Molecular Mechanisms Linking Risk Factors to Cholangiocarcinoma Development. Cancers 2022;14:1442. [DOI: 10.3390/cancers14061442] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
303 Ji G, Jiao C, Xu Z, Li X, Wang K, Wang X. Development and validation of a gradient boosting machine to predict prognosis after liver resection for intrahepatic cholangiocarcinoma. BMC Cancer 2022;22. [DOI: 10.1186/s12885-022-09352-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
304 Zhu J, Zhang Y, Chen X, Bian Y, Li J, Wang K. The Emerging Roles of LINC00665 in Human Cancers. Front Cell Dev Biol 2022;10:839177. [DOI: 10.3389/fcell.2022.839177] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
305 Puttalingaiah RT. Role of Swiprosin-1/EFHD2 as a biomarker in the development of chronic diseases. Life Sci 2022;:120462. [PMID: 35276221 DOI: 10.1016/j.lfs.2022.120462] [Reference Citation Analysis]
306 Alvisi G, Termanini A, Soldani C, Portale F, Carriero R, Pilipow K, Polidoro M, Franceschini B, Malenica I, Puccio S, Lise V, Galletti G, Zanon V, Colombo FS, Tufano M, Aghemo A, Di Tommaso L, Peano C, Cibella J, Iannacone M, Roychoudhuri R, Donadon M, Torzilli G, Kunderfranco P, Di Mitri D, Lugli E, Lleo A. Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target.. [DOI: 10.1101/2022.03.06.483155] [Reference Citation Analysis]
307 Zhao K, Li X, Shi Y, Lu Y, Qiu P, Deng Z, Yao W, Wang J. Exosomes in the tumor microenvironment of cholangiocarcinoma: current status and future perspectives. J Transl Med 2022;20. [DOI: 10.1186/s12967-022-03294-x] [Reference Citation Analysis]
308 Wang Y, Yang X, Wang D, Yang X, Wang Y, Long J, Zhou J, Lu Z, Mao Y, Sang X, Guan M, Zhao H. Lenvatinib Beyond First-Line Therapy in Patients With Advanced Biliary Tract Carcinoma. Front Oncol 2022;12:785535. [DOI: 10.3389/fonc.2022.785535] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
309 Gradilone S, Brunetti-Pierri N, Piccolo P. Cholangiopathies and the noncoding revolution. Curr Opin Gastroenterol 2022;38:128-35. [PMID: 35098934 DOI: 10.1097/MOG.0000000000000806] [Reference Citation Analysis]
310 Ding GY, Ma JQ, Yun JP, Chen X, Ling Y, Zhang S, Shi JY, Chang YQ, Ji Y, Wang XY, Tan WM, Yuan KF, Yan B, Zhang XM, Liang F, Zhou J, Fan J, Zeng Y, Cai MY, Gao Q. Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma. J Hepatol 2022;76:608-18. [PMID: 34793865 DOI: 10.1016/j.jhep.2021.10.030] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 21.0] [Reference Citation Analysis]
311 Rizzo A, Cusmai A, Giovannelli F, Acquafredda S, Rinaldi L, Misino A, Palmiotti G. Fluoropyrimidine-based doublet chemotherapy as second-line treatment for advanced biliary tract cancer: a meta-analysis of ABC-06 and NIFTY. Expert Rev Gastroenterol Hepatol 2022;16:273-8. [PMID: 35220866 DOI: 10.1080/17474124.2022.2047651] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
312 Rizzo A, Cusmai A, Palmiotti G. Second-line fluoropyrimidine-based doublet chemotherapy for advanced biliary tract cancer: a new standard of care? Expert Rev Gastroenterol Hepatol 2022;16:201-3. [PMID: 35220859 DOI: 10.1080/17474124.2022.2047652] [Reference Citation Analysis]
313 Paul B, Lewinska M, Andersen JB. Lipid alterations in chronic liver disease and liver cancer. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100479] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
314 Thol F, Gairing SJ, Czauderna C, Thomaidis T, Gamstätter T, Huber Y, Vollmar J, Lorenz J, Michel M, Bartsch F, Müller L, Kloeckner R, Galle PR, Wörns M, Marquardt JU, Moehler M, Weinmann A, Foerster F. Outcomes in patients receiving palliative chemotherapy for advanced biliary tract cancer. JHEP Reports 2022;4:100417. [DOI: 10.1016/j.jhepr.2021.100417] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
315 Cariello M, Gadaleta RM, Moschetta A. The gut-liver axis in cholangiopathies: focus on bile acid based pharmacological treatment. Curr Opin Gastroenterol 2022;38:136-43. [PMID: 35034082 DOI: 10.1097/MOG.0000000000000807] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
316 Chiow SM, Khoo HW, Low JK, Tan CH, Low HM. Imaging mimickers of cholangiocarcinoma: a pictorial review. Abdom Radiol (NY) 2022;47:981-97. [PMID: 34978593 DOI: 10.1007/s00261-021-03399-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
317 Desjonqueres E, Campani C, Marra F, Zucman-Rossi J, Nault JC. Preneoplastic lesions in the liver: Molecular insights and relevance for clinical practice. Liver Int 2022;42:492-506. [PMID: 34982503 DOI: 10.1111/liv.15152] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
318 Chueakwon P, Jatooratthawichot P, Talabnin K, Ketudat Cairns JR, Talabnin C. Inhibition of Ceramide Glycosylation Enhances Cisplatin Sensitivity in Cholangiocarcinoma by Limiting the Activation of the ERK Signaling Pathway. Life 2022;12:351. [DOI: 10.3390/life12030351] [Reference Citation Analysis]
319 Rehman O, Sackfield B, Thoguluva Chandrasekar V, Oliver J, Aswath G. A Case Report of CHEK2 and MUTYH Germline Mutations Associated With Cholangiocarcinoma in a Young Patient. Cureus 2022. [DOI: 10.7759/cureus.22631] [Reference Citation Analysis]
320 Pylypchuk IV, Suo H, Chucheepchuenkamol C, Jedicke N, Lindén PA, Lindström ME, Manns MP, Sevastyanova O, Yevsa T. High-Molecular-Weight Fractions of Spruce and Eucalyptus Lignin as a Perspective Nanoparticle-Based Platform for a Therapy Delivery in Liver Cancer. Front Bioeng Biotechnol 2021;9:817768. [PMID: 35198551 DOI: 10.3389/fbioe.2021.817768] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
321 Park MS, Rhee H. Editorial for "Multiparametric MRI-Based Radiomic Signature for Preoperative Evaluation of Overall Survival in Intrahepatic Cholangiocarcinoma After Partial Hepatectomy". J Magn Reson Imaging 2022. [PMID: 35218112 DOI: 10.1002/jmri.28130] [Reference Citation Analysis]
322 Lin J, Yan L, Wang X, Wu Z, Ke K, Lin X, Huang N, Yang W, Xia C. Administration of Iodine-125 Seeds Promotes Apoptosis in Cholangiocarcinoma through the PI3K/Akt Pathway. Advances in Polymer Technology 2022;2022:1-6. [DOI: 10.1155/2022/6934934] [Reference Citation Analysis]
323 Li H, Qu L, Yang Y, Zhang H, Li X, Zhang X. Single-cell Transcriptomic Architecture Unraveling the Complexity of Tumor Heterogeneity in Distal Cholangiocarcinoma. Cell Mol Gastroenterol Hepatol 2022;13:1592-1609.e9. [PMID: 35219893 DOI: 10.1016/j.jcmgh.2022.02.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
324 Ploeger C, Schreck J, Huth T, Fraas A, Albrecht T, Charbel A, Ji J, Singer S, Breuhahn K, Pusch S, Köhler BC, Springfeld C, Schirmacher P, Mehrabi A, Goeppert B, Roessler S. STAT1 and STAT3 Exhibit a Crosstalk and Are Associated with Increased Inflammation in Hepatocellular Carcinoma. Cancers (Basel) 2022;14:1154. [PMID: 35267462 DOI: 10.3390/cancers14051154] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
325 Oliviero B, Varchetta S, Mele D, Pessino G, Maiello R, Falleni M, Tosi D, Donadon M, Soldani C, Franceschini B, Torzilli G, Piccolo G, Barabino M, Opocher E, Maestri M, Bernuzzi S, Wucherpfennig KW, Mondelli MU, Mantovani S. MICA/B-targeted antibody promotes NK cell-driven tumor immunity in patients with intrahepatic cholangiocarcinoma. Oncoimmunology 2022;11:2035919. [PMID: 35223192 DOI: 10.1080/2162402X.2022.2035919] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
326 Pavicevic S, Reichelt S, Uluk D, Lurje I, Engelmann C, Modest DP, Pelzer U, Krenzien F, Raschzok N, Benzing C, Sauer IM, Stinzing S, Tacke F, Schöning W, Schmelzle M, Pratschke J, Lurje G. Prognostic and Predictive Molecular Markers in Cholangiocarcinoma. Cancers 2022;14:1026. [DOI: 10.3390/cancers14041026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
327 Massa A, Peraldo-neia C, Vita F, Varamo C, Basiricò M, Raggi C, Bernabei P, Erriquez J, Sarotto I, Leone F, Marchiò S, Cavalloni G, Aglietta M. Paclitaxel Restores Sensitivity to Chemotherapy in Preclinical Models of Multidrug-Resistant Intrahepatic Cholangiocarcinoma. Front Oncol 2022;12:771418. [DOI: 10.3389/fonc.2022.771418] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
328 Lefler DS, Tierno MB, Bashir B. Partial treatment response to capmatinib in MET -amplified metastatic intrahepatic cholangiocarcinoma: case report & review of literature. Cancer Biology & Therapy 2022;23:112-6. [DOI: 10.1080/15384047.2022.2029128] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
329 Chakrabarti S, Finnes HD, Mahipal A. Fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma: current status, insight on resistance mechanisms and toxicity management. Expert Opinion on Drug Metabolism & Toxicology. [DOI: 10.1080/17425255.2022.2039118] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
330 Tanaka T, Noguchi S, Wada Y, Nishida H, Akiyoshi H. Computed tomography findings in canine cholangiocellular carcinoma. Vet Record Case Reports. [DOI: 10.1002/vrc2.303] [Reference Citation Analysis]
331 Kim SR, Won HS, Yang JH, Sun S, Yim K, Hong M, Hong SA, Yoon JS, Chun SH, Kim KH, Ko YH. Prognostic value of Dickkopf-1 and ß-catenin expression according to the antitumor immunity of CD8-positive tumor-infiltrating lymphocytes in biliary tract cancer. Sci Rep 2022;12:1931. [PMID: 35121803 DOI: 10.1038/s41598-022-05914-4] [Reference Citation Analysis]
332 Cadamuro M, Macias RI, Strain AJ, Strazzabosco M, Simioni P, Marin JJ, Fabris L. Unmet needs in basic and translational research in Cholangiocarcinoma. Liver Cancer International 2022;3:5-16. [DOI: 10.1002/lci2.39] [Reference Citation Analysis]
333 Casadio M, Cardinale V, Klümpen H, Morement H, Lacasta A, Koerkamp B, Banales J, Alvaro D, Valle J, Lamarca A. Setup of multidisciplinary team discussions for patients with cholangiocarcinoma: current practice and recommendations from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). ESMO Open 2022;7:100377. [DOI: 10.1016/j.esmoop.2021.100377] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
334 Rizzo A, Ricci AD, Brandi G. Bile cell‑free DNA: a game changer for management of biliary tract cancer? ESMO Open 2022;7:100389. [PMID: 35121524 DOI: 10.1016/j.esmoop.2022.100389] [Reference Citation Analysis]
335 Di Martino M, Koh YX, Syn N, Ken Min Chin, Fernando Burdió, Velázquez PS, Manzoni A, Cacciaguerra AB, Prieto M, Lancellotti F, Malleo G, Marchegiani G, Salvia R, Vennarecci G, Hilal MA, Ielpo B. It is the lymph node ratio that determines survival and recurrence patterns in resected distal cholangiocarcinoma. A multicenter international study. European Journal of Surgical Oncology 2022. [DOI: 10.1016/j.ejso.2022.02.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
336 Xiao F, Xu F, Zhang H, Shuai X. Circ_0000591 served as endogenous RNA for miR-326 to promote progression of cholangiocarcinoma via the TLR4/MyD88/IL6 axis. Biochemical and Biophysical Research Communications 2022. [DOI: 10.1016/j.bbrc.2022.02.073] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
337 Thuehøj AU, Andersen NC, Worm ES, Høyer M, Tabaksblat EM, Weber B, Mortensen HR. Clinical outcomes after stereotactic ablative radiotherapy in locally advanced cholangiocarcinoma. Acta Oncol 2022;61:197-201. [PMID: 34726565 DOI: 10.1080/0284186X.2021.1995893] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
338 Da Fonseca LG, Forner A. The complexity of cholangiocarcinoma goes beyond clinical practice: Challenges in trials design and interpretation. Liver Int 2022;42:268-70. [PMID: 35092336 DOI: 10.1111/liv.15149] [Reference Citation Analysis]
339 Pant K, Richard S, Gradilone SA. Short-Chain Fatty Acid Butyrate Induces Cilia Formation and Potentiates the Effects of HDAC6 Inhibitors in Cholangiocarcinoma Cells. Front Cell Dev Biol 2021;9:809382. [PMID: 35096835 DOI: 10.3389/fcell.2021.809382] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
340 Mayr C, Kiesslich T, Modest DP, Stintzing S, Ocker M, Neureiter D. Chemoresistance and resistance to targeted therapies in biliary tract cancer: What have we learned? Expert Opin Investig Drugs 2022. [PMID: 35098846 DOI: 10.1080/13543784.2022.2034785] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
341 Venkatraman S, Balasubramanian B, Pongchaikul P, Tohtong R, Chutipongtanate S. Molecularly Guided Drug Repurposing for Cholangiocarcinoma: An Integrative Bioinformatic Approach. Genes 2022;13:271. [DOI: 10.3390/genes13020271] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
342 Rizzo A, Ricci AD, Cusmai A, Acquafredda S, De Palma G, Brandi G, Palmiotti G. Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future. Current Oncology 2022;29:551-64. [DOI: 10.3390/curroncol29020050] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
343 Beri N. Unmet needs in the treatment of intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements. Future Oncol 2022. [PMID: 35081733 DOI: 10.2217/fon-2021-1089] [Reference Citation Analysis]
344 Khiaowichit J, Talabnin C, Dechsukhum C, Silsirivanit A, Talabnin K. Down-Regulation of C1GALT1 Enhances the Progression of Cholangiocarcinoma through Activation of AKT/ERK Signaling Pathways. Life 2022;12:174. [DOI: 10.3390/life12020174] [Reference Citation Analysis]
345 Jinhuan Y, Yi W, Yuanwen Z, Delin M, Xiaotian C, Yan W, Liming D, Haitao Y, Lijun W, Tuo D, Kaiyu C, Jiawei H, Chongming Z, Daojie W, Bin J, Gang C. Laparoscopic Versus Open Surgery for Early-Stage Intrahepatic Cholangiocarcinoma After Mastering the Learning Curve: A Multicenter Data-Based Matched Study. Front Oncol 2021;11:742544. [PMID: 35070961 DOI: 10.3389/fonc.2021.742544] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
346 Yang Y, Zou X, Zhou W, Yuan G, Hu D, Kuang D, Shen Y, Xie Q, Zhang Q, Hu X, Li Z. Multiparametric MRI-Based Radiomic Signature for Preoperative Evaluation of Overall Survival in Intrahepatic Cholangiocarcinoma After Partial Hepatectomy. J Magn Reson Imaging 2022. [PMID: 35049076 DOI: 10.1002/jmri.28071] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
347 Louis C, Leclerc D, Coulouarn C. Emerging roles of circular RNAs in liver cancer. JHEP Rep 2022;4:100413. [PMID: 35036887 DOI: 10.1016/j.jhepr.2021.100413] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
348 Kankeu Fonkoua LA, Serrano Uson Junior PL, Mody K, Mahipal A, Borad MJ, Roberts LR. Novel and emerging targets for cholangiocarcinoma progression: therapeutic implications. Expert Opin Ther Targets 2022. [PMID: 35034558 DOI: 10.1080/14728222.2022.2029412] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
349 Wang SQ, Chai CX, Wang BR, Zhu F, Shang D, Li M. Liquid biopsy: Precise diagnosis and therapy for cholangiocarcinoma. World J Gastrointest Oncol 2022; 14(1): 362-365 [DOI: 10.4251/wjgo.v14.i1.362] [Reference Citation Analysis]
350 Cho MT, Gholami S, Gui D, Tejaswi SL, Fananapazir G, Abi-jaoudeh N, Jutric Z, Samarasena JB, Li X, Valerin JB, Mercer J, Dayyani F. Optimizing the Diagnosis and Biomarker Testing for Patients with Intrahepatic Cholangiocarcinoma: A Multidisciplinary Approach. Cancers 2022;14:392. [DOI: 10.3390/cancers14020392] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
351 Wang X, Lee J, Xie C. Autophagy Regulation on Cancer Stem Cell Maintenance, Metastasis, and Therapy Resistance. Cancers 2022;14:381. [DOI: 10.3390/cancers14020381] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
352 Nikas IP, Mountzios G, Sydney GI, Ioakim KJ, Won J, Papageorgis P. Evaluating Pancreatic and Biliary Neoplasms with Small Biopsy-Based Next Generation Sequencing (NGS): Doing More with Less. Cancers 2022;14:397. [DOI: 10.3390/cancers14020397] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
353 Krenzien F, Nevermann N, Krombholz A, Benzing C, Haber P, Fehrenbach U, Lurje G, Pelzer U, Pratschke J, Schmelzle M, Schöning W. Treatment of Intrahepatic Cholangiocarcinoma-A Multidisciplinary Approach. Cancers (Basel) 2022;14:362. [PMID: 35053523 DOI: 10.3390/cancers14020362] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
354 Lamarca A, Edeline J, Goyal L. How I treat biliary tract cancer. ESMO Open 2022;7:100378. [PMID: 35032765 DOI: 10.1016/j.esmoop.2021.100378] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
355 Tan X, Rosin M, Appinger S, Bednarsch J, Liu D, Wiltberger G, Vallejo JG, Lang S, Czigany Z, Boroojerdi S, Gaisa NT, Boor P, Bülow RD, de Vos-geelen J, Iersel LV, Groningen MC, de Jong EJ, Koerkamp BG, Doukas M, Rocha FG, Luedde T, Klinge U, Sivakumar S, Neumann U, Heij L. PD1+ T-cells correlate with Nerve Fiber Density as a prognostic biomarker in patients with resected perihilar cholangiocarcinoma.. [DOI: 10.1101/2022.01.07.475344] [Reference Citation Analysis]
356 Gao Z, Wang J, Shen S, Bo X, Suo T, Ni X, Liu H, Huang L, Liu H. The impact of preoperative biliary drainage on postoperative outcomes in patients with malignant obstructive jaundice: a retrospective analysis of 290 consecutive cases at a single medical center. World J Surg Oncol 2022;20:7. [PMID: 34991594 DOI: 10.1186/s12957-021-02476-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
357 Sekine K, Yasuda I, Doi S, Kuniyoshi N, Tsujikawa T, Takano Y, Mabuchi M, Takahashi K, Kawamoto M, Takahashi M, Aso T, Miyazaki T, Iwashita T. Peroral Cholangioscopy-Guided Targeted Biopsy versus Conventional Endoscopic Transpapillary Forceps Biopsy for Biliary Stricture with Suspected Bile Duct Cancer. J Clin Med 2022;11:289. [PMID: 35053987 DOI: 10.3390/jcm11020289] [Reference Citation Analysis]
358 Cousin S, Cantarel C, Guegan JP, Mazard T, Gomez-Roca C, Metges JP, Bellera C, Adenis A, Korakis I, Poureau PG, Bourcier K, Toulmonde M, Kind M, Rey C, Auzanneau C, Bessede A, Soubeyran I, Italiano A. Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial. Eur J Cancer 2022;162:161-9. [PMID: 34998048 DOI: 10.1016/j.ejca.2021.11.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
359 Huang X, Fan M, Huang W. Pleiotropic roles of FXR in liver and colorectal cancers. Mol Cell Endocrinol 2022;543:111543. [PMID: 34995680 DOI: 10.1016/j.mce.2021.111543] [Reference Citation Analysis]
360 Wu B, Zhang Y, Yu Y, Zhong C, Lang Q, Liang Z, Lv C, Xu F, Tian Y. Long Noncoding RNA H19: A Novel Therapeutic Target Emerging in Oncology Via Regulating Oncogenic Signaling Pathways. Front Cell Dev Biol 2021;9:796740. [PMID: 34977037 DOI: 10.3389/fcell.2021.796740] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
361 Zhang G, Liu X, Sun Z, Feng X, Wang H, Hao J, Zhang X. A2M is a potential core gene in intrahepatic cholangiocarcinoma. BMC Cancer 2022;22:5. [PMID: 34979994 DOI: 10.1186/s12885-021-09070-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
362 Rizzo A, Di Federico A, Palmiotti G, Brandi G. Ramucirumab or merestinib in biliary tract cancer: new combinations, old mistakes? Expert Review of Precision Medicine and Drug Development 2022;7:60-1. [DOI: 10.1080/23808993.2022.2095903] [Reference Citation Analysis]
363 Rodrigues MA, Gomes DA, Cosme AL, Sanches MD, Resende V, Cassali GD. Inositol 1,4,5-trisphosphate receptor type 3 (ITPR3) is overexpressed in cholangiocarcinoma and its expression correlates with S100 calcium-binding protein A4 (S100A4). Biomed Pharmacother 2022;145:112403. [PMID: 34798470 DOI: 10.1016/j.biopha.2021.112403] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
364 Bramel ER, Sia D. Novel insights into molecular and immune subtypes of biliary tract cancers. Advances in Cancer Research 2022. [DOI: 10.1016/bs.acr.2022.01.008] [Reference Citation Analysis]
365 Li D, Lin S, Hong J, Ho M. Immunotherapy for hepatobiliary cancers: Emerging targets and translational advances. Advances in Cancer Research 2022. [DOI: 10.1016/bs.acr.2022.01.013] [Reference Citation Analysis]
366 Luchini C, Simbolo M, Scarpa A. Pathology of Biliary Tract Cancers. The IASGO Textbook of Multi-Disciplinary Management of Hepato-Pancreato-Biliary Diseases 2022. [DOI: 10.1007/978-981-19-0063-1_8] [Reference Citation Analysis]
367 Lima Cavalcanti ID. Chemotherapeutic Protocols for the Treatment of Gastrointestinal Tract Cancer. Chemotherapy Protocols and Infusion Sequence 2022. [DOI: 10.1007/978-3-031-10839-6_5] [Reference Citation Analysis]
368 Aysal A, Sagol O. Biomarkers in Hepatopancreatobiliary Carcinomas. Biomarkers in Carcinoma of Unknown Primary 2022. [DOI: 10.1007/978-3-030-84432-5_8] [Reference Citation Analysis]
369 Arora M, Bogenberger JM, Abdelrahman AM, Yonkus J, Alva-Ruiz R, Leiting JL, Chen X, Serrano Uson Junior PL, Dumbauld CR, Baker AT, Gamb SI, Egan JB, Zhou Y, Nagalo BM, Meurice N, Eskelinen EL, Salomao MA, Kosiorek HE, Braggio E, Barrett MT, Buetow KH, Sonbol MB, Mansfield AS, Roberts LR, Bekaii-Saab TS, Ahn DH, Truty MJ, Borad MJ. Synergistic combination of cytotoxic chemotherapy and cyclin-dependent kinase 4/6 inhibitors in biliary tract cancers. Hepatology 2022;75:43-58. [PMID: 34407567 DOI: 10.1002/hep.32102] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
370 Louis C, Coulouarn C. One stone, two birds: circACTN4, a nexus for a coordinated activation of Hippo and Wnt/β-catenin pathways in cholangiocarcinoma. J Hepatol 2022;76:8-10. [PMID: 34653593 DOI: 10.1016/j.jhep.2021.10.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
371 Orhan A. Cancer Immunodiagnosis in Upper Gastrointestinal Cancers. Handbook of Cancer and Immunology 2022. [DOI: 10.1007/978-3-030-80962-1_147-1] [Reference Citation Analysis]
372 Sanceau J, Gougelet A. Noncoding RNAs in liver cancer patients. Clinical Applications of Non-Coding RNAs in Cancer 2022. [DOI: 10.1016/b978-0-12-824550-7.00007-2] [Reference Citation Analysis]
373 Lee Y, Singal A, Luu M, Nissen N, Gores G, Yang J. Increasing Incidence of Intrahepatic Cholangiocarcinoma Relative to Hepatocellular Carcinoma in the United States. Gastro Hep Advances 2022;1:121-4. [DOI: 10.1016/j.gastha.2021.10.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
374 Lin Y, Cai Q, Chen Y, Shi T, Liu W, Mao L, Deng B, Ying Z, Gao Y, Luo H, Yang X, Huang X, Shi Y, He R. CAFs shape myeloid-derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5-lipoxygenase. Hepatology 2022;75:28-42. [PMID: 34387870 DOI: 10.1002/hep.32099] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 18.0] [Reference Citation Analysis]
375 Trauner M, Fuchs CD. Novel therapeutic targets for cholestatic and fatty liver disease. Gut 2022;71:194-209. [PMID: 34615727 DOI: 10.1136/gutjnl-2021-324305] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 28.0] [Reference Citation Analysis]
376 Cadamuro M, Strazzabosco M. Inflammatory pathways and cholangiocarcinoma risk mechanisms and prevention. Advances in Cancer Research 2022. [DOI: 10.1016/bs.acr.2022.02.001] [Reference Citation Analysis]
377 Pant K, Gradilone SA. Hepatobiliary Cancers: Progress in Diagnosis, Pathogenesis, and Treatment. Technol Cancer Res Treat 2022;21:15330338221097203. [PMID: 35546130 DOI: 10.1177/15330338221097203] [Reference Citation Analysis]
378 Correnti M, Cappon A, Pastore M, Piombanti B, Lori G, Oliveira DVPN, Munoz-Garrido P, Lewinska M, Andersen JB, Coulouarn C, Sulpice L, Peraldo Neia C, Cavalloni G, Quarta S, Biasiolo A, Fassan M, Ramazzotti M, Parri M, Recalcati S, di Tommaso L, Campani C, Invernizzi P, Torzilli G, Marra F, Pontisso P, Raggi C. The protease-inhibitor SerpinB3 as a critical modulator of the stem-like subset in human cholangiocarcinoma. Liver Int 2022;42:233-48. [PMID: 34478594 DOI: 10.1111/liv.15049] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
379 刘 军. Treatment Status and Progress of Hilar Cholangiocarcinoma. ACM 2022;12:5375-5381. [DOI: 10.12677/acm.2022.126779] [Reference Citation Analysis]
380 Kalyan A, Shroff RT, Department of Hematology and Oncology, Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA, Department of Hematology and Oncology, University of Arizona Cancer Center, Tuscon, AZ, USA. Cholangiocarcinoma: The Present and Future of Targeted Therapies. Oncology & Haematology 2022;18:9. [DOI: 10.17925/ohr.2022.18.1.9] [Reference Citation Analysis]
381 . Viszeralchirurgie. FAP Allgemein- und Viszeralchirurgie 2022. [DOI: 10.1016/b978-3-437-23244-2.00005-7] [Reference Citation Analysis]
382 Wu R, Zhang Y, Cheng Q, Wu J, Zhu Y, Shi X, Qiu X, Yang S, Wang S, Zheng B, Wu T, Li Z, Wang K, Zhang Y, Zhao Y, Wang W, Bao J, Hu J, Wu X, Wang H, Jiang X, Chen L. The effect of biliary obstruction, biliary drainage and bile reinfusion on bile acid metabolism and gut microbiota in mice. Liver Int 2022;42:135-48. [PMID: 34459095 DOI: 10.1111/liv.15047] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
383 Vitale G, Gitto S, Campani C, Turco L, Baldan A, Marra F, Morelli MC. Biological therapies in patients with liver disease: are they really lifesavers? Expert Opin Biol Ther 2021;:1-18. [PMID: 34860629 DOI: 10.1080/14712598.2022.2013799] [Reference Citation Analysis]
384 Dong L, Lu D, Chen R, Lin Y, Zhu H, Zhang Z, Cai S, Cui P, Song G, Rao D, Yi X, Wu Y, Song N, Liu F, Zou Y, Zhang S, Zhang X, Wang X, Qiu S, Zhou J, Wang S, Zhang X, Shi Y, Figeys D, Ding L, Wang P, Zhang B, Rodriguez H, Gao Q, Gao D, Zhou H, Fan J. Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma. Cancer Cell 2021:S1535-6108(21)00659-0. [PMID: 34971568 DOI: 10.1016/j.ccell.2021.12.006] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 19.5] [Reference Citation Analysis]
385 Dana P, Kariya R, Lert-Itthiporn W, Seubwai W, Saisomboon S, Wongkham C, Okada S, Wongkham S, Vaeteewoottacharn K. Homophilic Interaction of CD147 Promotes IL-6-Mediated Cholangiocarcinoma Invasion via the NF-κB-Dependent Pathway. Int J Mol Sci 2021;22:13496. [PMID: 34948304 DOI: 10.3390/ijms222413496] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
386 Manzia TM, Parente A, Lenci I, Sensi B, Milana M, Gazia C, Signorello A, Angelico R, Grassi G, Tisone G, Baiocchi L. Moving forward in the treatment of cholangiocarcinoma. World J Gastrointest Oncol 2021; 13(12): 1939-1955 [DOI: 10.4251/wjgo.v13.i12.1939] [Reference Citation Analysis]
387 Wang Y, Li K, Zhao W, Liu Z, Liu J, Shi A, Chen T, Mu W, Xu Y, Pan C, Zhang Z. Aldehyde dehydrogenase 3B2 promotes the proliferation and invasion of cholangiocarcinoma by increasing Integrin Beta 1 expression. Cell Death Dis 2021;12:1158. [PMID: 34907179 DOI: 10.1038/s41419-021-04451-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
388 Albrecht T, Goeppert B, Brinkmann F, Charbel A, Zhang Q, Schreck J, Wilhelm N, Singer S, Köhler BC, Springfeld C, Mehrabi A, Schirmacher P, Kühl AA, Vogel MN, Jansen H, Utku N, Roessler S. The Transmembrane Receptor TIRC7 Identifies a Distinct Subset of Immune Cells with Prognostic Implications in Cholangiocarcinoma. Cancers 2021;13:6272. [DOI: 10.3390/cancers13246272] [Reference Citation Analysis]
389 Chaiyadet S, Tangkawattana S, Smout MJ, Ittiprasert W, Mann VH, Deenonpoe R, Arunsan P, Loukas A, Brindley PJ, Laha T. Knockout of liver fluke granulin, Ov-grn-1, impedes malignant transformation during chronic infection with Opisthorchis viverrini.. [DOI: 10.1101/2021.12.10.472085] [Reference Citation Analysis]
390 Gritskevich AA, Gurmikov BN, Baitman TP, Shipilova AN, Paichadze AA, Chzhao AV. Cholangiocarcinogenesis and targeted therapy for cholangiocarcinoma. Medicinskij sovet 2021. [DOI: 10.21518/2079-701x-2021-20-101-109] [Reference Citation Analysis]
391 Zou W, Wang Z, Zhang X, Xu S, Wang F, Li L, Deng Z, Wang J, Pan K, Ge X, Li C, Liu R, Hu M. PIWIL4 and SUPT5H combine to predict prognosis and immune landscape in intrahepatic cholangiocarcinoma. Cancer Cell Int 2021;21:657. [PMID: 34876138 DOI: 10.1186/s12935-021-02310-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
392 Guest RV. Targeted therapies in cholangiocarcinoma: emerging hope through novel trial design. Br J Surg 2021:znab410. [PMID: 34875028 DOI: 10.1093/bjs/znab410] [Reference Citation Analysis]
393 Rao B, Ren T, Wang X, Wang H, Zou Y, Sun Y, Liu S, Ren Z, Yu Z. Dysbiosis in the Human Microbiome of Cholangiocarcinoma. Front Physiol 2021;12:715536. [PMID: 34867436 DOI: 10.3389/fphys.2021.715536] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
394 Ledenko M, Patel T. What are the key challenges in the pharmacological management of cholangiocarcinoma? Expert Opin Pharmacother 2021;:1-3. [PMID: 34866539 DOI: 10.1080/14656566.2021.2010707] [Reference Citation Analysis]
395 Pant K, Peixoto E, Richard S, Biswas A, O'Sullivan MG, Giama N, Ha Y, Yin J, Carotenuto P, Salati M, Ren Y, Yang R, Franco B, Roberts LR, Gradilone SA. Histone Deacetylase Sirtuin 1 Promotes Loss of Primary Cilia in Cholangiocarcinoma. Hepatology 2021;74:3235-48. [PMID: 34322899 DOI: 10.1002/hep.32080] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
396 Qian M, Yan F, Wang W, Du J, Yuan T, Wu R, Zhao C, Wang J, Lu J, Zhang B, Lin N, Dong X, Dai X, Dong X, Yang B, Zhu H, He Q. Deubiquitinase JOSD2 stabilizes YAP/TAZ to promote cholangiocarcinoma progression. Acta Pharm Sin B 2021;11:4008-19. [PMID: 35024322 DOI: 10.1016/j.apsb.2021.04.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
397 De B, Abu-Gheida I, Patel A, Ng SSW, Zaid M, Thunshelle CP, Elganainy D, Corrigan KL, Rooney MK, Javle M, Raghav K, Lee SS, Vauthey JN, Tzeng CD, Tran Cao HS, Ludmir EB, Minsky BD, Smith GL, Holliday EB, Taniguchi CM, Koong AC, Das P, Koay EJ. Benchmarking Outcomes after Ablative Radiotherapy for Molecularly Characterized Intrahepatic Cholangiocarcinoma. J Pers Med 2021;11:1270. [PMID: 34945742 DOI: 10.3390/jpm11121270] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
398 Filippi L, Braat AJ. Theragnostics in primary and secondary liver tumors: the need for a personalized approach. Q J Nucl Med Mol Imaging 2021;65:353-70. [PMID: 34881847 DOI: 10.23736/S1824-4785.21.03407-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
399 Gruttadauria S, Barbera F, Pagano D, Liotta R, Miraglia R, Barbara M, Bavetta MG, Cammà C, Petridis I, Di Carlo D, Conaldi PG, Di Francesco F. Liver Transplantation for Unresectable Intrahepatic Cholangiocarcinoma: The Role of Sequencing Genetic Profiling. Cancers (Basel) 2021;13:6049. [PMID: 34885159 DOI: 10.3390/cancers13236049] [Reference Citation Analysis]
400 Carpino G, Cardinale V, Di Giamberardino A, Overi D, Donsante S, Colasanti T, Amato G, Mennini G, Franchitto M, Conti F, Rossi M, Riminucci M, Gaudio E, Alvaro D, Mancone C. Thrombospondin 1 and 2 along with PEDF inhibit angiogenesis and promote lymphangiogenesis in intrahepatic cholangiocarcinoma. J Hepatol 2021;75:1377-86. [PMID: 34329660 DOI: 10.1016/j.jhep.2021.07.016] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
401 Klinhom-On N, Seubwai W, Sawanyawisuth K, Obchoei S, Mahalapbutr P, Wongkham S. FOXM1 inhibitor, Siomycin A, synergizes and restores 5-FU cytotoxicity in human cholangiocarcinoma cell lines via targeting thymidylate synthase. Life Sci 2021;286:120072. [PMID: 34688691 DOI: 10.1016/j.lfs.2021.120072] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
402 Lobe C, Vallette M, Arbelaiz A, Gonzalez-Sanchez E, Izquierdo L, Pellat A, Guedj N, Louis C, Paradis V, Banales JM, Coulouarn C, Housset C, Vaquero J, Fouassier L. Zinc Finger E-Box Binding Homeobox 1 Promotes Cholangiocarcinoma Progression Through Tumor Dedifferentiation and Tumor-Stroma Paracrine Signaling. Hepatology 2021;74:3194-212. [PMID: 34297412 DOI: 10.1002/hep.32069] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
403 Roberts HJ, Wo JY. Stereotactic body radiation therapy for primary liver tumors: An effective liver-directed therapy in the toolbox. Cancer 2021. [PMID: 34847255 DOI: 10.1002/cncr.34033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
404 Rizzo A, Ricci AD, Gadaleta-caldarola G, Brandi G. Precision oncology in cholangiocarcinoma: current issues in clinical trial design and access to targeted therapies. Expert Review of Precision Medicine and Drug Development. [DOI: 10.1080/23808993.2021.2008144] [Reference Citation Analysis]
405 Roy S, Jefferys D, Rubbo S, Mayo-Ramsay T, Majid A. Anatomical reconstruction after pancreaticoduodenectomy in a patient with previous Roux-en-Y gastric bypass for obesity: a novel complication for the future. ANZ J Surg 2021. [PMID: 34820991 DOI: 10.1111/ans.17379] [Reference Citation Analysis]
406 Wang J, Loeuillard E, Gores GJ, Ilyas SI. Cholangiocarcinoma: what are the most valuable therapeutic targets - cancer-associated fibroblasts, immune cells, or beyond T cells? Expert Opin Ther Targets 2021;25:835-45. [PMID: 34806500 DOI: 10.1080/14728222.2021.2010046] [Reference Citation Analysis]
407 Xue W, Dong B, Zhao Y, Wang Y, Yang C, Xie Y, Niu Z, Zhu C. Upregulation of TTYH3 promotes epithelial-to-mesenchymal transition through Wnt/β-catenin signaling and inhibits apoptosis in cholangiocarcinoma. Cell Oncol (Dordr) 2021;44:1351-61. [PMID: 34796468 DOI: 10.1007/s13402-021-00642-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
408 Liu J, Ren G, Li K, Liu Z, Wang Y, Chen T, Mu W, Yang X, Li X, Shi A, Zhao W, Xu B, Chang J, Guo S, Pan C, Zhou T, Zhang Z, Xu Y. The Smad4-MYO18A-PP1A complex regulates β-catenin phosphorylation and pemigatinib resistance by inhibiting PAK1 in cholangiocarcinoma. Cell Death Differ 2021. [PMID: 34799729 DOI: 10.1038/s41418-021-00897-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
409 Gile JJ, Ou FS, Mahipal A, Larson JJ, Mody K, Jin Z, Hubbard J, Halfdanarson T, Alberts SR, Jatoi A, McWilliams RR, Ma WW, Ilyas S, Smoot R, Roberts L, Gores G, Borad M, Bekaii-Saab TS, Tran NH. FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience. JCO Precis Oncol 2021;5:PO. [PMID: 34778691 DOI: 10.1200/PO.21.00064] [Reference Citation Analysis]
410 Wang Y, Chen T, Li K, Mu W, Liu Z, Shi A, Liu J, Zhao W, Lian S, Huang S, Pan C, Zhang Z. Recent Advances in the Mechanism Research and Clinical Treatment of Anti-Angiogenesis in Biliary Tract Cancer. Front Oncol 2021;11:777617. [PMID: 34778094 DOI: 10.3389/fonc.2021.777617] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
411 Marcus R, Ferri-Borgogno S, Hosein A, Foo WC, Ghosh B, Zhao J, Rajapakshe K, Brugarolas J, Maitra A, Gupta S. Oncogenic KRAS Requires Complete Loss of BAP1 Function for Development of Murine Intrahepatic Cholangiocarcinoma. Cancers (Basel) 2021;13:5709. [PMID: 34830866 DOI: 10.3390/cancers13225709] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
412 Inchingolo R, Acquafredda F, Ferraro V, Laera L, Surico G, Surgo A, Fiorentino A, Marini S, de'Angelis N, Memeo R, Spiliopoulos S. Non-surgical treatment of hilar cholangiocarcinoma. World J Gastrointest Oncol 2021;13:1696-708. [PMID: 34853644 DOI: 10.4251/wjgo.v13.i11.1696] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
413 Ioffe D, Phull P, Dotan E. Optimal Management of Patients with Advanced or Metastatic Cholangiocarcinoma: An Evidence-Based Review. Cancer Manag Res 2021;13:8085-98. [PMID: 34737637 DOI: 10.2147/CMAR.S276104] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
414 Pangestu NS, Chueakwon P, Talabnin K, Khiaowichit J, Talabnin C. RNF43 overexpression attenuates the Wnt/β-catenin signalling pathway to suppress tumour progression in cholangiocarcinoma. Oncol Lett 2021;22:846. [PMID: 34733364 DOI: 10.3892/ol.2021.13107] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
415 Chen X, Rong D, Zhang L, Ni C, Han G, Lu Y, Chen X, Gao Y, Wang X. Evaluation of nodal status in intrahepatic cholangiocarcinoma: a population-based study. Ann Transl Med 2021;9:1359. [PMID: 34733911 DOI: 10.21037/atm-21-2785] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
416 Zhou SL, Xin HY, Sun RQ, Zhou ZJ, Hu ZQ, Luo CB, Wang PC, Li J, Fan J, Zhou J. Association of KRAS Variant Subtypes With Survival and Recurrence in Patients With Surgically Treated Intrahepatic Cholangiocarcinoma. JAMA Surg 2021. [PMID: 34730772 DOI: 10.1001/jamasurg.2021.5679] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
417 Wu CE, Yeh CN. Cutting Edge Research for Exploration of Biomolecules for Gemcitabine-Based Chemo-Resistant Advanced Bile Duct Cancer: From Basic Study to Clinical Trial. Biomolecules 2021;11:1626. [PMID: 34827625 DOI: 10.3390/biom11111626] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
418 Liang J, Zhou H, Huang XQ, Liu YF, Zhang L, He D, Cui Y, Guo J, Hu K, Wu C. A Myeloid Signature-Based Nomogram Predicts the Postoperative Recurrence of Intrahepatic Cholangiocarcinoma. Front Mol Biosci 2021;8:742953. [PMID: 34722632 DOI: 10.3389/fmolb.2021.742953] [Reference Citation Analysis]
419 Zhu AX, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, Cleary JM, Catenacci DVT, Borad MJ, Bridgewater JA, Harris WP, Murphy AG, Oh DY, Whisenant JR, Lowery MA, Goyal L, Shroff RT, El-Khoueiry AB, Chamberlain CX, Aguado-Fraile E, Choe S, Wu B, Liu H, Gliser C, Pandya SS, Valle JW, Abou-Alfa GK. Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial. JAMA Oncol 2021;7:1669-77. [PMID: 34554208 DOI: 10.1001/jamaoncol.2021.3836] [Cited by in Crossref: 51] [Cited by in F6Publishing: 63] [Article Influence: 25.5] [Reference Citation Analysis]
420 Govalan R, Guindi M, Yang JD. Liver Mass in a Young Male With Ollier Disease. Gastroenterology 2021;161:e4-5. [PMID: 33812890 DOI: 10.1053/j.gastro.2021.03.057] [Reference Citation Analysis]
421 Lee YT, Wang JJ, Luu M, Noureddin M, Nissen NN, Patel TC, Roberts LR, Singal AG, Gores GJ, Yang JD. Comparison of Clinical Features and Outcomes Between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States. Hepatology 2021;74:2622-32. [PMID: 34114675 DOI: 10.1002/hep.32007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
422 Gonçalves JPL, Bollwein C, Schlitter AM, Martin B, Märkl B, Utpatel K, Weichert W, Schwamborn K. The Impact of Histological Annotations for Accurate Tissue Classification Using Mass Spectrometry Imaging. Metabolites 2021;11:752. [PMID: 34822410 DOI: 10.3390/metabo11110752] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
423 Song J, Cui D, Wang J, Qin J, Wang S, Wang Z, Zhai X, Ma H, Ma D, Liu Y, Jin B, Liu Z. Overexpression of HMGA1 confers radioresistance by transactivating RAD51 in cholangiocarcinoma. Cell Death Discov 2021;7:322. [PMID: 34716319 DOI: 10.1038/s41420-021-00721-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
424 Zheng Y, Wang S, Cai J, Ke A, Fan J. The progress of immune checkpoint therapy in primary liver cancer. Biochim Biophys Acta Rev Cancer 2021;1876:188638. [PMID: 34688805 DOI: 10.1016/j.bbcan.2021.188638] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
425 Vignone A, Biancaniello F, Casadio M, Pesci L, Cardinale V, Ridola L, Alvaro D. Emerging Therapies for Advanced Cholangiocarcinoma: An Updated Literature Review. J Clin Med 2021;10:4901. [PMID: 34768421 DOI: 10.3390/jcm10214901] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
426 Wu L, Yan J, Bai Y, Chen F, Xu J, Zou X, Huang A, Hou L, Zhong Y, Jing Z, Zhou X, Sun H, Cheng M, Ji Y, Luo R, Li Q, Wu L, Wang P, Guo D, Huang W, Lei J, Liao S, Li Y, Jiang Z, Yao N, Yu Y, Li Y, Liu F, Zhang M, Yang H, Yang S, Xu X, Liu L, Wang X, Wang J, Fan J, Liu S, Yang X, Chen A, Zhou J. Spatially-resolved transcriptomics analyses of invasive fronts in solid tumors.. [DOI: 10.1101/2021.10.21.465135] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
427 Yosudjai J, Inpad C, Pothipan P, Saisomboon S, Surangkul D, Phimsen S, Hongsrichan N, Wongkham S, Jirawatnotai S, Roytrakul S, Kaewkong W. Overexpression of AGR2vH, an oncogenic AGR2 spliced transcript, potentiates tumorigenicity and proteomic alterations in cholangiocarcinoma cell. Biosci Biotechnol Biochem 2021;85:2263-73. [PMID: 34494080 DOI: 10.1093/bbb/zbab156] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
428 Marušić M, Paić M, Knobloch M, Vodanović M. Klatskin-Mimicking Lesions. Diagnostics (Basel) 2021;11:1944. [PMID: 34829291 DOI: 10.3390/diagnostics11111944] [Reference Citation Analysis]
429 Ney A, Garcia-Sampedro A, Goodchild G, Acedo P, Fusai G, Pereira SP. Biliary Strictures and Cholangiocarcinoma - Untangling a Diagnostic Conundrum. Front Oncol 2021;11:699401. [PMID: 34660269 DOI: 10.3389/fonc.2021.699401] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
430 Bauer M, Jasinski-Bergner S, Mandelboim O, Wickenhauser C, Seliger B. Epstein-Barr Virus-Associated Malignancies and Immune Escape: The Role of the Tumor Microenvironment and Tumor Cell Evasion Strategies. Cancers (Basel) 2021;13:5189. [PMID: 34680337 DOI: 10.3390/cancers13205189] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
431 Saffioti F, Mavroeidis VK. Review of incidence and outcomes of treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis. World J Gastrointest Oncol 2021; 13(10): 1336-1366 [PMID: 34721770 DOI: 10.4251/wjgo.v13.i10.1336] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
432 Koustas E, Trifylli EM, Sarantis P, Papavassiliou AG, Karamouzis MV. Role of autophagy in cholangiocarcinoma: An autophagy-based treatment strategy. World J Gastrointest Oncol 2021; 13(10): 1229-1243 [PMID: 34721764 DOI: 10.4251/wjgo.v13.i10.1229] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
433 Liu Y, Li G, Lu Z, Wang T, Yang Y, Wang X, Liu J. Effect of vascular resection for perihilar cholangiocarcinoma: a systematic review and meta-analysis. PeerJ 2021;9:e12184. [PMID: 34631316 DOI: 10.7717/peerj.12184] [Reference Citation Analysis]
434 Ness JR, Molvar C. Radioembolization of Intrahepatic Cholangiocarcinoma: Patient Selection, Outcomes, and Competing Therapies. Semin Intervent Radiol 2021;38:438-44. [PMID: 34629711 DOI: 10.1055/s-0041-1735526] [Reference Citation Analysis]
435 Gou Q, Zhang CZ, Sun ZH, Wu LG, Chen Y, Mo ZQ, Mai QC, He J, Zhou ZX, Shi F, Cui W, Zou W, Lv L, Zhuang WH, Xu RD, Li WK, Zhang J, Du HW, Xiang JX, Wang HZ, Hou T, Li ST, Li Y, Chen XM, Zhou ZJ. Cell-free DNA from bile outperformed plasma as a potential alternative to tissue biopsy in biliary tract cancer. ESMO Open 2021;6:100275. [PMID: 34653800 DOI: 10.1016/j.esmoop.2021.100275] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
436 Macias RIR, Monte MJ, Serrano MA, González-Santiago JM, Martín-Arribas I, Simão AL, Castro RE, González-Gallego J, Mauriz JL, Marin JJG. Impact of aging on primary liver cancer: epidemiology, pathogenesis and therapeutics. Aging (Albany NY) 2021;13:23416-34. [PMID: 34633987 DOI: 10.18632/aging.203620] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
437 Jayaraman P, Gaston K. Targeting protein kinase CK2 in the treatment of cholangiocarcinoma. Exploration of Targeted Anti-tumor Therapy 2021;2. [DOI: 10.37349/etat.2021.00055] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
438 Tóth M, Wehling L, Thiess L, Rose F, Schmitt J, Weiler SME, Sticht C, De La Torre C, Rausch M, Albrecht T, Grabe N, Duwe L, Andersen JB, Köhler BC, Springfeld C, Mehrabi A, Kulu Y, Schirmacher P, Roessler S, Goeppert B, Breuhahn K. Co-expression of YAP and TAZ associates with chromosomal instability in human cholangiocarcinoma. BMC Cancer 2021;21:1079. [PMID: 34615513 DOI: 10.1186/s12885-021-08794-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
439 Prasopdee S, Yingchutrakul Y, Roytrakul S, Pholhelm M, Phanaksri T, Kunjantarachot A, Kulsantiwong J, Butthongkomvong K, Tesana S, Sathavornmanee T, Thitapakorn V. Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta as a potential biomarker for Opisthorchis viverrini infection and cholangiocarcinoma. Parasitology. [DOI: 10.1017/s0031182021001694] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
440 Paillet J, Plantureux C, Lévesque S, Le Naour J, Stoll G, Sauvat A, Caudana P, Tosello Boari J, Bloy N, Lachkar S, Martins I, Opolon P, Checcoli A, Delaune A, Robil N, de la Grange P, Hamroune J, Letourneur F, Autret G, Leung PSC, Gershwin ME, Zhu JS, Kurth MJ, Lekbaby B, Augustin J, Kim Y, Gujar S, Coulouarn C, Fouassier L, Zitvogel L, Piaggio E, Housset C, Soussan P, Maiuri MC, Kroemer G, Pol JG. Autoimmunity affecting the biliary tract fuels the immunosurveillance of cholangiocarcinoma. J Exp Med 2021;218:e20200853. [PMID: 34495298 DOI: 10.1084/jem.20200853] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
441 Vithayathil M, Bridegwater J, Khan SA. Medical therapies for intra-hepatic cholangiocarcinoma. J Hepatol 2021;75:981-3. [PMID: 34215442 DOI: 10.1016/j.jhep.2021.04.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
442 Yoon JG, Kim MH, Jang M, Kim H, Hwang HK, Kang CM, Lee WJ, Kang B, Lee CK, Lee MG, Chung HC, Choi HJ, Park YN. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses. Hepatology 2021;74:1914-31. [PMID: 33884649 DOI: 10.1002/hep.31862] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
443 Silva M, Maddalo M, Leoni E, Giuliotti S, Milanese G, Ghetti C, Biasini E, De Filippo M, Missale G, Sverzellati N. Integrated prognostication of intrahepatic cholangiocarcinoma by contrast-enhanced computed tomography: the adjunct yield of radiomics. Abdom Radiol (NY) 2021;46:4689-700. [PMID: 34165602 DOI: 10.1007/s00261-021-03183-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
444 Vaquero J, Keitel V. Deciphering FAK in intrahepatic cholangiocarcinoma: A novel therapeutic target? J Hepatol 2021;75:765-7. [PMID: 34252516 DOI: 10.1016/j.jhep.2021.06.048] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
445 Sinniah RS, Shapses MS, Ahmed MU, Babiker H, Chandana SR. Novel biomarkers for cholangiocarcinoma: how can it enhance diagnosis, prognostication, and investigational drugs? Part-1. Expert Opin Investig Drugs 2021;30:1047-56. [PMID: 34579607 DOI: 10.1080/13543784.2021.1985461] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
446 Wang Q, Xu Y, Wang SM, Hu AY, Pan YC, Zhang SH. Histopathological evidence of intrahepatic cholangiocarcinoma occurring in ductal plate malformation: A clinicopathologic study of 5 cases. Ann Diagn Pathol 2021;55:151828. [PMID: 34571341 DOI: 10.1016/j.anndiagpath.2021.151828] [Reference Citation Analysis]
447 Izquierdo-Sanchez L, Banales JM, Rodrigues PM. A look back at cholangiocarcinoma in Finland. United European Gastroenterol J 2021. [PMID: 34581503 DOI: 10.1002/ueg2.12157] [Reference Citation Analysis]
448 Han SY, Park SH, Ko HS, Jang A, Seo HI, Lee SJ, Kim GH, Kim DU. Vimentin-Positive Circulating Tumor Cells as Diagnostic and Prognostic Biomarkers in Patients with Biliary Tract Cancer. J Clin Med 2021;10:4435. [PMID: 34640452 DOI: 10.3390/jcm10194435] [Reference Citation Analysis]
449 Zori AG, Yang D, Draganov PV, Cabrera R. Advances in the management of cholangiocarcinoma. World J Hepatol 2021; 13(9): 1003-1018 [PMID: 34630871 DOI: 10.4254/wjh.v13.i9.1003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
450 Kim YY, Yeom SK, Shin H, Choi SH, Rhee H, Park JH, Cho ES, Park S, Lee SS, Park MS. Clinical Staging of Mass-Forming Intrahepatic Cholangiocarcinoma: Computed Tomography Versus Magnetic Resonance Imaging. Hepatol Commun 2021;5:2009-18. [PMID: 34559470 DOI: 10.1002/hep4.1774] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
451 Rizzo A, Ricci AD, Gadaleta-Caldarola G, Brandi G. Toward personalized therapy for cholangiocarcinoma: new insights and challenges. Expert Rev Gastroenterol Hepatol 2021;15:1241-3. [PMID: 34553646 DOI: 10.1080/17474124.2021.1984879] [Reference Citation Analysis]
452 Zane KE, Cloyd JM, Mumtaz KS, Wadhwa V, Makary MS. Metastatic disease to the liver: Locoregional therapy strategies and outcomes. World J Clin Oncol 2021; 12(9): 725-745 [PMID: 34631439 DOI: 10.5306/wjco.v12.i9.725] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
453 Anichini G, Carrassa L, Stecca B, Marra F, Raggi C. The Role of the Hedgehog Pathway in Cholangiocarcinoma. Cancers (Basel) 2021;13:4774. [PMID: 34638259 DOI: 10.3390/cancers13194774] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
454 Safarpour AR, Askari H, Ejtehadi F, Azarnezhad A, Raeis-Abdollahi E, Tajbakhsh A, Abazari MF, Tarkesh F, Shamsaeefar A, Niknam R, Sivandzadeh GR, Lankarani KB, Ejtehadi F. Cholangiocarcinoma and liver transplantation: What we know so far? World J Gastrointest Pathophysiol 2021; 12(5): 84-105 [PMID: 34676129 DOI: 10.4291/wjgp.v12.i5.84] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
455 Boottanun P, Ino Y, Shimada K, Hiraoka N, Angata K, Narimatsu H. Association between the expression of core 3 synthase and survival outcomes of patients with cholangiocarcinoma. Oncol Lett 2021;22:760. [PMID: 34539864 DOI: 10.3892/ol.2021.13021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
456 Li X, Yang ZS, Cai WW, Deng Y, Chen L, Tan SL. Dihydromyricetin Inhibits Tumor Growth and Epithelial-Mesenchymal Transition through regulating miR-455-3p in Cholangiocarcinoma. J Cancer 2021;12:6058-70. [PMID: 34539879 DOI: 10.7150/jca.61311] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
457 Pol JG, Paillet J, Plantureux C, Kroemer G. Beneficial autoimmunity links primary biliary cholangitis to the avoidance of cholangiocarcinoma. Oncoimmunology 2021;10:1968595. [PMID: 34527429 DOI: 10.1080/2162402X.2021.1968595] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
458 Ding Y, Han X, Sun Z, Tang J, Wu Y, Wang W. Systemic Sequential Therapy of CisGem, Tislelizumab, and Lenvatinib for Advanced Intrahepatic Cholangiocarcinoma Conversion Therapy. Front Oncol 2021;11:691380. [PMID: 34527576 DOI: 10.3389/fonc.2021.691380] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
459 Hao J, Deng H, Yang Y, Chen L, Wu Q, Yao P, Li J, Li B, Jin X, Wang H, Duan H. Downregulation of MCM8 expression restrains the malignant progression of cholangiocarcinoma. Oncol Rep 2021;46:235. [PMID: 34523691 DOI: 10.3892/or.2021.8186] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
460 Kulezneva JV, Melekhina OV, Musatov AB, Efanov MG, Tsvirkun VV, Nedoluzhko IY, Shishin KV, Salnikov KK, Kantimerov DF. Controversial issues of biliary stenting in patients with proximal biliary obstruction. Ann hir gepatol 2021;26:79-88. [DOI: 10.16931/1995-5464.2021-3-79-88] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
461 Juratli MA, Struecker B, Katou S, Morguel MH, Pascher A. [Influence of molecular pathology on oncological surgery of liver and bile duct tumors]. Chirurg 2021;92:1003-10. [PMID: 34519849 DOI: 10.1007/s00104-021-01495-6] [Reference Citation Analysis]
462 Songjang W, Nensat C, Pongcharoen S, Jiraviriyakul A. The role of immunogenic cell death in gastrointestinal cancer immunotherapy (Review). Biomed Rep 2021;15:86. [PMID: 34512974 DOI: 10.3892/br.2021.1462] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
463 Roy S, Banerjee P, Ekser B, Bayless K, Zawieja D, Alpini G, Glaser SS, Chakraborty S. Targeting Lymphangiogenesis and Lymph Node Metastasis in Liver Cancer. Am J Pathol 2021;191:2052-63. [PMID: 34509441 DOI: 10.1016/j.ajpath.2021.08.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
464 Beetz O, Timrott A, Weigle CA, Schroeter A, Cammann S, Klempnauer J, Vondran FWR, Oldhafer F. Proposal of a New Definition of "Very Early" Intrahepatic Cholangiocarcinoma-A Retrospective Single-Center Analysis. J Clin Med 2021;10:4073. [PMID: 34575181 DOI: 10.3390/jcm10184073] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
465 Balasubramanian B, Venkatraman S, Janvilisri T, Suthiphongchai T, Jitkaew S, Sripa J, Tohtong R. RTK25: A Comprehensive Molecular Profiling Strategy in Cholangiocarcinoma Using an Integrated Bioinformatics Approach. Pharmaceuticals (Basel) 2021;14:898. [PMID: 34577598 DOI: 10.3390/ph14090898] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
466 Rizzo A, Dadduzio V, Lombardi L, Ricci AD, Gadaleta-Caldarola G. Ampullary Carcinoma: An Overview of a Rare Entity and Discussion of Current and Future Therapeutic Challenges. Curr Oncol 2021;28:3393-402. [PMID: 34590592 DOI: 10.3390/curroncol28050293] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
467 Xiang X, Liu Z, Zhang C, Li Z, Gao J, Zhang C, Cao Q, Cheng J, Liu H, Chen D, Cheng Q, Zhang N, Xue R, Bai F, Zhu J. IDH Mutation Subgroup Status Associates with Intratumor Heterogeneity and the Tumor Microenvironment in Intrahepatic Cholangiocarcinoma. Adv Sci (Weinh) 2021;8:e2101230. [PMID: 34250753 DOI: 10.1002/advs.202101230] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
468 Luo X, Campbell NA, He L, O'Brien DR, Singer MS, Lemjabbar-Alaoui H, Ahn KS, Smoot R, Torbenson MS, Rosen SD, Roberts LR. Sulfatase 2 (SULF2) Monoclonal Antibody 5D5 Suppresses Human Cholangiocarcinoma Xenograft Growth Through Regulation of a SULF2-Platelet-Derived Growth Factor Receptor Beta-Yes-Associated Protein Signaling Axis. Hepatology 2021;74:1411-28. [PMID: 33735525 DOI: 10.1002/hep.31817] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
469 Li Q, Che F, Wei Y, Jiang HY, Zhang Y, Song B. Role of noninvasive imaging in the evaluation of intrahepatic cholangiocarcinoma: from diagnosis and prognosis to treatment response. Expert Rev Gastroenterol Hepatol 2021;15:1267-79. [PMID: 34452581 DOI: 10.1080/17474124.2021.1974294] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
470 Rizzo A, Ricci AD, Gadaleta-Caldarola G, Brandi G. Radiofrequency ablation for intrahepatic cholangiocarcinoma: a tool upon the path of integrative modalities? Expert Rev Gastroenterol Hepatol 2021;15:1239-40. [PMID: 34449276 DOI: 10.1080/17474124.2021.1974296] [Reference Citation Analysis]
471 Cloyd JM, Pawlik TM. Trends in the use of adjuvant therapy for resected intrahepatic cholangiocarcinoma: getting ahead of the data. Hepatobiliary Surg Nutr 2021;10:515-7. [PMID: 34430532 DOI: 10.21037/hbsn-2021-12] [Reference Citation Analysis]
472 Yang JD, Ghoz H, Aboelsoud MM, Taylor WR, Yab TC, Berger CK, Cao X, Foote PH, Giama NH, Barr Fritcher EG, Mahoney DW, Moser CD, Smyrk TC, Kipp BR, Gores GJ, Roberts LR, Kisiel JB. DNA Methylation Markers for Detection of Cholangiocarcinoma: Discovery, Validation, and Clinical Testing in Biliary Brushings and Plasma. Hepatol Commun 2021;5:1448-59. [PMID: 34430788 DOI: 10.1002/hep4.1730] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
473 Ghidini M, Ramai D, Facciorusso A, Singh J, Tai W, Rijavec E, Galassi B, Grossi F, Indini A. Metabolic disorders and the risk of cholangiocarcinoma. Expert Rev Gastroenterol Hepatol 2021;15:999-1007. [PMID: 34423721 DOI: 10.1080/17474124.2021.1946393] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
474 Bourien H, Lamarca A, McNamara MG, Hubner RA, Valle JW, Edeline J. Druggable molecular alterations in bile duct cancer: potential and current therapeutic applications in clinical trials. Expert Opin Investig Drugs 2021;30:975-83. [PMID: 34420429 DOI: 10.1080/13543784.2021.1964470] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
475 Ilyas FZ, Beane JD, Pawlik TM. The State of Immunotherapy in Hepatobiliary Cancers. Cells 2021;10:2096. [PMID: 34440865 DOI: 10.3390/cells10082096] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
476 Thornblade LW, Wong P, Li D, Warner SG, Chang S, Raoof M, Kessler J, Amini A, Lin J, Chung V, Singh G, Fong Y, Melstrom LG. Patterns of Whole Exome Sequencing in Resected Cholangiocarcinoma. Cancers (Basel) 2021;13:4062. [PMID: 34439216 DOI: 10.3390/cancers13164062] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
477 Padthaisong S, Phetcharaburanin J, Klanrit P, Li JV, Namwat N, Khuntikeo N, Titapun A, Jarearnrat A, Wangwiwatsin A, Mahalapbutr P, Loilome W. Integration of global metabolomics and lipidomics approaches reveals the molecular mechanisms and the potential biomarkers for postoperative recurrence in early-stage cholangiocarcinoma. Cancer Metab 2021;9:30. [PMID: 34348794 DOI: 10.1186/s40170-021-00266-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
478 Javle M, Roychowdhury S, Kelley RK, Sadeghi S, Macarulla T, Weiss KH, Waldschmidt DT, Goyal L, Borbath I, El-Khoueiry A, Borad MJ, Yong WP, Philip PA, Bitzer M, Tanasanvimon S, Li A, Pande A, Soifer HS, Shepherd SP, Moran S, Zhu AX, Bekaii-Saab TS, Abou-Alfa GK. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol 2021:S2468-1253(21)00196-5. [PMID: 34358484 DOI: 10.1016/S2468-1253(21)00196-5] [Cited by in Crossref: 55] [Cited by in F6Publishing: 65] [Article Influence: 27.5] [Reference Citation Analysis]
479 van Keulen AM, Franssen S, van der Geest LG, de Boer MT, Coenraad M, van Driel LMJW, Erdmann JI, Haj Mohammad N, Heij L, Klümpen HJ, Tjwa E, Valkenburg-van Iersel L, Verheij J, Groot Koerkamp B, Olthof PB; Dutch Hepatocellular & Cholangiocarcinoma Group (DHCG). Nationwide treatment and outcomes of perihilar cholangiocarcinoma. Liver Int 2021;41:1945-53. [PMID: 33641214 DOI: 10.1111/liv.14856] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
480 Vallejo A, Erice O, Entrialgo-Cadierno R, Feliu I, Guruceaga E, Perugorria MJ, Olaizola P, Muggli A, Macaya I, O'Dell M, Ruiz-Fernandez de Cordoba B, Ortiz-Espinosa S, Hezel AF, Arozarena I, Lecanda F, Avila MA, Fernandez-Barrena MG, Evert M, Ponz-Sarvise M, Calvisi DF, Banales JM, Vicent S. FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted. J Hepatol 2021;75:363-76. [PMID: 33887357 DOI: 10.1016/j.jhep.2021.03.028] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
481 Mayr C, Kiesslich T, Erber S, Bekric D, Dobias H, Beyreis M, Ritter M, Jäger T, Neumayer B, Winkelmann P, Klieser E, Neureiter D. HDAC Screening Identifies the HDAC Class I Inhibitor Romidepsin as a Promising Epigenetic Drug for Biliary Tract Cancer. Cancers (Basel) 2021;13:3862. [PMID: 34359763 DOI: 10.3390/cancers13153862] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
482 Hack SP, Verret W, Mulla S, Liu B, Wang Y, Macarulla T, Ren Z, El-Khoueiry AB, Zhu AX. IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer. Ther Adv Med Oncol 2021;13:17588359211036544. [PMID: 34377158 DOI: 10.1177/17588359211036544] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
483 Nanashima A, Komi M, Imamura N, Yazaki S, Hiyoshi M, Hamada T, Yano K, Nishida T, Enzaki M, Sakae T. Novel analysis using magnetic resonance cholangiography for patients with pancreaticobiliary maljunction. Surg Today 2021. [PMID: 34324090 DOI: 10.1007/s00595-021-02349-8] [Reference Citation Analysis]
484 Byrling J, Hilmersson KS, Ansari D, Andersson R, Andersson B. Thrombospondin-2 as a diagnostic biomarker for distal cholangiocarcinoma and pancreatic ductal adenocarcinoma. Clin Transl Oncol 2021. [PMID: 34319497 DOI: 10.1007/s12094-021-02685-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
485 Chen X, Qin S, Gu S, Ren Z, Chen Z, Xiong J, Liu Y, Meng Z, Zhang X, Wang L, Zhang X, Zou J. Camrelizumab plus oxaliplatin-based chemotherapy as first-line therapy for advanced biliary tract cancer: A multicenter, phase 2 trial. Int J Cancer 2021. [PMID: 34309846 DOI: 10.1002/ijc.33751] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
486 Huang P, Zhou Y, Chen Y. Significant Response to Camrelizumab Plus Targeted Drugs in Recurrent Intrahepatic Cholangiocarcinoma: a Case Report and Literature Review. J Gastrointest Cancer 2021. [PMID: 34312770 DOI: 10.1007/s12029-021-00637-7] [Reference Citation Analysis]
487 Angelico R, Sensi B, Parente A, Siragusa L, Gazia C, Tisone G, Manzia TM. Vascular Involvements in Cholangiocarcinoma: Tips and Tricks. Cancers (Basel) 2021;13:3735. [PMID: 34359635 DOI: 10.3390/cancers13153735] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
488 Loilome W, Dokduang H, Suksawat M, Padthaisong S. Therapeutic challenges at the preclinical level for targeted drug development for Opisthorchis viverrini-associated cholangiocarcinoma. Expert Opin Investig Drugs 2021;:1-22. [PMID: 34292795 DOI: 10.1080/13543784.2021.1955102] [Reference Citation Analysis]
489 Bednarsch J, Tan X, Czigany Z, Liu D, Lang SA, Sivakumar S, Kather JN, Appinger S, Rosin M, Boroojerdi S, Dahl E, Gaisa NT, den Dulk M, Coolsen M, Ulmer TF, Neumann UP, Heij LR. The Presence of Small Nerve Fibers in the Tumor Microenvironment as Predictive Biomarker of Oncological Outcome Following Partial Hepatectomy for Intrahepatic Cholangiocarcinoma. Cancers (Basel) 2021;13:3661. [PMID: 34359564 DOI: 10.3390/cancers13153661] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
490 Fragkou N, Sideras L, Panas P, Emmanouilides C, Sinakos E. Update on the association of hepatitis B with intrahepatic cholangiocarcinoma: Is there new evidence? World J Gastroenterol 2021; 27(27): 4252-4275 [PMID: 34366604 DOI: 10.3748/wjg.v27.i27.4252] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
491 Janthamala S, Jusakul A, Kongpetch S, Kimawaha P, Klanrit P, Loilome W, Namwat N, Techasen A. Arctigenin inhibits cholangiocarcinoma progression by regulating cell migration and cell viability via the N-cadherin and apoptosis pathway. Naunyn Schmiedebergs Arch Pharmacol 2021. [PMID: 34283274 DOI: 10.1007/s00210-021-02123-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
492 Liu H, Lin L, Lin Z, Chen Y, Huang Q, Ding L, Lou J, Zheng S, Bi X, Wang J, Guo W, Li F, Wang J, Zheng Y, Li J, Cheng S, Zhou W, Cheng Z, Zeng Y. Impact of surgical margin width on long-term outcomes for intrahepatic cholangiocarcinoma: a multicenter study. BMC Cancer 2021;21:840. [PMID: 34284743 DOI: 10.1186/s12885-021-08560-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
493 Shi T, Morishita A, Kobara H, Masaki T. The Role of microRNAs in Cholangiocarcinoma. Int J Mol Sci 2021;22:7627. [PMID: 34299246 DOI: 10.3390/ijms22147627] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
494 Gao Y, Zhou R, Huang JF, Hu B, Cheng JW, Huang XW, Wang PX, Peng HX, Guo W, Zhou J, Fan J, Yang XR. Patient-Derived Xenograft Models for Intrahepatic Cholangiocarcinoma and Their Application in Guiding Personalized Medicine. Front Oncol 2021;11:704042. [PMID: 34327143 DOI: 10.3389/fonc.2021.704042] [Reference Citation Analysis]
495 Ju X, Tang Y, Qu R, Hao S. The Emerging Role of Circ-SHPRH in Cancer. Onco Targets Ther 2021;14:4177-88. [PMID: 34285509 DOI: 10.2147/OTT.S317403] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
496 Patel N, Lie X, Gwaltney C, Rokutanda N, Barzi A, Melisi D, Macarulla T, Ueno M, Kim ST, Meyers O, Workman C, Bachini M, Cohen G. Understanding Patient Experience in Biliary Tract Cancer: A Qualitative Patient Interview Study. Oncol Ther 2021. [PMID: 34244955 DOI: 10.1007/s40487-021-00159-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
497 Bahra M. [Surgical treatment of distal cholangiocarcinoma]. Chirurg 2021;92:788-95. [PMID: 34232340 DOI: 10.1007/s00104-021-01453-2] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
498 Younger NT, Wilson ML, Jarman EJ, Meynert AM, Grimes GR, Gournopanos K, Waddell SH, Tennant PA, Wilson DH, Guest RV, Wigmore SJ, Acosta JC, Kendall TJ, Taylor MS, Sproul D, Mill P, Boulter L. In vivo modelling of patient genetic heterogeneity identifies concurrent Wnt and PI3K activity as a potent driver of invasive cholangiocarcinoma growth.. [DOI: 10.1101/2021.07.05.449722] [Reference Citation Analysis]
499 Renzulli M, Ramai D, Singh J, Sinha S, Brandi N, Ierardi AM, Albertini E, Sacco R, Facciorusso A, Golfieri R. Locoregional Treatments in Cholangiocarcinoma and Combined Hepatocellular Cholangiocarcinoma. Cancers (Basel) 2021;13:3336. [PMID: 34283065 DOI: 10.3390/cancers13133336] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
500 Sato K, Baiocchi L, Kennedy L, Zhang W, Ekser B, Glaser S, Francis H, Alpini G. Current Advances in Basic and Translational Research of Cholangiocarcinoma. Cancers (Basel) 2021;13:3307. [PMID: 34282753 DOI: 10.3390/cancers13133307] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
501 Li H, Qu L, Zhang H, Liu J, Zhang X. A comprehensive transcriptomic landscape of cholangiocarcinoma based on bioinformatics analysis from large cohort of patients. Sci Rep 2021;11:13713. [PMID: 34211100 DOI: 10.1038/s41598-021-93250-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
502 Guardado NV, Llorente K, Blondeau B. Evaluation and Management of Malignant Biliary Obstruction. Surg Oncol Clin N Am 2021;30:491-503. [PMID: 34053664 DOI: 10.1016/j.soc.2021.03.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
503 Sato K, Zhang W, Safarikia S, Isidan A, Chen AM, Li P, Francis H, Kennedy L, Baiocchi L, Alvaro D, Glaser S, Ekser B, Alpini G. Organoids and Spheroids as Models for Studying Cholestatic Liver Injury and Cholangiocarcinoma. Hepatology 2021;74:491-502. [PMID: 33222247 DOI: 10.1002/hep.31653] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 10.5] [Reference Citation Analysis]
504 Wang H, Song X, Liao H, Wang P, Zhang Y, Che L, Zhang J, Zhou Y, Cigliano A, Ament C, Superville D, Ribback S, Reeves M, Pes GM, Liang B, Wu H, Evert M, Calvisi DF, Zeng Y, Chen X. Overexpression of Mothers Against Decapentaplegic Homolog 7 Activates the Yes-Associated Protein/NOTCH Cascade and Promotes Liver Carcinogenesis in Mice and Humans. Hepatology 2021;74:248-63. [PMID: 33368437 DOI: 10.1002/hep.31692] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
505 Kim-Fuchs C, Candinas D, Lachenmayer A. The Role of Conventional and Stereotactic Microwave Ablation for Intrahepatic Cholangiocarcinoma. J Clin Med 2021;10:2963. [PMID: 34279447 DOI: 10.3390/jcm10132963] [Reference Citation Analysis]
506 Bednarsch J, Czigany Z, Heij LR, Liu D, den Dulk M, Wiltberger G, Bruners P, Ulmer TF, Neumann UP, Lang SA. Compelling Long-Term Results for Liver Resection in Early Cholangiocarcinoma. J Clin Med 2021;10:2959. [PMID: 34209368 DOI: 10.3390/jcm10132959] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
507 Charalampakis N, Papageorgiou G, Tsakatikas S, Fioretzaki R, Kole C, Kykalos S, Tolia M, Schizas D. Immunotherapy for cholangiocarcinoma: a 2021 update. Immunotherapy 2021;13:1113-34. [PMID: 34190581 DOI: 10.2217/imt-2021-0126] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
508 Rodrigues PM, Vogel A, Arrese M, Balderramo DC, Valle JW, Banales JM. Next-Generation Biomarkers for Cholangiocarcinoma. Cancers (Basel) 2021;13:3222. [PMID: 34203269 DOI: 10.3390/cancers13133222] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
509 Czauderna C, Kirstein MM, Tews HC, Vogel A, Marquardt JU. Molecular Subtypes and Precision Oncology in Intrahepatic Cholangiocarcinoma. J Clin Med 2021;10:2803. [PMID: 34202401 DOI: 10.3390/jcm10132803] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
510 Ahn CS, Kim JG, Kang I, Kong Y. Omega-Class Glutathione Transferases of Carcinogenic Liver Fluke, Clonorchis sinensis, Modulate Apoptosis and Differentiation of Host Cholangiocytes. Antioxidants (Basel) 2021;10:1017. [PMID: 34202740 DOI: 10.3390/antiox10071017] [Reference Citation Analysis]
511 Gerber TS, Bartsch F, Wagner DC, Schindeldecker M, Heuft LK, Roth W, Lang H, Straub BK. Clinicopathological Significance of Syndecan-1 in Cholangiocarcinoma: A Study Based on Immunohistochemistry and Public Sequencing Data. J Clin Med 2021;10:2745. [PMID: 34206469 DOI: 10.3390/jcm10132745] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
512 Matsuda T, Umeda Y, Matsuda T, Endo Y, Sato D, Kojima T, Sui K, Inagaki M, Ota T, Hioki M, Oishi M, Kimura M, Murata T, Ishido N, Yagi T, Fujiwara T. Preoperative prognostic nutritional index predicts postoperative infectious complications and oncological outcomes after hepatectomy in intrahepatic cholangiocarcinoma. BMC Cancer 2021;21:708. [PMID: 34130648 DOI: 10.1186/s12885-021-08424-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
513 Pirozzi CJ, Yan H. The implications of IDH mutations for cancer development and therapy. Nat Rev Clin Oncol 2021. [PMID: 34131315 DOI: 10.1038/s41571-021-00521-0] [Cited by in Crossref: 43] [Cited by in F6Publishing: 52] [Article Influence: 21.5] [Reference Citation Analysis]
514 Yin L, Zhao S, Zhu H, Ji G, Zhang X. Primary tumor resection improves survival in patients with multifocal intrahepatic cholangiocarcinoma based on a population study. Sci Rep 2021;11:12166. [PMID: 34108604 DOI: 10.1038/s41598-021-91823-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
515 Massani M, Bonariol L, Stecca T. Hepatic Arterial Infusion Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma, a Comprehensive Review. J Clin Med 2021;10:2552. [PMID: 34207700 DOI: 10.3390/jcm10122552] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
516 Truong SDA, Tummanatsakun D, Proungvitaya T, Limpaiboon T, Wongwattanakul M, Chua-On D, Roytrakul S, Proungvitaya S. Serum Levels of Cytokine-Induced Apoptosis Inhibitor 1 (CIAPIN1) as a Potential Prognostic Biomarker of Cholangiocarcinoma. Diagnostics (Basel) 2021;11:1054. [PMID: 34201138 DOI: 10.3390/diagnostics11061054] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
517 Komuta M. Histological Heterogeneity of Primary Liver Cancers: Clinical Relevance, Diagnostic Pitfalls and the Pathologist's Role. Cancers (Basel) 2021;13:2871. [PMID: 34201284 DOI: 10.3390/cancers13122871] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
518 Hozaka Y, Seki N, Tanaka T, Asai S, Moriya S, Idichi T, Wada M, Tanoue K, Kawasaki Y, Mataki Y, Kurahara H, Ohtsuka T. Molecular Pathogenesis and Regulation of the miR-29-3p-Family: Involvement of ITGA6 and ITGB1 in Intra-Hepatic Cholangiocarcinoma. Cancers (Basel) 2021;13:2804. [PMID: 34199886 DOI: 10.3390/cancers13112804] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
519 Lamarca A, Santos-Laso A, Utpatel K, La Casta A, Stock S, Forner A, Adeva J, Folseraas T, Fabris L, Macias RIR, Krawczyk M, Krawczyk M, Cardinale V, Braconi C, Alvaro D, Evert M, Banales JM, Valle JW; Group: on behalf of the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System. Hepatology 2021;73:2311-25. [PMID: 33073396 DOI: 10.1002/hep.31598] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
520 Maa H, Wu Y. IGF2BP1 IS A POOR PROGNOSTIC FACTOR IN EXTRAHEPATIC CHOLANGIOCARCINOMA. ijsr 2021. [DOI: 10.36106/ijsr/9434894] [Reference Citation Analysis]
521 Titapun A, Luvira V, Srisuk T, Jareanrat A, Thanasukarn V, Thanee M, Sa-Ngiamwibool P, Padthaisong S, Duangkumpha K, Suksawat M, Loilome W, Sithithaworn P, Techasen A, Thinkhamrop B, Dzienny A, Caglayan A, Park D, Mahmud S, Khuntikeo N. High Levels of Serum IgG for Opisthorchis viverrini and CD44 Expression Predict Worse Prognosis for Cholangiocarcinoma Patients after Curative Resection. Int J Gen Med 2021;14:2191-204. [PMID: 34103974 DOI: 10.2147/IJGM.S306339] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
522 Ali A, Manzoor K, Weinstein JL, Faintuch S, Ahmed M, Sarwar A. Radioembolization for Cholangiocarcinoma. Digestive Disease Interventions 2021;05:093-102. [DOI: 10.1055/s-0041-1729874] [Reference Citation Analysis]
523 Raggi C, Taddei ML, Sacco E, Navari N, Correnti M, Piombanti B, Pastore M, Campani C, Pranzini E, Iorio J, Lori G, Lottini T, Peano C, Cibella J, Lewinska M, Andersen JB, di Tommaso L, Viganò L, Di Maira G, Madiai S, Ramazzotti M, Orlandi I, Arcangeli A, Chiarugi P, Marra F. Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma. J Hepatol 2021;74:1373-85. [PMID: 33484774 DOI: 10.1016/j.jhep.2020.12.031] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 10.5] [Reference Citation Analysis]
524 Sarcognato S, Sacchi D, Fassan M, Fabris L, Cadamuro M, Zanus G, Cataldo I, Capelli P, Baciorri F, Cacciatore M, Guido M. Cholangiocarcinoma. Pathologica 2021;113:158-69. [PMID: 34294934 DOI: 10.32074/1591-951X-252] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 7.5] [Reference Citation Analysis]
525 Wintachai P, Lim JQ, Techasen A, Lert-Itthiporn W, Kongpetch S, Loilome W, Chindaprasirt J, Titapun A, Namwat N, Khuntikeo N, Jusakul A. Diagnostic and Prognostic Value of Circulating Cell-Free DNA for Cholangiocarcinoma. Diagnostics (Basel) 2021;11:999. [PMID: 34070951 DOI: 10.3390/diagnostics11060999] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
526 Panayotova G, Guerra J, Guarrera JV, Lunsford KE. The Role of Surgical Resection and Liver Transplantation for the Treatment of Intrahepatic Cholangiocarcinoma. J Clin Med 2021;10:2428. [PMID: 34070772 DOI: 10.3390/jcm10112428] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
527 Kodali S, Shetty A, Shekhar S, Victor DW, Ghobrial RM. Management of Intrahepatic Cholangiocarcinoma. J Clin Med 2021;10:2368. [PMID: 34072277 DOI: 10.3390/jcm10112368] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
528 Casadio M, Biancaniello F, Overi D, Venere R, Carpino G, Gaudio E, Alvaro D, Cardinale V. Molecular Landscape and Therapeutic Strategies in Cholangiocarcinoma: An Integrated Translational Approach towards Precision Medicine. Int J Mol Sci 2021;22:5613. [PMID: 34070643 DOI: 10.3390/ijms22115613] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
529 Zou W, Wang Z, Wang F, Li L, Liu R, Hu M. A metabolism-related 4-lncRNA prognostic signature and corresponding mechanisms in intrahepatic cholangiocarcinoma. BMC Cancer 2021;21:608. [PMID: 34034689 DOI: 10.1186/s12885-021-08322-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
530 Nguyen Canh H, Takahashi K, Yamamura M, Li Z, Sato Y, Yoshimura K, Kozaka K, Tanaka M, Nakanuma Y, Harada K. Diversity in cell differentiation, histology, phenotype and vasculature of mass-forming intrahepatic cholangiocarcinomas. Histopathology 2021. [PMID: 34018212 DOI: 10.1111/his.14417] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
531 Marsee A, Roos FJM, Verstegen MMA, Gehart H, de Koning E, Lemaigre F, Forbes SJ, Peng WC, Huch M, Takebe T, Vallier L, Clevers H, van der Laan LJW, Spee B; HPB Organoid Consortium. Building consensus on definition and nomenclature of hepatic, pancreatic, and biliary organoids. Cell Stem Cell 2021;28:816-32. [PMID: 33961769 DOI: 10.1016/j.stem.2021.04.005] [Cited by in Crossref: 55] [Cited by in F6Publishing: 56] [Article Influence: 27.5] [Reference Citation Analysis]
532 Peng Y, Meng G, Sheng X, Gao H. Transcriptome and DNA methylation analysis reveals molecular mechanisms underlying intrahepatic cholangiocarcinoma progression. J Cell Mol Med 2021. [PMID: 34013637 DOI: 10.1111/jcmm.16615] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
533 Rompianesi G, Di Martino M, Gordon-Weeks A, Montalti R, Troisi R. Liquid biopsy in cholangiocarcinoma: Current status and future perspectives. World J Gastrointest Oncol 2021;13:332-50. [PMID: 34040697 DOI: 10.4251/wjgo.v13.i5.332] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
534 Lin Z, Gong J, Zhong G, Hu J, Cai D, Zhao L, Zhao Z. Identification of Mutator-Derived Alternative Splicing Signatures of Genomic Instability for Improving the Clinical Outcome of Cholangiocarcinoma. Front Oncol 2021;11:666847. [PMID: 34055632 DOI: 10.3389/fonc.2021.666847] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
535 Zhou M, Wang C, Lu S, Xu Y, Li Z, Jiang H, Ma Y. Tumor-associated macrophages in cholangiocarcinoma: complex interplay and potential therapeutic target. EBioMedicine 2021;67:103375. [PMID: 33993051 DOI: 10.1016/j.ebiom.2021.103375] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
536 Marin JJG, Sanchon-Sanchez P, Cives-Losada C, Del Carmen S, González-Santiago JM, Monte MJ, Macias RIR. Novel Pharmacological Options in the Treatment of Cholangiocarcinoma: Mechanisms of Resistance. Cancers (Basel) 2021;13:2358. [PMID: 34068398 DOI: 10.3390/cancers13102358] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
537 Izumiya M, Kato S, Hippo Y. Recent Advances in Implantation-Based Genetic Modeling of Biliary Carcinogenesis in Mice. Cancers (Basel) 2021;13:2292. [PMID: 34064809 DOI: 10.3390/cancers13102292] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
538 Lang SA, Bednarsch J, Joechle K, Amygdalos I, Czigany Z, Heij L, Ulmer TF, Neumann UP. Prognostic biomarkers for cholangiocarcinoma (CCA): state of the art. Expert Rev Gastroenterol Hepatol 2021;15:497-510. [PMID: 33970740 DOI: 10.1080/17474124.2021.1912591] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
539 Wakiyama H, Kato T, Furusawa A, Choyke PL, Kobayashi H. Near infrared photoimmunotherapy of cancer; possible clinical applications. Nanophotonics 2021;10:3135-51. [DOI: 10.1515/nanoph-2021-0119] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
540 Bednarsch J, Kather J, Tan X, Sivakumar S, Cacchi C, Wiltberger G, Czigany Z, Ulmer F, Neumann UP, Heij LR. Nerve Fibers in the Tumor Microenvironment as a Novel Biomarker for Oncological Outcome in Patients Undergoing Surgery for Perihilar Cholangiocarcinoma. Liver Cancer 2021;10:260-74. [PMID: 34239812 DOI: 10.1159/000515303] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
541 Marin JJ, Macias RI. Understanding drug resistance mechanisms in cholangiocarcinoma: assisting the clinical development of investigational drugs. Expert Opin Investig Drugs 2021;30:675-9. [PMID: 33934687 DOI: 10.1080/13543784.2021.1916912] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
542 Casolino R, Braconi C. CD40-agonist: A new avenue for immunotherapy combinations in cholangiocarcinoma. J Hepatol 2021;74:1021-4. [PMID: 33612309 DOI: 10.1016/j.jhep.2021.01.030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
543 Affo S, Nair A, Brundu F, Ravichandra A, Bhattacharjee S, Matsuda M, Chin L, Filliol A, Wen W, Song X, Decker A, Worley J, Caviglia JM, Yu L, Yin D, Saito Y, Savage T, Wells RG, Mack M, Zender L, Arpaia N, Remotti HE, Rabadan R, Sims P, Leblond AL, Weber A, Riener MO, Stockwell BR, Gaublomme J, Llovet JM, Kalluri R, Michalopoulos GK, Seki E, Sia D, Chen X, Califano A, Schwabe RF. Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations. Cancer Cell 2021;39:866-882.e11. [PMID: 33930309 DOI: 10.1016/j.ccell.2021.03.012] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 22.0] [Reference Citation Analysis]
544 Lleo A, Colapietro F, Maisonneuve P, Aloise M, Craviotto V, Ceriani R, Rimassa L, Badalamenti S, Donadon M, Pedicini V, Repici A, Di Tommaso L, Voza A, Torzilli G, Aghemo A. Risk Stratification of Cholangiocarcinoma Patients Presenting with Jaundice: A Retrospective Analysis from a Tertiary Referral Center. Cancers (Basel) 2021;13:2070. [PMID: 33922972 DOI: 10.3390/cancers13092070] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
545 Cigliano A, Chen X, Calvisi DF. Current challenges to underpinning the genetic basis for cholangiocarcinoma. Expert Rev Gastroenterol Hepatol 2021;15:511-26. [PMID: 33888034 DOI: 10.1080/17474124.2021.1915128] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
546 Park HJ, Park B, Park SY, Choi SH, Rhee H, Park JH, Cho ES, Yeom SK, Park S, Park MS, Lee SS. Preoperative prediction of postsurgical outcomes in mass-forming intrahepatic cholangiocarcinoma based on clinical, radiologic, and radiomics features. Eur Radiol 2021. [PMID: 33890153 DOI: 10.1007/s00330-021-07926-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
547 Klinhom-On N, Seubwai W, Sawanyawisuth K, Lert-Itthiporn W, Waraasawapati S, Detarya M, Wongkham S. FOXM1c is the predominant FOXM1 isoform expressed in cholangiocarcinoma that associated with metastatic potential and poor prognosis of patients. Heliyon 2021;7:e06846. [PMID: 33997388 DOI: 10.1016/j.heliyon.2021.e06846] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
548 Fiste O, Ntanasis-Stathopoulos I, Gavriatopoulou M, Liontos M, Koutsoukos K, Dimopoulos MA, Zagouri F. The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma. Vaccines (Basel) 2021;9:422. [PMID: 33922362 DOI: 10.3390/vaccines9050422] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
549 Neureiter D, Mayr C, Kiesslich T. The challenges of combinatory immunotherapy for biliary tract cancer. Expert Opin Investig Drugs 2021;30:591-4. [PMID: 33874822 DOI: 10.1080/13543784.2021.1916467] [Reference Citation Analysis]
550 Nara S, Esaki M, Ban D, Takamoto T, Mizui T, Shimada K. Role of adjuvant and neoadjuvant therapy for resectable biliary tract cancer. Expert Rev Gastroenterol Hepatol 2021;15:537-45. [PMID: 33793366 DOI: 10.1080/17474124.2021.1911645] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
551 Okusaka T. Cholangiocarcinoma: is it time for a revolution? Expert Rev Gastroenterol Hepatol 2021;15:467-70. [PMID: 33840344 DOI: 10.1080/17474124.2021.1915766] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
552 Lücke J, Sabihi M, Zhang T, Bauditz LF, Shiri AM, Giannou AD, Huber S. The good and the bad about separation anxiety: roles of IL-22 and IL-22BP in liver pathologies. Semin Immunopathol 2021. [PMID: 33851257 DOI: 10.1007/s00281-021-00854-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
553 Rizzo A, Ricci AD, Brandi G. Ivosidenib in IDH-mutant cholangiocarcinoma: where do we stand? Expert Review of Precision Medicine and Drug Development 2021;6:217-24. [DOI: 10.1080/23808993.2021.1915126] [Reference Citation Analysis]
554 Soares KC, Jarnagin WR. The Landmark Series: Hilar Cholangiocarcinoma. Ann Surg Oncol 2021;28:4158-70. [PMID: 33829358 DOI: 10.1245/s10434-021-09871-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
555 Rizzo A. The evolving landscape of systemic treatment for advanced hepatocellular carcinoma and biliary tract cancer. Cancer Treat Res Commun 2021;27:100360. [PMID: 33799005 DOI: 10.1016/j.ctarc.2021.100360] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
556 Kawasaki K, Kuboki S, Furukawa K, Takayashiki T, Takano S, Ohtsuka M. LGR5 induces β-catenin activation and augments tumour progression by activating STAT3 in human intrahepatic cholangiocarcinoma. Liver Int 2021;41:865-81. [PMID: 33249719 DOI: 10.1111/liv.14747] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
557 Dwyer BJ, Jarman EJ, Gogoi-Tiwari J, Ferreira-Gonzalez S, Boulter L, Guest RV, Kendall TJ, Kurian D, Kilpatrick AM, Robson AJ, O'Duibhir E, Man TY, Campana L, Starkey Lewis PJ, Wigmore SJ, Olynyk JK, Ramm GA, Tirnitz-Parker JEE, Forbes SJ. TWEAK/Fn14 signalling promotes cholangiocarcinoma niche formation and progression. J Hepatol 2021;74:860-72. [PMID: 33221352 DOI: 10.1016/j.jhep.2020.11.018] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
558 Yoo C, Shin SH, Park JO, Kim KP, Jeong JH, Ryoo BY, Lee W, Song KB, Hwang DW, Park JH, Lee JH. Current Status and Future Perspectives of Perioperative Therapy for Resectable Biliary Tract Cancer: A Multidisciplinary Review. Cancers (Basel) 2021;13:1647. [PMID: 33916008 DOI: 10.3390/cancers13071647] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
559 Goyal L, Kongpetch S, Crolley VE, Bridgewater J. Targeting FGFR inhibition in cholangiocarcinoma. Cancer Treatment Reviews 2021;95:102170. [DOI: 10.1016/j.ctrv.2021.102170] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 16.5] [Reference Citation Analysis]
560 Rizzo A, Ricci AD, Brandi G. Detecting and targeting NTRK gene fusions in cholangiocarcinoma: news and perspectives. Expert Review of Precision Medicine and Drug Development 2021;6:225-7. [DOI: 10.1080/23808993.2021.1910023] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
561 Hu J, Wang YN, Song DJ, Tan JP, Cao Y, Fan J, Wang Z, Zhou J. A High-Accuracy Model Based on Plasma miRNAs Diagnoses Intrahepatic Cholangiocarcinoma: A Single Center with 1001 Samples. Diagnostics (Basel) 2021;11:610. [PMID: 33805513 DOI: 10.3390/diagnostics11040610] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
562 Kimawaha P, Jusakul A, Junsawang P, Thanan R, Titapun A, Khuntikeo N, Techasen A. Establishment of a Potential Serum Biomarker Panel for the Diagnosis and Prognosis of Cholangiocarcinoma Using Decision Tree Algorithms. Diagnostics (Basel) 2021;11:589. [PMID: 33806004 DOI: 10.3390/diagnostics11040589] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
563 Boilève A, Verlingue L, Hollebecque A, Boige V, Ducreux M, Malka D. Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers. Expert Opin Investig Drugs 2021;30:401-9. [PMID: 33641556 DOI: 10.1080/13543784.2021.1896703] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
564 Kajioka H, Muraoka A. Rapid recurrence of spindle cell type undifferentiated carcinoma early after radical surgery in a bile duct cancer patient - A case report. Int J Surg Case Rep 2021;81:105800. [PMID: 33756162 DOI: 10.1016/j.ijscr.2021.105800] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
565 Rizzo A, Brandi G. Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review. Cancer Treat Res Commun 2021;27:100354. [PMID: 33756174 DOI: 10.1016/j.ctarc.2021.100354] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
566 Rizzo A, Brandi G. TRK inhibition in cholangiocarcinoma: Trying to teach an old dog new tricks. Cancer Treat Res Commun 2021;27:100351. [PMID: 33752169 DOI: 10.1016/j.ctarc.2021.100351] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
567 Fung BM, Tabibian JH. Primary sclerosing cholangitis-associated cholangiocarcinoma: special considerations and best practices. Expert Rev Gastroenterol Hepatol 2021;15:487-96. [PMID: 33682586 DOI: 10.1080/17474124.2021.1900732] [Reference Citation Analysis]
568 Rizzo A, Ricci AD, Brandi G. Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer. Expert Opin Investig Drugs 2021;30:343-50. [PMID: 33645367 DOI: 10.1080/13543784.2021.1897102] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 12.0] [Reference Citation Analysis]
569 Uson Junior PLS, Arora M, Bogenberger JM, Borad MJ. Recent advances in understanding cholangiocarcinoma. Fac Rev 2020;9:15. [PMID: 33659947 DOI: 10.12703/b/9-15] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
570 Merdrignac A, Papoutsoglou P, Coulouarn C. Long Noncoding RNAs in Cholangiocarcinoma. Hepatology 2021;73:1213-26. [PMID: 32865244 DOI: 10.1002/hep.31534] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
571 Tantau AI, Mandrutiu A, Pop A, Zaharie RD, Crisan D, Preda CM, Tantau M, Mercea V. Extrahepatic cholangiocarcinoma: Current status of endoscopic approach and additional therapies. World J Hepatol 2021; 13(2): 166-186 [PMID: 33708349 DOI: 10.4254/wjh.v13.i2.166] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
572 Cadamuro M, Lasagni A, Lamarca A, Fouassier L, Guido M, Sarcognato S, Gringeri E, Cillo U, Strazzabosco M, Marin JJ, Banales JM, Fabris L. Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic. Expert Opin Investig Drugs 2021;30:377-88. [PMID: 33622120 DOI: 10.1080/13543784.2021.1880564] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
573 Tian C, Li L, Li Y, Fan L, Brown A, Morrison M, Norris EJ, Yang JJ, Glazer ES, Zhu L. Paradoxical Roles of Peritumoral Myofibroblasts in Intrahepatic Cholangiocarcinoma Growth and Metastasis.. [DOI: 10.1101/2021.02.19.432035] [Reference Citation Analysis]
574 Rizzo A, Brandi G. Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer. Expert Review of Gastroenterology & Hepatology 2021;15:547-54. [DOI: 10.1080/17474124.2021.1890031] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 20.5] [Reference Citation Analysis]
575 Rizzo A, Ricci AD, Brandi G. Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma. Cancer Treat Res Commun 2021;27:100337. [PMID: 33611090 DOI: 10.1016/j.ctarc.2021.100337] [Cited by in Crossref: 38] [Cited by in F6Publishing: 44] [Article Influence: 19.0] [Reference Citation Analysis]
576 Waddell SH, Boulter L. Developing models of cholangiocarcinoma to close the translational gap in cancer research. Expert Opin Investig Drugs 2021;30:439-50. [PMID: 33513027 DOI: 10.1080/13543784.2021.1882993] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
577 Sawanyawisuth K, Sashida G, Sheng G. Epithelial-Mesenchymal Transition in Liver Fluke-Induced Cholangiocarcinoma. Cancers (Basel) 2021;13:791. [PMID: 33672838 DOI: 10.3390/cancers13040791] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
578 Rizzo A, Brandi G. Adjuvant systemic treatment in resected biliary tract cancer: State of the art, controversies, and future directions. Cancer Treat Res Commun 2021;27:100334. [PMID: 33592563 DOI: 10.1016/j.ctarc.2021.100334] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
579 Rizzo A, Brandi G. First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: "And Yet It Moves!". Cancer Treat Res Commun 2021;27:100335. [PMID: 33592561 DOI: 10.1016/j.ctarc.2021.100335] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
580 Louis C, Edeline J, Coulouarn C. Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy. Expert Opin Ther Targets 2021;25:153-62. [PMID: 33502260 DOI: 10.1080/14728222.2021.1882998] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
581 Mariotti V, Fiorotto R, Cadamuro M, Fabris L, Strazzabosco M. New insights on the role of vascular endothelial growth factor in biliary pathophysiology. JHEP Rep 2021;3:100251. [PMID: 34151244 DOI: 10.1016/j.jhepr.2021.100251] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
582 Zhang R, Li Q, Fu J, Jin Z, Su J, Zhang J, Chen C, Geng Z, Zhang D. Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma. BMC Cancer 2021;21:112. [PMID: 33535978 DOI: 10.1186/s12885-021-07788-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
583 Keenan BP, Kelley RKK. Key challenges for drugs in clinical development for cholangiocarcinoma. Expert Opin Investig Drugs 2021;30:285-90. [PMID: 33530767 DOI: 10.1080/13543784.2021.1880565] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
584 Muñoz-Martínez S, Forner A. The tireless search to improve the prognostic assessment of intrahepatic cholangiocarcinoma: An urgent need. Liver Int 2021;41:252-4. [PMID: 33464725 DOI: 10.1111/liv.14768] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
585 Noguchi D, Kuriyama N, Nakagawa Y, Maeda K, Shinkai T, Gyoten K, Hayasaki A, Fujii T, Iizawa Y, Tanemura A, Murata Y, Kishiwada M, Sakurai H, Mizuno S. The prognostic impact of lymphocyte-to-C-reactive protein score in patients undergoing surgical resection for intrahepatic cholangiocarcinoma: A comparative study of major representative inflammatory / immunonutritional markers. PLoS One 2021;16:e0245946. [PMID: 33507925 DOI: 10.1371/journal.pone.0245946] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
586 Di Matteo S, Nevi L, Overi D, Landolina N, Faccioli J, Giulitti F, Napoletano C, Oddi A, Marziani AM, Costantini D, De Rose AM, Melandro F, Bragazzi MC, Grazi GL, Berloco PB, Giuliante F, Donato G, Moretta L, Carpino G, Cardinale V, Gaudio E, Alvaro D. Metformin exerts anti-cancerogenic effects and reverses epithelial-to-mesenchymal transition trait in primary human intrahepatic cholangiocarcinoma cells. Sci Rep 2021;11:2557. [PMID: 33510179 DOI: 10.1038/s41598-021-81172-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
587 Moeini A, Haber PK, Sia D. Cell of origin in biliary tract cancers and clinical implications. JHEP Rep 2021;3:100226. [PMID: 33665585 DOI: 10.1016/j.jhepr.2021.100226] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
588 Gil-Hernández A, Arroyo-Campuzano M, Simoni-Nieves A, Zazueta C, Gomez-Quiroz LE, Silva-Palacios A. Relevance of Membrane Contact Sites in Cancer Progression. Front Cell Dev Biol 2020;8:622215. [PMID: 33511135 DOI: 10.3389/fcell.2020.622215] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
589 Balasubramanian B, Venkatraman S, Myint KZ, Janvilisri T, Wongprasert K, Kumkate S, Bates DO, Tohtong R. Co-Clinical Trials: An Innovative Drug Development Platform for Cholangiocarcinoma. Pharmaceuticals (Basel) 2021;14:51. [PMID: 33440754 DOI: 10.3390/ph14010051] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
590 Rizzo A, Ricci AD, Brandi G. Recent advances of immunotherapy for biliary tract cancer. Expert Rev Gastroenterol Hepatol 2021;15:527-36. [PMID: 33215952 DOI: 10.1080/17474124.2021.1853527] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 27.5] [Reference Citation Analysis]
591 Wu H, Wei Y, Jian M, Lu H, Song Q, Hao L, Yue Y. Clinicopathological and Prognostic Significance of Immunoscore and PD-L1 in Intrahepatic Cholangiocarcinoma. Onco Targets Ther 2021;14:39-51. [PMID: 33442265 DOI: 10.2147/OTT.S288982] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
592 Vogel A, Saborowski A. Current and Future Systemic Therapies in Biliary Tract Cancer. Visc Med 2021;37:32-8. [PMID: 33708816 DOI: 10.1159/000513969] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
593 蒋 银. The Necessity and Method of Preoperative Drainage for Hilar Cholangiocarcinoma. ACM 2021;11:1952-1958. [DOI: 10.12677/acm.2021.114281] [Reference Citation Analysis]
594 Kishikawa T. Biomarkers for Pancreatic Cancer and Cholangiocarcinoma. Management of Pancreatic Cancer and Cholangiocarcinoma 2021. [DOI: 10.1007/978-981-16-2870-2_3] [Reference Citation Analysis]
595 Pechetov A, Chzhao A, Ragimov S, Volchansky D, Makov M, Gurmikov B. Thoracoscopic metastasectomy is the method of choice in the stepwise treatment of disseminated cholangiocellular carcinoma. Onkol Z im P A Gercena 2021;10:39. [DOI: 10.17116/onkolog20211002139] [Reference Citation Analysis]
596 Herting CJ, Lesinski GB. An Overview of the Tumor Microenvironment and Response to Immunotherapy in Gastrointestinal Malignancies. Cancer Immunotherapy 2021. [DOI: 10.1007/13905_2021_1] [Reference Citation Analysis]
597 Meadows V, Francis H. Doublecortin-Like Kinase Protein 1 in Cholangiocarcinoma: Is This the Biomarker and Target We Have Been Looking For? Hepatology 2021;73:4-6. [PMID: 33179783 DOI: 10.1002/hep.31630] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
598 García-sampedro A, Acedo P, Pereira SP. Established and Emerging Biomarkers for Prediction, Early Detection, and Prognostication of Cholangiocarcinoma. Diagnosis and Management of Cholangiocarcinoma 2021. [DOI: 10.1007/978-3-030-70936-5_19] [Reference Citation Analysis]
599 Hamada T, Nakai Y. Risk Factors for Pancreatic Cancer and Cholangiocarcinoma. Management of Pancreatic Cancer and Cholangiocarcinoma 2021. [DOI: 10.1007/978-981-16-2870-2_1] [Reference Citation Analysis]
600 Rizzo A, Federico AD, Ricci AD, Frega G, Palloni A, Pagani R, Tavolari S, Marco MD, Brandi G. Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges. Cancer Control 2020;27:1073274820983013. [PMID: 33356500 DOI: 10.1177/1073274820983013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
601 Susak YM, Palytsya RY, Markulan LY, Dyrda OO. Palliative surgical treatment of patients, suffering proximal tumoral affection of biliary ducts and the jaundice syndrome. KH 2020;87:40-47. [DOI: 10.26779/2522-1396.2020.11-12.40] [Reference Citation Analysis]
602 Wang J, Ilyas S. Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy. Expert Opin Investig Drugs 2021;30:429-38. [PMID: 33322977 DOI: 10.1080/13543784.2021.1865308] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
603 Di Federico A, Rizzo A, Ricci AD, Frega G, Palloni A, Tavolari S, Brandi G. Nivolumab: an investigational agent for the treatment of biliary tract cancer. Expert Opin Investig Drugs 2021;30:325-32. [PMID: 33307866 DOI: 10.1080/13543784.2021.1863946] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
604 Rizzo A, Brandi G. BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care. Expert Review of Gastroenterology & Hepatology 2021;15:483-5. [DOI: 10.1080/17474124.2021.1864325] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
605 Rinaldi Adithya Lesmana C, Kirana D. Mandasari B. The New Era of Immunotherapy in Bile Duct Cancer Management. Immunosuppression 2020. [DOI: 10.5772/intechopen.94754] [Reference Citation Analysis]
606 Yao Y, Jiao D, Liu Z, Chen J, Zhou X, Li Z, Li J, Han X. Novel miRNA Predicts Survival and Prognosis of Cholangiocarcinoma Based on RNA-seq Data and In Vitro Experiments. Biomed Res Int 2020;2020:5976127. [PMID: 33490245 DOI: 10.1155/2020/5976127] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
607 Sirica AE, Strazzabosco M, Cadamuro M. Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression. Adv Cancer Res 2021;149:321-87. [PMID: 33579427 DOI: 10.1016/bs.acr.2020.10.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
608 Baiocchi L, Sato K, Ekser B, Kennedy L, Francis H, Ceci L, Lenci I, Alvaro D, Franchitto A, Onori P, Gaudio E, Wu C, Chakraborty S, Glaser S, Alpini G. Cholangiocarcinoma: bridging the translational gap from preclinical to clinical development and implications for future therapy. Expert Opin Investig Drugs 2021;30:365-75. [PMID: 33226854 DOI: 10.1080/13543784.2021.1854725] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
609 Rizzo A, Ricci AD, Bonucci C, Tober N, Palloni A, Frega G, Brandi G. Experimental HER2- targeted therapies for biliary tract cancer. Expert Opin Investig Drugs 2021;30:389-99. [PMID: 33218269 DOI: 10.1080/13543784.2021.1854724] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
610 Carbone M, Baiocchi L. Management of cholangiocarcinoma in the third millennium: time to be guided! Dig Liver Dis 2020;52:1428-9. [PMID: 33248542 DOI: 10.1016/j.dld.2020.11.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
611 Sipra QUAR, Shroff R. The impact of molecular profiling on cholangiocarcinoma clinical trials and experimental drugs. Expert Opinion on Investigational Drugs 2021;30:281-4. [DOI: 10.1080/13543784.2021.1849139] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
612 Han S, Lee SY, Wang WW, Tan YB, Sim RHZ, Cheong R, Tan C, Hopkins R, Connolly J, Shuen WH, Toh HC. A Perspective on Cell Therapy and Cancer Vaccine in Biliary Tract Cancers (BTCs). Cancers (Basel) 2020;12:E3404. [PMID: 33212880 DOI: 10.3390/cancers12113404] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
613 Personeni N, Lleo A, Pressiani T, Colapietro F, Openshaw MR, Stavraka C, Pouptsis A, Pinato DJ, Rimassa L. Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options. Cancers (Basel) 2020;12:E3370. [PMID: 33202975 DOI: 10.3390/cancers12113370] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
614 Hao WY, Guo LW, Luo J, Shao GL, Zheng JP. LncRNA TUG1 Promotes Growth and Metastasis of Cholangiocarcinoma Cells by Inhibiting miR-29a. Cancer Manag Res 2020;12:11103-11. [PMID: 33173343 DOI: 10.2147/CMAR.S270515] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
615 Fabris L, Andersen JB, Fouassier L. Intrahepatic cholangiocarcinoma: A single-cell resolution unraveling the complexity of the tumor microenvironment. J Hepatol 2020;73:1007-9. [PMID: 32900521 DOI: 10.1016/j.jhep.2020.07.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
616 Rizzo A, Ricci AD, Brandi G. Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives. Expert Opinion on Investigational Drugs 2021;30:317-24. [DOI: 10.1080/13543784.2021.1837774] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 14.0] [Reference Citation Analysis]
617 Mancinelli R, Cutone A, Rosa L, Lepanto MS, Onori P, Pannarale L, Franchitto A, Gaudio E, Valenti P. Different iron-handling in inflamed small and large cholangiocytes and in small and large-duct type intrahepatic cholangiocarcinoma. Eur J Histochem 2020;64. [PMID: 33131269 DOI: 10.4081/ejh.2020.3156] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
618 Lomphithak T, Choksi S, Mutirangura A, Tohtong R, Tencomnao T, Usubuchi H, Unno M, Sasano H, Jitkaew S. Receptor-interacting protein kinase 1 is a key mediator in TLR3 ligand and Smac mimetic-induced cell death and suppresses TLR3 ligand-promoted invasion in cholangiocarcinoma. Cell Commun Signal 2020;18:161. [PMID: 33036630 DOI: 10.1186/s12964-020-00661-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
619 Wijetunga I, McVeigh LE, Charalambous A, Antanaviciute A, Carr IM, Nair A, Prasad KR, Ingram N, Coletta PL. Translating Biomarkers of Cholangiocarcinoma for Theranosis: A Systematic Review. Cancers (Basel) 2020;12:E2817. [PMID: 33007872 DOI: 10.3390/cancers12102817] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
620 Chang YC, Chen MH, Yeh CN, Hsiao M. Omics-Based Platforms: Current Status and Potential Use for Cholangiocarcinoma. Biomolecules 2020;10:E1377. [PMID: 32998289 DOI: 10.3390/biom10101377] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
621 Klufah F, Mobaraki G, Chteinberg E, Alharbi RA, Winnepenninckx V, Speel EJM, Rennspiess D, Olde Damink SW, Neumann UP, Kurz AK, Samarska I, Zur Hausen A. High Prevalence of Human Polyomavirus 7 in Cholangiocarcinomas and Adjacent Peritumoral Hepatocytes: Preliminary Findings. Microorganisms 2020;8:E1125. [PMID: 32726909 DOI: 10.3390/microorganisms8081125] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
622 Mohr R, Özdirik B, Knorr J, Wree A, Demir M, Tacke F, Roderburg C. In Vivo Models for Cholangiocarcinoma-What Can We Learn for Human Disease? Int J Mol Sci 2020;21:E4993. [PMID: 32679791 DOI: 10.3390/ijms21144993] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
623 Jones J, Di Muzio B. Mass-forming intrahepatic cholangiocarcinoma. Radiopaedia.org 2019. [DOI: 10.53347/rid-70566] [Reference Citation Analysis]
624 Niknejad M, Gaillard F. Cholangiocarcinoma. Radiopaedia.org 2008. [DOI: 10.53347/rid-1114] [Reference Citation Analysis]